ALS TREATMENT USING INDUCED REGULATORY T (iTREG) CELLS
The dedifferentiation and differentiation of T cells into iTREG cells, combined with a specific treatment regimen, addresses inefficiencies in ALS treatment by enhancing T cell therapeutic potential and modulating neuroinflammation, offering a promising approach for ALS management.
Patent Information
- Application Number
- JP2024135447
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-10-28
- Filing Date
- 2024-08-14
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2039-11-15
AI Technical Summary
Current adoptive T-cell therapies for diseases like ALS face inefficiencies in converting differentiated T cells to a more primitive state for effective treatment, with challenges in dedifferentiation processes and limited therapeutic potential of peripheral effector T cells, and the need for improved strategies in ALS treatment due to the lack of effective biomarkers and delayed diagnosis.
A method involving the dedifferentiation of T cells using pharmacological interventions like vitamin D, temsirolimus, and IL-2 signaling inhibitors, followed by differentiation into inducible regulatory T (iTREG) cells, combined with a treatment regimen of pentostatin and cyclophosphamide to enhance therapeutic efficacy in ALS.
The method produces iTREG cells with enhanced proliferative potential and immune regulatory properties, effectively modulating neuroinflammation and potentially slowing ALS progression by reducing Th1-type immune responses.
Smart Images

Figure 2024167242000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 768,176, filed November 16, 2018, and U.S. Provisional Application No. 62 / 927,075, filed October 28, 2019, each of which is incorporated by reference in its entirety herein. [Background technology]
[0002] Adoptive T cell therapy is an emerging intervention for the effective treatment of cancer and infectious, autoimmune, and neurodegenerative diseases. It is becoming increasingly clear that the transfer of T cells with a more primitive differentiation state, which translates into higher proliferative potential and other important attributes, is associated with improved in vivo efficacy after adoptive transfer. However, most forms of adoptive T cell therapy require an ex vivo production step that typically results in further cell differentiation. This is highly problematic because T cells from adult humans are already primarily in an advanced differentiation state (termed effector memory cells) and often exist in a senescent state under the control of checkpoint inhibitory molecules. Approaches can be taken to alleviate this limitation, including the isolation (purification) of more naive T cell subsets at the initiation of culture, but this approach is limited in part by the small number of naive T cells present in adult human peripheral blood. Thus, isolated T cells in a primitive differentiation state are greatly needed.
[0003] It is well known that even highly differentiated cells have an inherent ability to dedifferentiate towards a more primitive state. Indeed, in the most extreme case, differentiated cells can be engineered to achieve an induced pluripotent stem cell (iPSC) state, whereby such iPS cells share important characteristics with embryonic stem cells and can then be further conditioned towards redifferentiation into different tissue fates. Cell therapy using such iPSC methodologies has many potential clinical applications. The generation of iPS cells from differentiated somatic cells was initially demonstrated by the transfer of key transcription factors, including Sox2, Oct3 / 4, KLF4, and c-myc, or Sox2, Oct3 / 4, Nanog, and Lin28, via viral or non-viral mediated approaches.
[0004] However, the ability to convert somatic cells into iPS cells is inefficient and depends in part on the degree of somatic differentiation. As an example, the ability to convert mature mouse immune T cells into iPS cells is 300-fold less efficient compared to converting mouse hematopoietic stem cells into iPS cells. Nevertheless, using gene transfer methods, it has been demonstrated that mature human peripheral blood T cells maintain the ability to be converted to an iPS cell state. Over the past decade, researchers have also characterized the transcription factors associated with the early stages of T cell differentiation. However, redifferentiation of T cells from various types of stem cell precursors is a relatively inefficient process that typically takes 1–2 months.
[0005] Although the biology of dedifferentiation is increasingly being characterized, much remains unknown regarding the specific transcription factors and transcription factor dynamics associated with dedifferentiation. It is also important to recognize that gene transfer methods to achieve dedifferentiation are laborious and associated with complications such as the generation of teratomas that must be addressed through additional genetic interventions such as cell fate suicide gene programming. As a potential alternative, various pharmacological interventions can be utilized to achieve some degree of dedifferentiation. As an example, calcineurin inhibition during cell culture through the use of the immunosuppressant cyclosporine resulted in molecular changes that replaced the need for gene delivery of the Sox2 transcription factor for the promotion of mouse iPS cells. In addition, rapamycin, an immunosuppressant that inhibits the mammalian target of rapamycin (mTOR), can have a dedifferentiating effect on end-stage effector T cells via starvation-induced upregulation of the transcription factor KLF2, which increases the T-center memory molecules CD62L and CCR7. In addition, rapamycin and the resulting inhibition of mTOR signaling are important for the maintenance of cell quiescence in naive T cells with reduced differentiation status. It is important to note that the mTOR pathway consists of both the mTORC1 complex (containing the Raptor subunit) and the mTORC2 complex (containing the Rictor subunit). Inhibition of both mTORC1 and mTORC2 is associated with increased promotion and maintenance of memory T cells. Of note, rapamycin can directly inhibit only mTORC1, but with prolonged rapamycin-mediated inhibition of mTORC1, downstream inhibition of mTORC2 may occur. Reduction of T cell growth factor signaling via mTOR inhibition or inhibition of other pathways is also known to upregulate another key molecule associated with a more primitive differentiation state of T cells, namely, IL-7 receptor alpha (CD127). In further studies, inhibition of the mTOR pathway in T cells via the pharmacological agent rapamycin or the Wnt-β-catenin signaling activator TWS11 promoted dedifferentiation of human naive T cells toward a less differentiated T stem cell memory population, previously identified and characterized in mouse and human T cells.In further experimental model studies, pharmacological inhibition of the AKT signaling pathway, or combined inhibition of the PI3 kinase and vasoactive intestinal peptide signaling pathways, upon adoptive transfer, led to the generation of T cells with a reduced differentiation state and increased T cell function.
[0006] Blockade of mTOR via ex vivo culture of human T cells in rapamycin has been demonstrated to reduce T cell expression of molecules associated with effector differentiation, such as cytokine secretion and cytolytic effector molecules.
[0007] In addition, the 1,25-hydroxylated form of vitamin D (as used herein, "vitamin D") can inhibit human T cell effector function. The inhibitory effect of vitamin D on human T cell proliferation can be synergistic with immunosuppressive drug exposure, using agents such as cyclosporine A or rapamycin. However, previous studies have shown that the inhibitory effect of vitamin D on T cell effectors is relatively specific for Th1-type molecules rather than Th2-type molecules. Furthermore, vitamin D inhibits the immunosuppressive regulatory T (T REG ) cell populations.
[0008] In somewhat contradictory findings, human CD8 + It was determined that T cells expressed high levels of vitamin D receptors, and individuals with the highest values tended to have high levels of T cell effector function and immunosenescence.
[0009] More recent studies have used mouse models of Mycobacterium tuberculosis infection to demonstrate that vitamin D is important for macrophage elimination of intracellular pathogens through mechanisms involving IFN-γ production and autophagy. In addition, in human non-small cell carcinoma cell lines, vitamin D signaling can promote a cytotoxic form of autophagy that contributes to antitumor effects when combined with radiation. Finally, vitamin D receptor signaling promotes autophagy in normal human breast tissue. Such loss of vitamin D receptor signaling was associated with an increased risk of developing breast cancer. Despite this evidence linking vitamin D to autophagy in innate immunity (in the context of macrophages), data are scarce regarding the effect of vitamin D on autophagy in T cells during adaptive immunity, and whether the potential effects of vitamin D and rapamycin on T cell autophagy are redundant in this context.
[0010] These somewhat contradictory results regarding the potential role of vitamin D in T cell biology are likely related to the recently discovered broad genome-wide effects of vitamin D, both at the mRNA and microRNA levels. Therefore, the effects of vitamin D on immunity need to be evaluated in a context-dependent framework.
[0011] To maintain immune tolerance, regulatory T (T REG ) cells are essential. REG A decrease in cell quantity or quality is the underlying cause of many primary autoimmune diseases, including type 1 diabetes mellitus (T1DM), multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus, to name a few. REG Deficiency is associated with an acceleration in the natural history of primary neurodegenerative diseases. REG Deficiency is associated with severe complications in solid organ and hematopoietic cell transplant settings, most notably increased rates of graft rejection and graft-versus-host disease (GVHD). REGGiven this important role of T cells, therapies for the treatment of diseases REG Many experimental approaches have been developed to promote T REG Adoptive transfer of cells, which exist in two major subtypes: (1) nT cells that become committed with age and are therefore available for adoptive transfer. REG Thymus-derived natural (n)T cells, which reduce the number of REG cells (“nT REG " or "Natural T REG "), and (2) inducible (i)T cells that are converted in the periphery from a larger pool of effector T cells. REG cell. nT REG Because cells are limited in number, nT REG Attempts to use cells in adoptive T cell therapy have included the nT REG It relies on ex vivo production methods for cell isolation and subsequent expansion. REG Clinical trials of iT cells are in the early stages of implementation, primarily in Phase I / II clinical trials for the prevention of GVHD and treatment of T1DM. REG Cells (T REG and T REG Ex vivo generated T including Th2 cells REG Other challenges exist with respect to the potential use of iT cells in adoptive cell therapy: (1) although peripheral effector T cells are relatively abundant, they exist primarily in an effector memory mature state with limited replicative and therapeutic potential, and (2) such peripheral effector T cells have a high degree of pre-existing effector differentiation toward T cell subsets that contribute to disease pathogenesis, i.e., Th1 and Th17 subsets. Thus, iT REG For cell therapy to become highly feasible, the following must be achieved: (1) Increased proliferation potential and T REG (1) causing dedifferentiation of effector T cells into a less differentiated memory phenotype, with demonstrable improvement in cell therapy potential; and (2) REGIt will be necessary to develop ex vivo production methods that include both promoting T cell differentiation towards a phenotype while eradicating pathogenic Th1- and Th17-type pathways.
[0012] IT REG The production of cells begins with the collection of lymphocyte-containing peripheral blood mononuclear cells from the subject to be treated (in the case of autologous therapy) or from a normal donor (in the case of allogeneic gene therapy). Typically, this collection is performed at steady state, i.e., without administration of any growth factors. However, in the allogeneic context, collection may also be performed in the context of administration of molecules such as granulocyte colony-stimulating factor (G-CSF) or plerixafor, as described in DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720-5726. In this disclosure, the inventors propose that anti-TNF-α therapeutics are effective in inhibiting T REG iT to enrich for phenotypic input T cells REG We describe that etanercept can be administered prior to collection of lymphocytes for production. That is, we demonstrate that the anti-TNF-α agent etanercept, a recombinant receptor that preferentially inhibits serum-free, cell-free TNF-α while relatively preserving cell surface membrane-bound TNF-α, induces profound changes in the T cell receptor (TCR) repertoire as measured by RNA sequencing. Membrane-bound TNF-α mediates T cell proliferation via the TNFR2 receptor. REG To provide a positive signal to cells, our method uses iT REG Before cell production REGOther therapeutic agents that preferentially inhibit serum-free, cell-free TNF-α, including but not limited to the anti-TNF-α monoclonal antibody, adalimumab, can also be used for this intervention, providing a robust intervention to enrich for cells.
[0013] Amyotrophic lateral sclerosis (ALS) is a primary neurodegenerative disease involving the cerebral cortex, brainstem, and spinal cord that results in progressive disability and typically results in death due to respiratory failure. ALS is a familial disease in 10% of patients resulting from various genetic events, while the remaining patients have sporadic ALS, with no known etiology but which may involve environmental factors. The most recent registry data (2013) indicate that the prevalence of ALS in the United States was approximately 16,000 cases, and these data also indicate that ALS disproportionately affects white people, males, and individuals in the 60-69 age group. Military veterans, and potentially professional American football players, appear to be at increased risk for developing ALS, thereby suggesting that chemical exposure or traumatic brain injury may increase the risk of developing the disease. ALS is a heterogeneous disease with a variety of clinical presentations and rates of progression. The average survival time for ALS patients is 2-4 years from diagnosis, but survival can be as short as a few months or exceed 10 years. It is difficult to estimate prognosis in ALS patients because disease score systems such as the patient-reported ALSFRS-R score (ALS Functional Rating Scale, Revised) do not take into account linear and nonlinear aspects of disease progression. This difficulty in estimating disease progression rate represents a limitation of clinical trials in ALS and indicates that potential disease biomarkers, including immunological monitoring, developed by the inventors, should be emphasized as components of protocol therapy. Clinical onset of ALS is insidious, with most patients presenting with upper or lower limb weakness, or difficulty speaking or swallowing (bulbar onset). ALS remains a diagnosis of exclusion because no confirmatory blood, spinal fluid, or radiological tests have been performed. As a result, ALS is usually a diagnosis of exclusion, after other diseases have been ruled out. This process of excluding other diseases can typically take up to a year, thereby delaying the occurrence of therapeutic attempts and clinical trials. This delay in referral is likely a natural course of events, since up to 50% of motor neurons may no longer function at the time ALS is ultimately diagnosed.Given this situation, it is usually recommended that ALS patients be included in clinical trials relatively early after diagnosis.
[0014] ALS is a primary neurodegenerative disease, with neuroinflammation acting as a secondary growth factor. Evidence for this conclusion derives in part from the observation that functional abnormalities of TAR DNA-binding protein 43 (TDP-43) occur in the majority of familial and sporadic ALS patients. TDP-43 is an RNA- and DNA-binding protein that is restricted to the nucleus and prone to aggregation in healthy conditions, thereby occupying the cytoplasmic inclusions found in neurons of ALS patients. The exact mechanisms that lead to alterations in the TDP-43 pathway have yet to be fully elucidated, but appear to involve various cellular stress events, or the amplification of genetic elements that replicate themselves via RNA intermediates (retrotransplantable elements, RTEs). Ultimately, such events lead to pleiotropic programmed cell death in neurons, including programmed necrosis. Notably, the necrotic cell death pattern that occurs in ALS patients has been shown to be particularly immunogenic compared to the more orderly apoptotic cell death. Indeed, TNF-α, a known molecular mediator of motor neuron death in ALS, can produce a necrotic form of cell death. Necrotic cell death can result in the release of autoantigens that can be presented to the adaptive immune system for autoimmunity induction. In addition, protein aggregates occurring in ALS patients (including but not limited to TDP-43, SOD-1, p62) may be targets for autoimmune responses that emanate after neurodegeneration, since protein aggregates themselves can be immunogenic. Indeed, it has recently been shown that monocytes from ALS patients develop a proinflammatory phenotype when pulsed with exosomes containing TDP-43.
[0015] There is extensive evidence that in response to primary neurodegeneration, the innate inflammasome and adaptive peripheral immune systems combine to further derail ALS disease progression. In a superoxide dismutase-1 (SOD1) transgenic mouse model of ALS, spinal cord CD3 +T cell infiltration and microglial cell activation were recognized as pro-inflammatory factors that contribute to disease progression. Moreover, transplantation of wild-type microglial cells, which have reduced inflammatory tendencies compared to host microglial cells in the PU.1 knockout mouse model of ALS, reduced neurodegeneration and improved survival. In addition, for the first time in the SOD1 mouse model of ALS, CD4 + A protective role for T cells was described, thereby illustrating the double-edged sword-like nature of the peripheral immune T cell pool in ALS (acting either as a growth factor or a protective factor). In ALS patients, direct evidence of a detrimental role of peripheral adaptive immune system T cells could be confirmed by demonstrating that T cells infiltrating the spinal cord express an oligoclonal T cell receptor (TCR) repertoire. Moreover, professional antigen-presenting cells (dendritic cells) emanating from the peripheral immune system could be isolated within ALS patient spinal cord tissue in close association with inflammatory peripherally derived monocytes and resident CNS microglial cells. Moreover, in ALS patients, purified monocytes express a pro-inflammatory RNA expression profile, including an increase in the innate inflammatory molecule IL-1-β, followed by CD4 + T-helper-1 (Th1), CD8 + T cytotoxicity-1 (Tc1), and CD4 + Subsequent studies have demonstrated that SOD1-dependent transcription factors mediate the protective CD4+ / CD5+ signaling pathway in the ALS mouse model. + The phenotype of T cell subsets is regulatory T (T ), which reduces inflammation through a mechanism mediated in part through the anti-regulatory Th2-type cytokines IL-4 and IL-10. REG ) cell population.
[0016] This biology posits that microglial cells are key cellular components in the brain that drive neurodegeneration, and that microglial cells and CNS-infiltrating peripheral CD4 + Consistent with abundant data from neuroinflammation studies showing that T cells interact and influence disease pathogenesis, consistent with mouse modeling results, FoxP3 + T REGPatients with peripheral immune systems enriched for Th1 and Th2-type T cells had a slower rate of ALS progression compared with patients with a predominantly pro-inflammatory Th1-type immune profile. REG It has recently been discovered that cells are dysfunctional and that such dysfunction correlates with the rate and severity of disease progression. Current clinical trials are investigating the use of nT REG The use of multiple infusions of cells plus low-dose IL-2 is being evaluated (ClinicalTrials.gov; NCT03241784); IL-2 is a cytokine that stimulates the STAT5 signaling pathway, thereby increasing nT REG The in vivo proliferation of cells can be promoted.
[0017] Induced (i)T REG Cells are nT REG They are not derived from the thymus like the iT REG nT are a population that is converted from other pathogenic post-thymic T cell subsets such as Th1 cells. REG and iT REG Although both play important and nonredundant roles in suppressing inflammatory responses, iT REG The development of therapeutics is relatively advantageous in terms of the potency and ease of production of regulatory T cells. Furthermore, adoptive iT REG The therapy is particularly effective when combined with immune monitoring techniques and host treatment regimens (pentostatin, cyclophosphamide, lamivudine) that we describe in this disclosure.
[0018] Riluzole (Rilutek®), the first drug approved for ALS treatment in 1995, is only modestly effective in reducing ALS morbidity and mortality. Despite significant clinical research with over 60 molecules investigated for ALS therapy, only two additional molecules, the antioxidant edaravone and the tyrosine kinase inhibitor masitinib, have shown modest clinical success. Recently, edaravone (Radicava®), approved by the FDA for the treatment of ALS, offers minimal clinical benefit, is expensive, requires daily continuous infusion therapy 2 weeks on, 2 weeks off, and masitinib is not FDA approved. A phase II trial of rapamycin for the treatment of ALS is currently being initiated (ClinicalTrials.gov Identifier: NCT03359538). Rapamycin has also been shown to be effective in reducing the incidence of T REG Due to its propensity to promote cellular remodeling, it may be a preferred agent for use in ALS. However, chronic therapy with rapamycin has substantial toxicity, requires pharmacological monitoring, may have contradictory effects in that it actually exacerbates ALS in some models, and may limit the expansion of adoptively transferred T cell populations.
[0019] Therefore, given the current state of affairs with very limited therapeutic options, there is a great need to evaluate novel strategies for the treatment of ALS. In this application, we present a novel method for the treatment of ALS using inducible (i) regulated T (T REG ) We describe a novel therapeutic approach for ALS centered on cell therapy. Summary of the Invention
[0020] The present disclosure provides methods for dedifferentiating T cells and inhibiting the T REG or T REG The present invention is directed to a method for differentiation into Th2 cells.
[0021] In some embodiments, the initial dedifferentiation method can involve initiating the culture with an input cell population harvested at steady state (without drug administration).
[0022] In some embodiments, the method involves initiating a dedifferentiated culture with an input cell population taken from the subject (in an autologous context) or a normal donor (in an allogeneic context) that has been or is being treated with an anti-TNF-α therapeutic that is preferentially selective for inhibition of serum-free, cell-free forms of TNF-α, with relative preservation of membrane-bound TNF-α. Such therapeutics include, but are not limited to, the recombinant receptor etanercept, which can be administered at conventional doses of 25-50 mg per week by subcutaneous injection, or the monoclonal antibody adalimumab, which can be administered at conventional doses of 40 mg per week or 40 mg every other week by intravenous injection. In all of these cases, the dosage of the anti-TNF-α therapeutic can be adjusted according to the desired biomarker changes, which may include, but are not limited to, changes in the TCR repertoire by RNA sequencing analysis, as well as a shift toward TNF receptor type 2 (TNFR2) and away from TNF receptor type 1 (TNFR1) as measured by flow cytometry.
[0023] In some embodiments, the method includes seeding a culture input population of cells comprising T cells from a subject at a cell density in a culture medium containing vitamin D, temsirolimus, and an IL-2 signaling inhibitor, adding anti-CD3 / anti-CD28 coated magnetic beads to the T cells and culture medium at a bead:T cell ratio of 1:1 or less to stimulate the T cells, or in the most extreme case, adding no anti-CD3 / anti-CD28 costimulation, and incubating the culture input population and culture medium for a period of time to obtain dedifferentiated T cells. It is also possible to perform this dedifferentiation procedure in the absence of any bead costimulation.
[0024] In any of the above embodiments, the method may further comprise harvesting said dedifferentiated T cells.
[0025] In any of the above embodiments, the method may further include, after harvesting the dedifferentiated T cells, packaging at least a portion of the dedifferentiated T cells into a package and freezing the package containing the portion of the dedifferentiated T cells.
[0026] In any of the above embodiments, the method may further include harvesting said culture input population of cells from said subject prior to seeding said culture input population of cells into said culture medium.
[0027] In any of the above embodiments, the method may further comprise measuring the expression level of RAPTOR or RICTOR in said culture input population of cells, wherein said period of time continues until the expression level of RAPTOR or RICTOR, respectively, in said culture input population of cells is reduced by at least 50%, more preferably 90%, compared to a control population of T cells, said control population of T cells being produced under the same conditions as the culture input population of cells without temsirolimus, an IL-2 signaling inhibitor, and vitamin D.
[0028] In any of the above embodiments, the method may further comprise measuring expression levels of RAPTOR or RICTOR and a housekeeping protein in the culture input population of cells, wherein the above period continues until the housekeeping protein-normalized expression level of RAPTOR or RICTOR in the produced T cells is reduced by at least 50%, more preferably 90%, below the housekeeping protein-normalized expression level of RAPTOR or RICTOR, respectively, in a control population of T cells produced under the same conditions as the culture input population of cells without temsirolimus, an IL-2 signaling inhibitor, and vitamin D.
[0029] The present disclosure is also directed to de-differentiated T cells produced by the method of any of the above embodiments.
[0030] The present disclosure is also directed to a composition comprising a population of de-differentiated cells, at least a portion of which expresses at least 50%, more preferably 90%, less RAPTOR or RICTOR compared to a control population of T cells produced under the same conditions as the culture input population of cells without temsirolimus, an IL-2 signaling inhibitor, and vitamin D.
[0031] In any of the above embodiments, the method may further comprise measuring at least a portion of said population of said de-differentiated cells, whereby they express at least a 10%, more preferably a 50% change in RNA expression of the following molecules, compared to a control population of T cells: a reduction in T cell effector molecules, including but not limited to granzyme B, IL-10, and IFN-γ; an increase in transcription factors associated with less differentiated cells, including but not limited to Nanog, KLF4, and KLF10; an increase in expression of molecules preferentially expressed on naive T cell subsets, including but not limited to CD127, the IL-7 receptor alpha chain; a reduction in transcription factors associated with TH1 type differentiation, including but not limited to T-BET and STAT1; and a relative preservation of transcription factors that promote cell survival, including but not limited to HIF-1α.
[0032] In any of the above embodiments, the method may further comprise measuring at least a portion of the above population of dedifferentiated cells, whereby they express at least a 10%, more preferably 50% change in expression of a molecule indicative of a cell undergoing autophagy. As an example, the dedifferentiated cells have an increased expression of p62 by Western blot analysis compared to control T cells. Other methods of measuring autophagy may also be applied, such as the method described in Yoshii SR.Mizushima N.Monitoring and Measuring Autophagy.International Journal of Molecular Sciences.2017;18(9):1865.
[0033] The present disclosure is also directed to de-differentiated T cells produced by the method of any of the above embodiments.
[0034] The present disclosure is also directed to compositions comprising a population of de-differentiated cells, at least a portion of which express at least a 10%, more preferably a 50% change in RNA expression of the following molecules compared to a control population of T cells: reduced T cell effector molecules, including but not limited to, granzyme B, IL-10, and IFN-γ; increased transcription factors associated with less differentiated cells, including but not limited to, Nanog, KLF4, and KLF10; increased expression of molecules preferentially expressed on naive T cell subsets, including but not limited to, CD127, the IL-7 receptor alpha chain; reduced transcription factors associated with TH1 type differentiation, including but not limited to, T-BET and STAT1; and relative preservation of transcription factors that promote cell survival, including but not limited to, HIF-1α.
[0035] The present disclosure is also directed to a composition comprising a population of dedifferentiated cells defined by the above dedifferentiated cells, which express at least a 10%, more preferably a 50%, change in expression of molecules indicative of cells undergoing autophagy. As an example, the above dedifferentiated cells have an increased expression of p62 by Western blot analysis compared to control T cells. Other methods of measuring autophagy can also be applied, such as the method described in Yoshii SR, Mizushima N. Monitoring and Measuring Autophagy. International Journal of Molecular Sciences. 2017; 18(9): 1865.
[0036] The present disclosure is also directed to a composition comprising a population of de-differentiated cells, at least a portion of said population of de-differentiated cells expressing less than 50% of both RAPTOR and RICTOR compared to a control population of T cells.
[0037] The present disclosure relates to a method for the preparation of dedifferentiated T cells. REG or T REG The present invention relates to a method for differentiating into Th2 cells.
[0038] In some embodiments, the method includes culturing the dedifferentiated T cells of the present disclosure, or T cells dedifferentiated by other methods, in a culture medium containing IL-2, IL-4, and TGF-β, adding anti-CD3 / anti-CD28 coated magnetic beads at a ratio of 3:1 (beads:T cells ratio), and incubating the dedifferentiated T cells for a period of time to identify T cells. REG / Obtaining Th2 cells.
[0039] In some embodiments, the method includes culturing dedifferentiated T cells having at least a 50% reduction in expression of RAPTOR or RICTOR compared to a control population of T cells produced under the same conditions as a culture input population of cells without temsirolimus, an IL-2 signaling inhibitor, and vitamin D in a culture medium containing IL-2, IL-4, and TGF-β; adding anti-CD3 / anti-CD28 coated magnetic beads at a ratio of 3:1 (beads:T cells); and incubating the dedifferentiated T cells for a period of time to produce T cells. REG / Obtaining Th2 cells.
[0040] In some embodiments, the method includes culturing dedifferentiated T cells having at least 90% reduced expression of RAPTOR or RICTOR compared to a control population of T cells produced under the same conditions as a culture input population of cells without temsirolimus, an IL-2 signaling inhibitor, and vitamin D in a culture medium containing IL-2 and TGF-β; adding anti-CD3 / anti-CD28 coated magnetic beads at a ratio of 3:1 (beads:T cells); and incubating the dedifferentiated T cells for a period of time to produce T cells. REG and obtaining the cells.
[0041] In any of the above embodiments, the culture medium can further include pemetrexed.
[0042] The present disclosure also provides a T produced by any of the above methods. REG or T REG / Targeting Th2 cells.
[0043] The present disclosure is also directed to a method of treating amyotrophic lateral sclerosis in a subject in need thereof.
[0044] In some embodiments, the method includes subjecting the subject to one or more primary treatment cycles, each of which comprises administering pentostatin to the subject and / or administering cyclophosphamide to the subject, and administering a therapeutically effective amount of the manufactured T REG and subjecting the subject to one or more immunotherapy treatment cycles comprising administering a composition comprising the cells to the subject.
[0045] In some embodiments, the method comprises a first therapeutic cycle, a second therapeutic cycle, optionally one or more additional therapeutic cycles, and one or more immunotherapy treatment cycles, wherein said first therapeutic cycle comprises administering pentostatin to said subject and / or administering cyclophosphamide to said subject, said second therapeutic cycle comprises administering pentostatin to said subject and / or administering cyclophosphamide to said subject, and each of said one or more additional therapeutic cycles comprises administering pentostatin to said subject and / or administering cyclophosphamide to said subject, and each of said one or more immunotherapy treatment cycles comprises administering pentostatin to said subject and / or administering cyclophosphamide to said subject and administering a manufactured T REG and administering the cells to said subject.
[0046] In some embodiments, the method comprises administering to the subject a therapeutically effective amount of the manufactured T REG The method includes administering the cells to a patient in need of treatment, comprising administering one or more treatment cycles.
[0047] In some embodiments, the method comprises administering to the subject a therapeutically effective amount of the manufactured T REG This can include administering the cells to the subject. [Brief description of the drawings]
[0048] [Figure 1A] Normalized GAPDH mRNA expression in control cells and cells treated under various conditions is shown. [Figure 1B] Normalized granzyme B mRNA expression in control cells and cells treated under various conditions is shown. [Figure 1C] Normalized IL-10 mRNA expression in control cells and cells treated under various conditions is shown. [Figure 1D] Normalized IFN-γ mRNA expression in control cells and cells treated under various conditions is shown in Figures 1A-1D, which illustrate that the combination of vitamin D and temsirolimus reduces effector molecule expression in human CD4+ and CD8+ cells. [Figure 2A] Normalized NANOG mRNA expression in control cells and cells treated under various conditions is shown. [Figure 2B] Normalized KLF4 mRNA expression for control cells and cells treated under various conditions is shown. [Figure 2C] Normalized KLF10 mRNA expression for control cells and cells treated under various conditions is shown. [Figure 2D] 2A-D show normalized IL-7 receptor mRNA expression for control cells and cells treated under various conditions. Figures 2A-D illustrate that the combination of vitamin D and temsirolimus increases expression of stem cell-associated transcription factor and prototypical T cell molecule IL-7 receptor-α in human CD4+ and CD8+ T cells. [Figure 3A] Normalized T-BET mRNA expression in control cells and cells treated under various conditions is shown. [Figure 3B] Normalized STAT1 mRNA expression for control cells and cells treated under various conditions is shown. [Figure 3C] Normalized HIF-1-α mRNA expression for control cells and cells treated under various conditions is shown in Figures 3A-C, which show that the combination of vitamin D and temsirolimus reduces expression of a transcription factor associated with effector Th1 / Tc1 cells without reducing expression of the transcription factor associated with T cell survival, HIF-1-α. [Figure 4] Figure 2 shows p62 expression normalized by actin expression for cells treated under various conditions and shows that the combination of vitamin D, temsirolimus, and anti-IL-2 receptor blockade induces the expression of the autophagy-related molecule p62. [Diagram 5] 1 shows RAPTOR expression normalized by actin expression for cells treated under various conditions, and shows that the combination of vitamin D, temsirolimus, and anti-IL-2 receptor blockade reduces expression of the mTORC1 associated molecule RAPTOR. [Figure 6] Western blots of GAPDH, p70S6K, SGK1, Raptor, and Rictor expression for cells treated under various conditions are shown, demonstrating that a combination of vitamin D, temsirolimus, and anti-IL-2 receptor blockade reduces expression of the mTORC1-associated molecule Raptor, and the mTORC2-associated molecule Rictor. [Figure 7] Figure 8 shows BIM expression normalized by actin expression of cells treated under various conditions, illustrating that a combination of vitamin D, temsirolimus, and anti-IL-2 receptor blockade reduces expression of the pro-apoptotic molecule BIM. Figure 9 illustrates the effect of culture components on subsequent T cell yield during the dedifferentiation section (at day 13 of culture). [Figure 8]FIG. 1 illustrates the effect of culture components during the dedifferentiation section on subsequent T cell yield (at day 13 of culture). [Figure 9A] The percentage of CD4 cells that are CD45RA+ for cells treated under various conditions is shown. [Figure 9B] The percentage of CD4 cells that are CD62L+ and CCR7+ for cells treated under various conditions is shown. [Figure 9C] The percentage of CD4+ cells that are CD62L+, CCR7+, and CD127+ for cells treated under various conditions is shown. Figures 9A-9C illustrate the effect of culture components during the dedifferentiation section on CD4+ T cell expression of memory markers (at day 13 of culture). [Figure 10A] The percentage of CD8 cells that are CD62L+ and CCR7+ for cells treated under various conditions is shown. [Figure 10B] The percentage of CD8 cells that are CD62L+, CCR7+, and CD127+ for cells treated under various conditions is shown. Figures 10A and 10B illustrate the effect of culture components during the dedifferentiation section on CD8+ T cell expression of memory markers. [Figure 11A] Figures 11A-11D show inflammatory Th1 / Th17 cytokine analysis of dedifferentiated T cells cultured in polarizing neutral medium: Figure 11A: IFN-γ secretion for cells treated under various conditions. [Figure 11B] GM-CSF secretion is shown for cells treated under various conditions. [Figure 11C] TNF-α secretion is shown for cells treated under various conditions. [Figure 11D] IL-17 secretion is shown for cells treated under various conditions. [Figure 12A] Figures 12A-D show IL-2 and Th2-type cytokine analysis of dedifferentiated T cells cultured in polarizing neutral medium. Figure 12A: IL-2 secretion for cells treated under various conditions. [Figure 12B]IL-4 secretion is shown for cells treated under various conditions. [Figure 12C] IL-5 secretion is shown for cells treated under various conditions. [Figure 12D] IL-13 secretion is shown for cells treated under various conditions. [Figure 13] In hybrid Th2 / TREG polarizing conditions, there is a favorable expansion of dedifferentiated T cells compared to Th1 polarizing conditions. [Figure 14A] The percentage of CD4+CD45RA+ cells among total CD4+ cells for cells treated under various conditions is shown. [Figure 14B] The percentage of CD4+CD62L+CCR7+ cells out of total CD4+ cells for cells treated under various conditions is shown. [Figure 14C] Figures 14A-C show the percentage of CD4+CD62L+CCR7+CD127+ cells out of total CD4+ cells for cells treated under various conditions. Figures 14A-C illustrate that culture of dedifferentiated T cells in hybrid Th2 / TREG polarizing conditions results in the generation of naive and triple positive T central memory CD4+ T cells. [Figure 15A] The percentage of CD8+CD62L+CCR7+ cells out of total CD8 cells for cells treated under various conditions is shown. [Figure 15B] Figures 15A and 15B show the percentage of CD8+CD62L+CCR7+CD127+ cells among total CD8 cells for cells treated under various conditions. Figures 15A and 15B illustrate that culturing dedifferentiated T cells in hybrid Th2 / TREG polarizing conditions results in the generation of triple positive T central memory CD8+ T cells. [Figure 16A] IL-2 secretion is shown for cells treated under various conditions. [Figure 16B] IL-4 secretion is shown for cells treated under various conditions. [Figure 16C]IL-5 secretion for cells treated under various conditions. Figures 16A-C illustrate that culturing dedifferentiated T cells in hybrid Th2 / TREG polarizing conditions results in the generation of T cells with a typical Th2 cell cytokine phenotype: IL-2, IL-4, and IL-5 secretion. [Figure 17A] IL-10 secretion is shown for cells treated under various conditions. [Figure 17B] IL-13 secretion is shown for cells treated under various conditions. [Figure 17C] IL-17 secretion for cells treated under various conditions is shown. Figures 17A-C illustrate that culturing dedifferentiated T cells in hybrid Th2 / TREG polarizing conditions results in the generation of T cells with a typical Th2 cell cytokine phenotype: IL-10, IL-13, and IL-17 secretion. [Figure 18A] IFN-γ secretion is shown for cells treated under various conditions. [Figure 18B] TNF-α secretion is shown for cells treated under various conditions. [Figure 18C] Figures 18A-C show GM-CSF secretion for cells treated under various conditions. Figures 18A-C illustrate that culture of dedifferentiated T cells in hybrid Th2 / TREG polarizing conditions results in the generation of T cells with a typical Th2 cell cytokine phenotype: IFN-γ, TNF-α, and GM-CSF secretion. [Figure 19A] The percentage of CD4+ T cells in the cultures by day and by culture inhibitor is shown. [Figure 19B] The percentage of CD4+FOXP3+ T cells in cultures by day and by culture inhibitor is shown. [Figure 19C] The percentage of CD4+Tbet+ T cells in the cultures by day and by culture inhibitor is shown. [Figure 19D]The percentage of CD4+GATA3+ T cells in culture by day and by culture inhibitor is shown. Figures 19A-19D illustrate that expanded culture of dedifferentiated T cells in hybrid Th2 / TREG polarizing conditions containing pemetrexed results in the generation of CD4+ T cells expressing FOXP3 and GATA3 transcription factors. [Figure 20A] The percentage of CD8+ T cells in the cultures by day and by culture inhibitor is shown. [Figure 20B] The percentage of CD8+FOXP3+ T cells in cultures by day and by culture inhibitor is shown. [Figure 20C] The percentage of CD8+Tbet+ T cells in the cultures per day and per culture inhibitor is shown. [Figure 20D] The percentage of CD8+GATA3+ T cells in cultures by day and by culture inhibitor is shown. Figures 20A-20D illustrate that expanded culture of dedifferentiated T cells in hybrid Th2 / TREG polarizing conditions containing pemetrexed results in the generation of CD8+ T cells expressing FOXP3 and GATA3 transcription factors. [Figure 21A] IL-4 secretion is shown for cells in culture by day and by culture inhibitor. [Figure 21B] IL-5 secretion is shown for cells in culture by day and by culture inhibitor. [Figure 21C] IL-13 secretion is shown for cells in culture by day and by culture inhibitor. Figures 21A-C illustrate that extended culture of dedifferentiated T cells in hybrid Th2 / TREG polarizing conditions results in the generation of T cells expressing a predominant Th2 cytokine phenotype: IL-4, IL-5, and IL-13 secretion. [Figure 22A] IL-2 secretion is shown for cells in culture by day and by culture inhibitor. [Figure 22B] IFN-γ secretion is shown for cells in culture by day and by culture inhibitor. [Figure 22C]GM-CSF secretion is shown for cells in culture by day and by culture inhibitor. Figures 22A-C illustrate that expanded culture of dedifferentiated T cells in hybrid Th2 / TREG polarizing conditions results in the generation of T cells expressing a predominant Th2 cytokine phenotype: IL-2, IFN-γ, and GM-CSF secretion. [Figure 23A] We illustrate that anti-TNF-α etanercept therapy results in significant changes in the TCR repertoire as measured by RNA sequencing, thereby representing a new approach for targeted treatment prior to lymphocyte collection by apheresis. [Figure 23B] We illustrate that anti-TNF-α etanercept therapy results in significant changes in the TCR repertoire as measured by RNA sequencing, thereby representing a new approach for targeted treatment prior to lymphocyte collection by apheresis. [Figure 24-1] We illustrate that expanded culture of dedifferentiated T cells in hybrid Th2 / TREG polarizing conditions results in the generation of T cells expressing increased levels of the following molecules: CD25, CD27, 2B4, BTLA, and CTLA compared to control Th1 / Tc1 cells. [Figure 24-2] (Continuation of Figure 24-1) [Figure 25-1] We illustrate that expanded culture of dedifferentiated T cells in hybrid Th2 / TREG polarizing conditions results in the generation of T cells expressing increased levels of the following molecules: TIGIT, TIM3, ICOS, LAIR1, and OX40 compared to control Th1 / Tc1 cells. [Figure 25-2] (Continuation of Figure 25-1) [Figure 26A-1] 1 shows FOXP3 expression in CD4+ and CD8+ T cells at the initiation and post-culture as measured by flow cytometry. [Figure 26A-2] (Continuation of Figure 26A-1) [Figure 26B-1]GATA3 expression in CD4+ and CD8+ T cells at the initiation and post-culture as measured by flow cytometry. [Figure 26B-2] (Continuation of Figure 26B-1) [Figure 27A-1] Shown is CD73 expression in CD4+ and CD8+ T cells at the initiation and post-culture as measured by flow cytometry. [Figure 27A-2] (Continuation of Figure 27A-1) [Figure 27B-1] CD103 expression in CD4+ and CD8+ T cells at the initiation and post-culture as measured by flow cytometry is shown. [Figure 27B-2] (Continuation of Figure 27B-1) [Figure 28A] 1 shows CD150 frequencies measured by flow cytometry in CD4+ and CD8+ T cells at the initiation of culture, after culture, and in control T cells not exposed to mTOR inhibitors. [Figure 28B] Shown is CD27 vs. CD95 expression for CD4+ T cells at the initiation and after culture as measured by flow cytometry. [Figure 29-1] IL-4, IL-2, IFN-γ, TNF-α, IL-17, and GM-CSF for the differently cultured and control cells are shown. [Figure 29-2] (Continuation of Figure 29-1) [Figure 29-3] (Continuation of Figure 29-1) [Figure 30A-1] Cytokine content for transwell assay of Th1 / Tc1 cells with or without RAPA-501 cells is shown. [Figure 30A-2] (Continuation of Figure 30A-1) [Figure 30B-1] 1 shows flow cytometry results of CD4 and PD1 assays in Example 24. [Figure 30B-2] (Continuation of Figure 30B-1) [Figure 31A]IL-6, IP-10, and IFN-γ secretion for human microglial cells with or without exposure to RAPA-501 cells is shown. [Figure 31B] IL-6, IP-10, and IFN-γ secretion for human microglial cells with or without exposure to RAPA-501 cells is shown. [Diagram 32] The PC regimen and overall therapeutic approach are outlined. [Diagram 33] FIG. 1 shows a schematic of lymphocyte collection according to pre-PC and post-PC regimens. [Diagram 34] Schematic depiction of the PC regimen prior to each repeated dose of iTREG cells. [Diagram 35] Schematic showing monitoring of patients treated with iTREG cells. [Figure 36A] We show that anti-TNF-α etanercept therapy leads to significant changes in the TCR repertoire as measured by RNA sequencing, thereby representing a new approach for targeted treatment prior to lymphocyte collection by apheresis. [Figure 36B] We show that anti-TNF-α etanercept therapy leads to significant changes in the TCR repertoire as measured by RNA sequencing, thereby representing a new approach for targeted treatment prior to lymphocyte collection by apheresis. [Figure 37-1] We illustrate that expanded culture of dedifferentiated T cells in hybrid Th2 / TREG polarizing conditions results in the generation of T cells expressing increased levels of the following molecules: CD25, CD27, 2B4, BTLA, and CTLA compared to control Th1 / Tc1 cells. [Figure 37-2] (Continuation of Figure 37-1) [Figure 38-1] We illustrate that expanded culture of dedifferentiated T cells in hybrid Th2 / TREG polarizing conditions results in the generation of T cells expressing increased levels of the following molecules: TIGIT, TIM3, ICOS, LAIR1, and OX40 compared to control Th1 / Tc1 cells. [Figure 38-2] (Continuation of Figure 38-1) [Figure 39] An alternative protocol design is presented. [Figure 40A] Shown are RAPA-501 GATA3 and FOXP3 measured by flow cytometry on CD4+ cells. [Figure 40B] Shown are RAPA-501 GATA3 and FOXP3 measured by flow cytometry on CD8+ cells. [Figure 41-1] 1 shows an exemplary workflow of the dedifferentiation method of the present disclosure. [Figure 41-2] (Continuation of Figure 41-1) [Figure 41-3] (Continuation of Figure 41-1) [Diagram 42] 1 shows a putative mechanism of action of the hybrid TREG / Th2 cells of the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0049] The present disclosure relates to methods for T cell dedifferentiation and the resulting cells, the generation of human hybrid regulatory T / Th2 cells (hybrid T REG / Th2 cells), and inducible regulatory T (iT REG The present invention provides a method for treating ALS using the .
[0050] definition As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0051] The use of the term "or" in the claims and this disclosure is used to mean "and / or," unless expressly stated to refer to alternatives only or where the alternatives are mutually exclusive.
[0052] Use of the term "about" when used in conjunction with a numerical value is intended to include + / - 10%. For example, if a number of amino acids is specified as about 200, this includes 180 to 220 (plus or minus 10%).
[0053] The terms "patient," "individual," and "subject" are used interchangeably herein and refer to the mammalian subject being treated, with human patients being preferred. In some cases, the methods of the present invention find use in laboratory animals, veterinary applications, and in the development of animal models for disease, including, but not limited to, rodents, including mice, rats, and hamsters, and primates.
[0054] "Sample" is used herein in its broadest sense. Samples containing cells, polynucleotides, polypeptides, peptides, antibodies, etc. may include body fluids, soluble fractions of cell preparations, or media in which cells have been grown; chromosomes, organelles, or membranes isolated or extracted from cells; genomic DNA, RNA, or cDNA, polypeptides, or peptides in solution or bound to a matrix; cells, tissues, tissue prints, fingerprints, skin, or hair, etc.
[0055] "Treatment" is an intervention intended to prevent or modify the onset of pathology or symptoms of a disorder. Thus, "treatment" can refer to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those who already suffer from a disorder and those whose disorder should be prevented. In tumor (e.g., cancer) treatment, a therapeutic agent can directly reduce the pathology of tumor cells or further sensitize tumor cells to treatment with other therapeutic agents, such as radiation and / or chemotherapy.
[0056] As used herein, a "treatment cycle" can generally refer to either a primary treatment cycle, a first treatment cycle, a second treatment cycle, or one or more additional treatment cycles.
[0057] "Immune cell" as used herein is meant to include any cell of the immune system that may be assayed, including, but not limited to, B lymphocytes, also known as B cells, T lymphocytes, also known as T cells, natural killer (NK) cells, natural killer T (NKT) cells, lymphokine-activated killer (LAK) cells, monocytes, macrophages, neutrophils, granulocytes, mast cells, platelets, Langerhans cells, stem cells, dendritic cells, peripheral blood mononuclear cells, tumor infiltrating (TIL) cells, genetically modified immune cells including hybridomas, drug-modified immune cells, as well as derivatives, precursors or progenitors of the above cell types.
[0058] "T cells" or "T lymphocytes" are a subset of lymphocytes that originate from the thymus and have heterodimeric receptors associated with proteins of the CD3 complex (e.g., rearranged T cell receptor, a heterodimeric protein on the T cell surface that is responsible for the antigen / MHC specificity of the cell). T cell responses can be detected by assays for their effects on other cells (e.g., target cell killing, activation of other immune cells such as B cells), or for the cytokines they produce.
[0059] As used herein, the term "dedifferentiated T cells" refers to T cells that have been dedifferentiated by any of the methods of the present disclosure. In certain embodiments, the dedifferentiated T cells have reduced expression of RAPTOR or RICTOR compared to a control population of T cells produced under the same conditions without temsirolimus, IL-2 signaling inhibitors, and vitamin D. "Dedifferentiated T cells" do not include T cells collected from a patient, i.e., naturally occurring T cells.
[0060] As used herein, the term "anti-CD3 / anti-CD28" should be understood to refer to anti-CD3 / anti-CD28 antibodies. For example, "anti-CD3 / anti-CD28 magnetic beads" should be understood to refer to magnetic beads having anti-CD3 / anti-CD28 antibody moieties associated therewith. In cases disclosed in which anti-CD3 / anti-CD28 costimulation is not provided, it should be understood that even with a particular form such as anti-CD3 / anti-CD28 magnetic beads, this can also exclude costimulation with other forms of anti-CD3 / anti-CD28.
[0061] In the present disclosure where costimulation with anti-CD3 / anti-CD28 antibodies is performed, it should also be understood that this costimulation may be provided with any form of anti-CD3 / anti-CD28 antibodies. As an example and not by way of limitation, where costimulation is indicated to be performed by using anti-CD3 / anti-CD28 beads, anti-CD3 / anti-CD28 nanoparticles or microparticles can be used. In cases disclosed where anti-CD3 / anti-CD28 costimulation is not provided, it should be understood that even with a particular form such as anti-CD3 / anti-CD28 magnetic beads, this can also exclude costimulation with other forms of anti-CD3 / anti-CD28.
[0062] As used herein, the terms "human hybrid TREG / Th2 cells", "iTREG", and "TREG / Th2 cells" refer to cells differentiated by the methods of the present disclosure, unless otherwise specified. The "human hybrid TREG / Th2 cells", "iTREG", and "TREG / Th2 cells" of the present disclosure do not include T cells collected from a patient, i.e., naturally occurring T cells.
[0063] As used herein, the term "manufactured TREG cells" refers to cells produced by the dedifferentiation and redifferentiation methods of the present disclosure, and unless otherwise specified, may be understood to include TREG cells and human hybrid TREG / Th2 cells.
[0064] As used herein, "control Th1 / Tc1 cells," unless otherwise stated, refer to cells that were not treated with vitamin D, temsirolimus, or IL-2 signaling inhibitors, but rather were co-stimulated with anti-CD3 / anti-CD28 magnetic coated beads at a ratio of 3:1 (beads:T cells) in medium supplemented with 20 IU / mL IL-2 and 20,000 IU / mL IFN-α, and were otherwise cultured identically to the cells to which they are being compared. It should also be understood that when a control population of cells (or control T cells) is referred to as one treated without culture additives including temsirolimus, vitamin D and IL-2 signaling inhibitors, or in the context of de-differentiated cells, this population (or T cells) was additionally co-stimulated with anti-CD3 / anti-CD28 magnetic coated beads (beads:T cells) at a ratio of 3:1 in medium supplemented with 20 IU / mL IL-2 and 20,000 IU / mL IFN-α, and was otherwise cultured identically to the cells to which they are being compared, i.e., they are "control Th1 / Tc1 cells".
[0065] The present disclosure provides a new methodology for the ex vivo generation of reduced differentiation state T cells based on converting differentiated effector memory T cells into less differentiated central memory type T cells using novel pharmacological combinations and defined T cell costimulatory conditions.
[0066] As shown in Figure 41, dedifferentiated T cells of the present disclosure can have a quiescent phenotype with low or no expression of checkpoint inhibitor receptors (such as PD1, CTLA4, TIM3, and LAG3), memory markers (such as CD45RO), and fate molecules (such as TBET, RORy, FOXP3, and GATA3). Redifferentiated T cells can have a hybrid fate characterized by GATA3 and FOXP3 expression, and stem cell memory characterized by CD45RA and CD150 expression, and no checkpoint protein expression.
[0067] FIG. 42 shows a hybrid T REGA putative mechanism of action of Th2 / Th2 cells was presented, which is through inflammation via CD39 or CD73 receptors and through TNF-α to induce hybrid T REG / Th2 cells can be activated, which can enable the cells to regulate pathogenic T cells and prevent them from killing.
[0068] Methods for T cell dedifferentiation and resulting cells The inventors provide a new methodology for the ex vivo generation of T cells with reduced differentiation state, based on converting differentiated effector memory T cells into less differentiated central memory type T cells using novel pharmacological combinations and defined T cell costimulatory conditions.
[0069] In one embodiment, the method includes seeding a culture input population of cells comprising T cells from a subject at a cell density in a culture medium comprising vitamin D, temsirolimus, and an IL-2 signaling inhibitor, stimulating the T cells by adding anti-CD3 / anti-CD28 coated magnetic beads to the T cells and culture medium at a bead:T cell ratio of 1:1 or less or without adding any costimulatory beads, and incubating the culture input population and culture medium for a period of time to obtain dedifferentiated T cells. In some embodiments, the subject has been treated with an anti-TNF-α therapy prior to collection of the culture input population of cells. In some embodiments, the anti-TNF-α therapy is etanercept or adalimumab. In some embodiments, costimulation with anti-CD3 / anti-CD28 is not performed.
[0070] In any of the above embodiments, the culture medium may not contain IL-2 or may not be supplemented with IL-2.
[0071] In any of the above embodiments, the cell density may be about 1.5×106 T cells per mL to 18×106 T cells per mL. Examples include, but are not limited to, 6×106 T cells per mL to 18×106 T cells per mL, 12×106 T cells per mL to 18×106 T cells per mL, 1.5×106 T cells per mL to 12×106 T cells per mL, 1.5×106 T cells per mL to 6×106 T cells per mL, 6×106 T cells per mL to 12×106 T cells per mL, or 1.5×106 T cells per mL, 3×106 T cells per mL, 6×106 T cells per mL, 9×106 T cells per mL, 12×106 T cells, 15×106 T cells per mL, or 18×106 T cells per mL. It is anticipated that in some embodiments, it may be preferable to initiate cell cultures at higher densities, such as, by way of example and not limitation, 9×10 T cells per mL or 18×10 T cells per mL.
[0072] In any of the above embodiments, the temsirolimus may be present at a concentration of about 0.3 μM to about 10 μM. By way of example and not limitation, the temsirolimus may be present at a concentration of about 0.3 μM to about 1 μM, 0.3 μM to about 0.75 μM, 0.3 μM to about 0.5 μM, 0.5 μM to about 1 μM, 0.75 μM to about 1 μM, 0.5 μM to about 0.75 μM, 0.3 μM to about 10 μM, 0.3 μM to about 5 μM, 0.3 μM to about 3.3 μM, 1 μM to about 3.3 μM, 5 μM to about 10 μM, 3.3 The agonist can be present in the above culture medium at a concentration of about 0.3 μM to about 10 μM, 3.3 μM to about 5 μM, or, by way of example and not limitation, at a concentration of about 0.3 μM, 0.4 μM, 0.5 μM, 0.6 μM, 0.7 μM, 0.8 μM, 0.9 μM, or 1 μM, 2 μM, 3 μM, 3.3 μM, 4 μM, 5 μM, 6 μM, 7 μM, 8 μM, 9 μM, or 10 μM.
[0073] In any of the above embodiments, the IL-2 signaling inhibitor may be an anti-IL-2 receptor antibody or a fragment thereof. As a non-limiting example, the IL-2 signaling inhibitor may be basiliximab or daclizumab. As a non-limiting example, the IL-2 signaling inhibitor may be 5-50 μg / mL, 5-40 μg / mL, 5-30 μg / mL, 5-20 μg / mL, 5-10 μg / mL, 10-50 μg / mL, 20-50 μg / mL, 30-50 μg / mL, 40-50 μg / mL, 30-40 μg / mL, 20-40 μg / mL, 10-40 μg / mL, 5-40 μg / mL, 5-30 μg / mL, The antibody is present in the above culture medium at a concentration of, for example and without limitation, 5 μg / mL, 10 μg / mL, 15 μg / mL, 20 μg / mL, 25 μg / mL, 30 μg / mL, 35 μg / mL, 40 μg / mL, 45 μg / mL, or 50 μg / mL.
[0074] In any of the above embodiments, by way of example and not limitation, the above period may be about 1.5 days to about 5 days, 1.5 days to about 3.5 days, 1.5 days to about 2.5 days, 2.5 days to about 3.5 days, 2.5 days to about 5 days, 3.5 days to about 5 days, or about 1.5 days, 2 days, 2.5 days, 3 days, 3.5 days, 4 days, 4.5 days, or 5 days. In some embodiments, the levels of mTORC1 and mTORC2 reduction may be used as a guide to determine the optimal culture interval. In some embodiments, other molecular signatures of dedifferentiated cells may be used to determine the optimal culture interval, including but not limited to: RNA expression of T cell effector molecules (i.e., decreased IFN-γ), RNA expression of transcription factors (i.e., increased KLF4), evidence of an autophagy signature (i.e., increased p62), and upregulation of markers present on naive T cell subsets (i.e., increased CD127).
[0075] In any of the above embodiments, by way of example and not by way of limitation, the bead:T cell ratio may be 1:3 or no costimulation may be performed. By way of example and not by way of limitation, the bead:T cell ratio may be 1:1 to 1:12, 1:1 to 1:3, 1:3 to 1:12. By way of further example and not by way of limitation, the bead:T cell ratio may be 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, or 1:12. Finally, in the most extreme case, no anti-CD3 / anti-CD28 costimulation may be utilized, i.e., in some embodiments, no anti-CD3 / anti-CD28 costimulation is performed during the initial dedifferentiation process.
[0076] In any of the above embodiments, costimulation of the culture input population of cells may be achieved using anti-CD3 / anti-CD28-containing nanoparticles, which may be used at lower concentrations than those recommended. By way of example and not limitation, such nanoparticles may be used at about 0.01 to about 0.1 times, about 0.025 to about 0.1 times, about 0.05 to about 0.1 times, about 0.075 to about 0.1 times, about 0.01 to about 0.075 times, about 0.01 to about 0.05 times, about 0.01 to about 0.025 times, about 0.025 to about 0.075 times, about 0.025 to about 0.05 times, about 0.05 to about 0.075 times, or about 0.01 times, about 0.025 times, about 0.05 times, about 0.075 times, or about 0.01 times the recommended dose. By way of example, reagents such as Miltenyi® T Cell TransAct™ can be used at reduced doses compared to the recommended dose of 10 μL per 1×106 T cells, such as, but not limited to, 1.1 μL (a 9-fold reduction) or about 0.11-fold. Finally, in the most extreme cases, anti-CD3 / anti-CD28 costimulation cannot be utilized, i.e., in some embodiments, anti-CD3 / anti-CD28 costimulation is not performed during the initial dedifferentiation process.
[0077] Alternatively, when using anti-CD3 / anti-CD28 costimulation to generate manufactured T cells, the costimulatory source can be provided by soluble anti-CD3 / anti-CD28 microparticles. As an example and not by way of limitation, soluble anti-CD3 / anti-CD28 microparticles can be used at 20% of the strength recommended by the manufacturer (e.g., Cloudz®; Bio-Techne). As a further example, soluble anti-CD3-anti-CD28 microparticles can be used at 5%, 10%, 15%, 20%, 25%, or 30% of the strength recommended by the manufacturer.
[0078] In any of the above embodiments, anti-CD3 / anti-CD28 stimulation, if performed, can be performed using an amount of anti-CD3 / anti-CD28 sufficient to achieve the desired dedifferentiated cell characteristics.
[0079] In any of the above embodiments, the medium can further comprise 5% human serum. As an example and not by way of limitation, the culture medium can comprise at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% human serum, and any range therebetween, including values therebetween.
[0080] In any of the above embodiments, the medium can include X-Vivo 20 medium. Any suitable culture medium for culturing T cells can be used.
[0081] In any of the above embodiments, the vitamin D may be present at a concentration of, by way of example and not limitation, about 0.03 nM to about 1 nM, 0.03 nM to about 0.5 nM, 0.03 nM to about 0.1 nM, 0.03 nM to about 0.05 nM, 0.05 nM to about 0.1 nM, 0.05 nM to about 0.5 nM, 0.05 nM to 1 nM, 0.1 nM to about 1 nM, 0.1 nM to about 0.5 nM, or 0.5 nM to about 1 nM, or, by way of example and not limitation, the vitamin D may be present at a concentration of about 0.03 nM, 0.05 nM, 0.1 nM, 0.5 nM, or 1 nM.
[0082] In any of the above embodiments, the method may further comprise measuring expression levels of RAPTOR or RICTOR and a housekeeping protein in the culture input population of cells, the above period continuing until the expression levels of RAPTOR or RICTOR in the manufactured T cells are reduced by at least 50% compared to a control population of T cells, the control population of T cells being manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitors, and vitamin D. In some embodiments, the period continuing until the expression levels of RAPTOR or RICTOR in the manufactured T cells are reduced by 50% or more, respectively, compared to a control population of T cells manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitors, and vitamin D. By way of example, and not by way of limitation, the period continuing until the expression levels of RAPTOR or RICTOR are reduced by at least 50%, 60%, 70%, 80%, 90%, 95%, 99% or more, respectively, compared to a control population of T cells manufactured under the same conditions as the culture input population of cells without temsirolimus, IL-2 signaling inhibitors, and vitamin D.
[0083] In any of the above embodiments, the housekeeping protein may be actin. In some embodiments, the housekeeping protein may be GAPDH. In any of the above embodiments, measuring the expression level may be performed by Western blot analysis.
[0084] In any of the above embodiments, this period can continue until the expression levels of RAPTOR or RICTOR in the culture input population of cells described above are reduced by at least 50% compared to a control population of T cells produced under the same conditions as the culture input population of cells without temsirolimus, an IL-2 signaling inhibitor, and vitamin D. In some embodiments, the reduction in the expression levels of RAPTOR or RICTOR can be at least 50%, 60%, 70%, 80%, 90%, 95%, 99%, or more compared to the control population of T cells.
[0085] In any of the above embodiments, the initial period of de-differentiation culture can be continued until the RNA expression pattern differs by at least 10%, more optimally 50%, compared to control T cells cultured under the same conditions without temsirolimus, vitamin D, and IL-2 signaling inhibitors, i.e., reduction in T cell effector molecules, including but not limited to, granzyme B, IL-10, and IFN-γ; increase in transcription factors associated with cells in a reduced differentiated state, including but not limited to, Nanog, KLF4, and KLF10; increased expression of molecules preferentially expressed on naive T cell subsets, including but not limited to, CD127, the IL-7 receptor alpha chain; reduction in transcription factors associated with Th1-type differentiation, including but not limited to, T-BET and STAT1; and relative preservation of transcription factors that promote cell survival, including but not limited to, HIF-1α.
[0086] In any of the above embodiments, the initial dedifferentiated culture period can be continued until the RNA expression pattern is at least 10%, more optimally 50%, different from control T cells cultured under the same conditions without temsirolimus, vitamin D, and IL-2 signaling inhibitors, i.e., until there is at least a 10%, more preferably a 50% change in the expression of molecules indicative of cells undergoing autophagy. As an example, the dedifferentiated cells have an increased expression of p62 by Western blot analysis compared to control T cells, and other methods of measuring autophagy, such as, but not limited to, those described in Yoshii SR, Mizushima N. Monitoring and Measuring Autophagy. International Journal of Molecular Sciences. 2017; 18(9): 1865, may also be applied.
[0087] In any of the above embodiments, the culture medium does not contain human serum, temsirolimus, vitamin D, an IL-2 signaling inhibitor, or any combination thereof, and may not be present in the culture medium at the initiation of the culture. In such embodiments, the human serum, temsirolimus, vitamin D, or an IL-2 signaling inhibitor may be added to the culture medium at about the same time as inoculation of the culture input population of cells, or at a subsequent time.
[0088] As an example and not by way of limitation, an intravenous formulation of 1,25-vitamin D ("calcitriol") can be used. This formulation is preferred because it is completely soluble in culture medium and has 1,25 hydroxylation that is naturally produced in the kidney and must be present when vitamin D is added to the culture. Trade names for calcitriol include Rocaltrol, Calcijex, and Decostriol). It is also envisioned that other vitamin D receptor (VDR) ligands can be substituted for calcitriol, including but not limited to lithocholic acid, as described in Maestro et al; Vitamin D receptor 2016: novel ligands and structural insights; Expert Opinion on Therapeutic Patents; Volume 26, 2016; issue 11.
[0089] In some embodiments, dedifferentiated T cells obtained by any of the methods of the present disclosure are provided. In some embodiments, compositions comprising a population of dedifferentiated T cells are provided. In some embodiments, at least a portion of the dedifferentiated T cells express less than 50% RAPTOR or RICTOR compared to a control population of T cells produced under the same conditions as a culture input population of cells without temsirolimus, IL-2 signaling inhibitors, and vitamin D. In some embodiments, the dedifferentiated T cells express less than 50% RAPTOR or RICTOR compared to a control population of T cells produced under the same conditions as a culture input population of cells without temsirolimus, IL-2 signaling inhibitors, and vitamin D. As an example and not by way of limitation, the above de-differentiated T cells or populations of de-differentiated T cells can express 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 1% or less RAPTOR or RICTOR, respectively, compared to a control population of T cells produced under the same conditions as the culture input population of cells without temsirolimus, an IL-2 signaling inhibitor, and vitamin D.
[0090] In some embodiments, the dedifferentiated T cell population or dedifferentiated T cells can be characterized by a decrease in RNA expression for cytolytic molecules, including but not limited to, granzyme B, and / or for cytokine molecules, including but not limited to, IFN-γ, compared to a control T cell population incubated under the same conditions without temsirolimus, vitamin D, or IL-2 signaling inhibitors. Such a decrease can be, by way of example and not limitation, at least 10%, at least 20%, at least 30%, at least 40%, at least 50% or more.
[0091] In some embodiments, the dedifferentiated T cell population or dedifferentiated T cells can be characterized by increased RNA expression for transcription factors associated with iPSCs, including but not limited to Nanog, KLF4, and KLF10, and / or for molecules associated with naive T cells, including but not limited to IL-7 receptor, CD127, compared to a control T cell population incubated under the same conditions without temsirolimus, vitamin D, or IL-2 signaling inhibitors. Such an increase can be, by way of example and not limitation, at least 10%, at least 20%, at least 30%, at least 40%, at least 50% or more.
[0092] In some embodiments, the dedifferentiated T cell population or dedifferentiated T cells can be characterized by a reduction in RNA expression for transcription factors associated with Th1 effector T cells, including but not limited to T-Bet and STAT1, while simultaneously maintaining approximately equivalent HIF-1-α expression, compared to a control T cell population incubated under the same conditions without temsirolimus, vitamin D, or IL-2 signaling inhibitors. Such a reduction can be, by way of example and not by way of limitation, at least 10%, at least 20%, at least 30%, at least 40%, at least 50% or more. By way of example and not by way of limitation, HIF-1-α expression can be about 20%, 15%, 10%, or 5% or within the control T cell population.
[0093] In some embodiments, the population of dedifferentiated T cells or dedifferentiated T cells can be characterized by an increase in protein expression of p62 compared to a control population of T cells incubated under the same conditions without temsirolimus, vitamin D, and an IL-2 signaling inhibitor. Such an increase can be, by way of example and not limitation, at least 10%, at least 20%, at least 30%, at least 40%, at least 50% or more.
[0094] Human hybrid regulatory T / Th2 cells (hybrid T REG / Th2 cells) and T from dedifferentiated T cells REG Manufacturing method In this disclosure, we provide an ex vivo manufacturing process that results in the generation of iTREG cells enhanced for an early differentiation state combined with depletion of Th1 and Th17 type polarization. This method requires a two-step process, the first step consisting of dedifferentiation of T cells, and the second step consisting of iTREG cell production. The production of human iTREG cells from this dedifferentiated T cell substrate can be performed using a novel cytokine combination (standard iTREG use of IL-2 and TGF-β cytokines + additional use of the cytokine IL-4 classically associated with Th2 differentiation), and optionally the novel drug pemetrexed described herein. In some embodiments, iTREG cells can be generated without pemetrexed. Because such cells have expression of both TREG and Th2 molecules, the cells generated by this method are referred to as "human hybrid TREG / Th2 cells."
[0095] In some embodiments, the method includes culturing the dedifferentiated T cells of the present disclosure in a culture medium containing IL-2, IL-4, and TGF-β, adding anti-CD3 / anti-CD28 coated magnetic beads, for example, at a ratio of 3:1 (ratio of beads:T cells), and incubating the dedifferentiated T cells for a period of time to obtain TREG / Th2 cells. In some embodiments, the method includes culturing a population of dedifferentiated T cells of the present disclosure. The ratio of anti-CD3 / anti-CD28 beads can be varied as long as costimulation is sufficient to differentiate the cells.
[0096] In some embodiments, the method includes culturing dedifferentiated T cells having reduced expression of RAPTOR or RICTOR in a culture medium containing IL-2, IL-4, and TGF-β compared to a control population of T cells produced under the same conditions without temsirolimus, IL-2 signaling inhibitor, and vitamin D, adding anti-CD3 / anti-CD28 coated magnetic beads, for example, at a ratio of 3:1 (ratio of beads:T cells), and incubating the dedifferentiated T cells for a period of time to obtain TREG / Th2 cells. In some embodiments, the method includes culturing a population of dedifferentiated T cells of the present disclosure. The ratio of anti-CD3 / anti-CD28 beads can be varied as long as costimulation is sufficient to differentiate the cells. In some embodiments, the expression of RAPTOR or RICTOR is normalized by a housekeeping protein, for example, but not limited to, actin or GAPDH.
[0097] In any of the above embodiments, IL-2 can be present in the culture medium at a concentration of about 100 IU / ml to 10,000 IU / ml, 100 IU / ml to 1,000 IU / ml, 1,000 IU / ml to 10,000 IU / ml, or about 100 IU / ml, 1,000 IU / ml, or 10,000 IU / ml.
[0098] In any of the above embodiments, the culture medium can further include IL-4. In any of the above embodiments, IL-4 can be present in the culture medium at a concentration of about 100 IU / mL to 1000 IU / mL, 100 IU / mL to 1000 IU / mL, 100 IU / mL to 250 IU / mL, 100 IU / mL to 500 IU / mL, 250 IU / mL to 1000 IU / mL, 500 IU / mL to 1000 IU / mL, 250 IU / mL to 500 IU / mL, or 100 IU / mL, 200 IU / mL, 300 IU / mL, 400 IU / mL, 500 IU / mL, 600 IU / mL, 700 IU / mL, 800 IU / mL, 900 IU / mL, or 1000 IU / mL. In some embodiments, as an example and not by way of limitation, where it is desired to achieve reduced Th2 polarization, lower concentrations may be used, such as 100 IU / mL.
[0099] In any of the above embodiments, TGF-β can be present in the culture medium at a concentration of about 10 ng / mL. By way of example and not limitation, the concentration of TGF-β can be about 5 ng / mL, 6 ng / mL, 7 ng / mL, 8 ng / mL, 9 ng / mL, or 10 ng / mL.
[0100] In any of the above embodiments for differentiation, the ratio of beads:T cells can be 3:1. In some embodiments, equivalent amounts of alternative forms of anti-CD3 / anti-CD28 can be used with the same effect. In some embodiments, the amount of costimulation is sufficient to saturate cells. In any of the above embodiments, the amount of costimulation can be sufficient to increase the expression of GATA3 and FOXP3 in human hybrid TREG / Th2 cells.
[0101] In any of the above embodiments, the medium can further comprise pemetrexed. By way of example and not limitation, pemetrexed can be present at a concentration of about 1 nM to 100 nM, 5 nM to 100 nM, 10 nM to 100 nM, 25 nM to 100 nM, 50 nM to 100 nM, 75 nM to 100 nM, 50 nM to 75 nM, 25 nM to 75 nM, 10 nM to 50 nM, 10 nM to 25 nM, or values such as 5 nM, 10 nM, 25 nM, 50 nM, 75 nM, or 100 nM. In some embodiments, the medium does not comprise pemetrexed, and pemetrexed is not added to the medium.
[0102] In any of the above embodiments, the time period for incubating the dedifferentiated T cells can be, by way of example and not limitation, 3-40 days, 2-20 days, 3-10 days, 3-6 days, 6-10 days, 10-40 days, 10-20 days, 10-15 days, 15-40 days, 20-40 days, 30-40 days, 20-30 days, or 15-30 days, or 15-20 days. In some embodiments, by way of example and not limitation, shorter intervals of culture, such as 3-10 days, can be considered for hybrid Th2 / TREG cells in a very limited differentiation state.
[0103] The present disclosure is also directed to methods and TREG cells produced by any of the above methods without the use of IL-4.
[0104] In some embodiments, TREG or TREG / Th2 cells produced by the methods of the present disclosure may have increased expression by flow cytometry of at least one of CD25, CD27, 2B4, BTLA, CTLA4, TIGIT, TIM3, ICOS, LAIR1, and OX40 compared to control Th1 / Tc1 cells. In some embodiments, the increase may be, by way of example and not limitation, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or more.
[0105] In some embodiments, the TREG or TREG / Th2 cells produced by the methods of the present disclosure can have a reduction in the secretion of inflammatory cytokines compared to control Th1 / Tc1 cells. By way of example and not by way of limitation, such cytokines can include IFN-γ and TNF-α. In some embodiments, the reduction can be, by way of example and not by way of limitation, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or more.
[0106] In some embodiments, TREG or TREG / Th2 cells produced by the methods of the present disclosure may have reduced TBET, increased FOXP3 expression, and / or increased IL-4 secretion and increased expression of GATA3 compared to control Th1 / Tc1 cells. In some embodiments, this reduction or increase may be, by way of example and not limitation, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or more.
[0107] In some embodiments, a population of TREG or TREG / Th2 cells can have at least 5% of CD4+ or CD8+ cells expressing GATA3. As an example and not by way of limitation, a population of TREG or TREG / Th2 cells can have at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 45%, at least 50%, or at least 60% of CD4+ or CD8+ T cells expressing GATA3. In some embodiments, whether a cell expresses GATA3 is determined by flow cytometry. In some embodiments, T REG or T REGThe Th2 cell population is REG or T REG The GATA3 expressing CD4 / Th2 cell population was compared to the control T cell population characteristics of the T cells generated. + or CD8 + The increased frequency of T cells may be indicative. In some embodiments, the increased frequency may be an increase of 50% or more. As an example and not by way of limitation, the increase may be 50%, 100%, 200%, 300%, 500%, 1000%, 2000%, 3000% or more.
[0108] In some embodiments, a population of TREG or TREG / Th2 cells can have at least 5% of CD4+ or CD8+ cells expressing FoxP3. As an example and not by way of limitation, a population of TREG or TREG / Th2 cells can have at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, or at least 45% of CD4+ or CD8+ T cells expressing FoxP3. In some embodiments, whether a cell expresses FoxP3 is determined by flow cytometry. In some embodiments, T REG or T REG The Th2 cell population is REG or T REG The FOXP3 expressing CD4 / Th2 cell population was compared to the control T cell population characteristics of the T cells generated. + or CD8 + The increased frequency of T cells may be indicative. In some embodiments, the increased frequency may be an increase of 50% or more. As an example and not by way of limitation, the increase may be 50%, 100%, 200%, 300%, 500%, 1000%, 2000%, 3000% or more.
[0109] In some embodiments, a population of TREG or TREG / Th2 cells can have at least 10% of CD4+ or CD8+ cells expressing CD73. As an example and not by way of limitation, a population of TREG or TREG / Th2 cells can have at least 10%, at least 15%, at least 20%, or at least 25% of CD4+ T cells expressing CD73. As an example and not by way of limitation, a population of TREG or TREG / Th2 cells can have at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, or at least 80% of CD8+ T cells expressing CD73. In some embodiments, whether a cell expresses CD73 is determined by flow cytometry. In some embodiments, T REG or T REG The Th2 cell population is REG or T REG / Th2 cell population compared to control T cell population characteristics of generated T cells expressing CD73 CD4 + or CD8 + The increased frequency of T cells may be indicative. In some embodiments, the increased frequency may be an increase of 50% or more. As an example and not by way of limitation, the increase may be 50%, 100%, 200%, 300%, 500%, 1000%, 2000%, 3000% or more.
[0110] In some embodiments, a population of TREG or TREG / Th2 cells can have at least 10% of CD4+ or CD8+ cells expressing CD103. By way of example and not limitation, a population of TREG or TREG / Th2 cells can have at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of CD4+ or CD8+ T cells expressing CD103. In some embodiments, whether a cell expresses CD103 is determined by flow cytometry. In some embodiments, T REG or T REG The Th2 cell population is REG or T REG / Th2 cell population compared to control T cell population characteristics of generated T cells expressing CD103 CD4 + or CD8 + The increased frequency of T cells may be indicative. In some embodiments, the increased frequency may be an increase of 50% or more. As an example and not by way of limitation, the increase may be 50%, 100%, 200%, 300%, 500%, 1000%, 2000%, 3000% or more.
[0111] In some embodiments, T REG or T REG The Th2 cell population is a CD4+ / Th2 population that expresses both FOXP3 and GATA3 as measured by flow cytometry. + or CD8 + The present invention can include, but is not limited to, at least 5% of cells in the T REG or T REG The Th2 cell population is CD4+ / Th2-expressing + or CD8 + It may have at least 5%, 10%, 20%, 30%, 40%, or 50% of the cells.
[0112] In some embodiments, a population of TREG or TREG / Th2 cells can have at least 20% of CD4+ or CD8+ cells expressing CD150. As an example and not by way of limitation, a population of TREG or TREG / Th2 cells can have at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50% of CD4+ or CD8+ T cells expressing CD150. In some embodiments, a population of TREG or TREG / Th2 cells can have an increased frequency of cells expressing CD150 compared to a control population of T cells incubated without exposure to an mTOR inhibitor. In some embodiments, whether a cell expresses CD150 is determined by flow cytometry. In some embodiments, a population of TREG or TREG / Th2 cells can have at least 20% of CD4+ or CD8+ T cells expressing CD150. REG or T REG The Th2 cell population is REG or T REG / Th2 cell population compared to control T cell population characteristics of generated T cells expressing CD150 CD4 + or CD8 + The increased frequency of T cells may be indicative. In some embodiments, the increased frequency may be an increase of 50% or more. As an example and not by way of limitation, the increase may be 50%, 100%, 200%, 300%, 500%, 1000%, 2000%, 3000% or more.
[0113] In some embodiments, a population of TREG or TREG / Th2 cells can express at least 5 pg / mL / 1×106 cells / day of IL-4 after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1. By way of example and not limitation, a population of TREG or TREG / Th2 cells can express at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100 pg / mL / 1×106 cells / day of IL-4. 6The cells are capable of expressing IL-4.
[0114] In some embodiments, the population of TREG or TREG / Th2 cells can express at least 100 pg / mL / 1 x 106 cells / day of IL-2 after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1.
[0115] In some embodiments, the population of TREG or TREG / Th2 cells can express at least 100 pg / mL / 1 x 106 cells / day of IFN-γ or GM-CSF after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1.
[0116] In some embodiments, the population of TREG or TREG / Th2 cells can express less than 10 pg / mL / 1 x 106 cells / day of TNF-α or IL-17 after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1.
[0117] In some embodiments, TREG or TREG / Th2 cells can express both GATA3 and FOXP3. In some embodiments, TREG or TREG / Th2 cells can express GATA3, FOXP3, CD103 and CD73. In some embodiments, a population of TREG or TREG / Th2 cells can be characterized by at least 5% of T cells expressing GATA3, at least 5% of T cells expressing FOXP3, at least 5% of T cells expressing CD103, and at least 5% of T cells expressing CD73, as measured by flow cytometry.
[0118] In any of the above embodiments, the TREG or TREG / Th2 cells, or populations thereof, can have at least one or any combination of the above characteristics, so long as the characteristics are compatible.
[0119] Inducible controllability T(iT REG ) A method for treating ALS using cells In this protocol, we demonstrate the iT of ALS. REG We use a pentostatin plus cyclophosphamide regimen as an immunodepletion and immunosuppression method to enhance cell therapy. This PC regimen may have direct beneficial effects due to its ability to deplete and suppress Th1-type immune cells associated with ALS pathogenesis. In addition, the PC regimen may promote more effective iT REG It functions as a host regulation to increase immune T cell space for cell therapy. Specifically, in this protocol, we reduced the dosage of the PC regimen to mitigate any potential adverse effects of the regimen in the new ALS patient population. In this protocol, we reduced the starting dose of pentostatin to 4 mg / m 2 to 1 mg / m 2 The dose of pentostatin was reduced from the previous value of 4 injections per cycle to the current protocol value of 1 injection per cycle, and the dose of initial cyclophosphamide was reduced from 200 mg per day to 100 mg per day. Second, we reduced the intensity of the PC regimen in terms of the stated goal of the degree of immune depletion conferred by the PC regimen. Since a more cautious approach is mandated in the ALS patient population, the current protocol PC regimen attempted to reduce the ALC count more conservatively, i.e., to less than 750 cells per microliter. In general, this level of immune depletion is not associated with severe long-term immune deficiency in terms of a high rate of opportunistic infections.
[0120] Without being bound by theory, it is expected that PC regimens deplete and suppress Th1 / Tc1-type adaptive immune subsets that are involved in the progression of ALS pathology. However, this therapy does not address the underlying primary events in ALS, namely misfolded RNA species, insufficient autophagy for the clearance of harmful RNA / DNA products, and the subsequent RNA / DNA activation of innate inflammation at the level of the P2X7 receptor-driven NLRP3 inflammasome. Such inflammasome activation, shown to be operational in ALS models, subsequently drives IL-1-β activation, one of the earliest and most potent pro-inflammatory signals that drive adaptive T cell inflammation mediated primarily by the Th1 / Tc1 subset. Indeed, it has been recently proposed that NLRP3 inhibition represents a novel approach for the treatment of diverse neurodegenerative diseases. Nucleoside reverse transcriptase inhibitors (NRTIs) are antiviral agents approved for the treatment of HIV disease that may also play a role in the treatment of ALS. Patients with ALS can have increased levels of human endogenous retrovirus-K (HERV-K) that drives disease onset in model systems, in part through regulation by TDP-43 accumulation, a major mechanistic component of ALS. Toward clinical translation of this biology, a clinical trial (NCT02437110) has been initiated evaluating an HIV antiviral cocktail of darunavir, ritonavir, raltegravir, and zidovudine. The NRTI molecule lamivudine (3TC) has also been described to inhibit the P2X7 receptor, which drives NLRP3 activation that occurs in ALS. Based in part on these observations, a Phase II clinical trial (NCT02363452) has been initiated to evaluate the ability of a three-drug regimen of lamivudine, zidovudine, and abacavir to reduce inflammation in patients with Aicardi-Goutières syndrome (AGS), a disease that mimics the innate inflammatory events in ALS, namely the accumulation of intracellular RNA species, activation of inflammatory pathways, and the resulting generation of systemic Th1-driven inflammation.Because lamivudine has been characterized as a potent inhibitor of the NLRP3 inflammasome and it was hoped to generate a treatment regimen that would be well tolerated in the ALS patient population, we chose to pursue single-agent NRTI therapy with lamivudine in this protocol.
[0121] Therefore, without being bound by theory, the sequential strategy of first depleting and suppressing Th1 / Tc1 responses (via PC regimens) and then controlling the driving inflammasome activation is expected to represent a novel approach to provide sustainable regulation of the complex neuroinflammatory network involved in ALS. The use of lamivudine in an ALS therapeutic platform is expected to be a promising tool for iT REG It may also be beneficial for the next step to further incorporate cell therapy into the platform: three therapeutic modalities (pentostatin / cyclophosphamide, lamivudine, and iT REG Each of the iT (IL-1, IL-2, and iT) receptors works at least in part by shunting ATP transport away from the P2X7-driven NLRP3-mediated inflammasome and towards the immunosuppressive molecule, adenosine. First, pentostatin increases adenosine by inhibiting adenosine deaminase, thereby preventing the conversion of adenosine to inosine. Second, lamivudine is a known inhibitor of P2X7, thereby directly inhibiting the inflammasome. Third, iT REG The cells provide CD39- and CD73-mediated ectonucleotidase activity that processes ATP towards adenosine. With regard to this last process, it is important to note that microglial cells inherently utilize CD39 and CD73 to suppress neuroinflammation.
[0122] In summary, these data provide evidence that the primary neurodegenerative process in ALS generates a secondary inflammatory response, which, on the one hand, can still promote disease progression, but, on the other hand, can also contribute to the regulation of inflammasome activation, the depletion and suppression of Th1 / Tc1-type subsets, and the upregulation of T REGThese results provide evidence that immunomodulatory therapies can be a multi-step therapeutic intervention, including the promotion of Th1-type subsets. Given this information, there is great interest in evaluating immunomodulatory therapies in ALS patients. Optimal control of neuroinflammation in ALS patients will require a three-step treatment that addresses each of the components listed above: (1) control of innate inflammasome activation (by lamivudine administration, as described below); (2) reduction of pre-existing Th1-type inflammatory cells (by pentostatin / cyclophosphamide regimens, as described in more detail below); and (3) iT cell transfer by adoptive T cell transfer. REG We hypothesized that a combination approach, including the promotion of T cells, may be necessary. There are several reasons why such a combination approach may be necessary. First, if the underlying inflammasome activation is not addressed by a maintenance therapy, then a host modulation therapy and T REG Immunological and therapeutic gains achieved during cell therapy are likely eroded by the underlying primary neurodegenerative process. Second, optimized T cell delivery to a host with uncontrolled Th1-driven inflammation. REG Even infusion of a cell population alone represents a difficult immunological challenge for a number of reasons: pre-existing Th1-type cells may be ineffective in regulating the adoptively transferred T REG cells can express differentiation plasticity, thereby forming protective T REG Third, the efficacy of adoptively transferred T cell populations is intricately linked to the degree of immune T cell space, which can be defined largely by the presence of T cell growth factors such as IL-7 and IL-15, and the creation of such immune space is created by host preparation regimens including pentostatin + cyclophosphamide (PC) regimens, which have been utilized for decades in allogeneic hematopoietic stem cell transplantation and are now being utilized in the field of using adoptive T cell transfer for cancer treatment. Notably, the efficacy of T cell populations in neurodegenerative or autoimmune diseases is intricately linked to the degree of immune T cell space, which can be defined largely by the presence of T cell growth factors such as IL-7 and IL-15, and the creation of such immune space is created by host preparation regimens including pentostatin + cyclophosphamide (PC) regimens, which have been utilized for decades in allogeneic hematopoietic stem cell transplantation and are now being utilized in the field of using adoptive T cell transfer for cancer treatment. Notably, the efficacy of adoptively transferred T cell populations in neurodegenerative or autoimmune diseases is also intricately linked to the degree of immune T cell space, which can be defined largely by the presence of T cell growth factors such as IL-7 and IL-15, and the creation of such immune space is created by host preparation regimens including pentostatin + cyclophosphamide (PC) regimens, which have been utilized for decades in allogeneic hematopoietic stem cell transplantation and are now being utilized in the field of using adoptive T cell transfer for cancer treatment. REG Previous clinical trials involving cell therapy have not incorporated host-preparation regimens such as PC regimens.
[0123] In some embodiments, the method includes subjecting the subject to one or more primary treatment cycles, each of which comprises administering pentostatin to the subject and / or administering cyclophosphamide to the subject, and administering a therapeutically effective amount of the manufactured T REG and subjecting the subject to one or more immunotherapy treatment cycles comprising administering a composition comprising the cells to the subject. A person skilled in the art can determine the therapeutically effective amount by methods known in the art and disclosed herein.
[0124] In the above embodiment, each of the one or more immunotherapy treatment cycles further comprises administering a nucleoside reverse transcriptase inhibitor to the subject. The nucleoside reverse transcriptase inhibitor can be an inhibitor of NLRP3 inflammasome, or the nucleoside reverse transcriptase inhibitor can be lamivudine. Each of the one or more immunotherapy treatment cycles can further comprise administering pentostatin to the subject and / or administering cyclophosphamide to the subject. The step of administering pentostatin to the subject during each of the one or more immunotherapy treatment cycles can be performed on the first and fourth days of each of the one or more immunotherapy treatment cycles. The step of administering pentostatin to the subject during each of the one or more immunotherapy treatment cycles can be performed on the first, second, third, fourth, and fifth days of each of the one or more immunotherapy treatment cycles. The method can include two or more immunotherapy treatment cycles, each of which is separated by any value between, for example and not limited to, 0-4 weeks, 0-3 weeks, 0-2 weeks, 0-1 week, and for example and not limited to, 0 weeks, 1 week, 2 weeks, 3 weeks, or 4 weeks. Each of the one or more immunotherapy treatment cycles can be 18 weeks long. Each of the one or more immunotherapy treatment cycles can further include administering to the subject an adenosine receptor modulator, such as those disclosed in U.S. Pat. No. 9,326,983, which is incorporated herein by reference, lamivudine, zidovudine, stavudine, cordycepin, azidothymidine, abacavir, [ka] Other nucleoside reverse transcriptase inhibitors can be used, including, but not limited to, chemical derivatives thereof, pharma- ceutically acceptable salts thereof, and combinations thereof.
[0125] In the above embodiments, by way of example and not limitation, the one or more primary treatment cycles may be 2 weeks to 5 weeks, 2 weeks to 4 weeks, 2 weeks to 3 weeks, 3 weeks to 4 weeks, or 4 weeks to 5 weeks, and any value therebetween, such as, by way of example and not limitation, 2 weeks, 3 weeks, 4 weeks, or 5 weeks. The above method may include two or more primary treatment cycles, each of the two or more primary treatment cycles being 0 to 2 weeks apart. By way of example and not limitation, each of the two or more primary treatment cycles being 0 to 1 week or 1 to 2 weeks apart, and any value therebetween, such as, by way of example and not limitation, 1 day, 1 week, or 2 weeks.
[0126] In the above embodiment, the method may further comprise harvesting peripheral lymphocytes from the subject prior to the one or more first treatment cycles. The method may further comprise harvesting peripheral lymphocytes from the subject, followed by culturing the produced T REG The method may further comprise culturing said peripheral lymphocytes to obtain said cells. The method may further comprise harvesting peripheral lymphocytes from said subject after said one or more primary treatment cycles. The method may further comprise culturing said produced T cells after harvesting peripheral lymphocytes from said subject after said one or more primary treatment cycles. REG The method may further comprise culturing the peripheral lymphocytes to obtain cells. The method may further comprise measuring the absolute lymphocyte count (ALC) in the subject after each of the one or more primary treatment cycles, and proceeding to one or more immunotherapy treatment cycles if the ALC is less than 750 per μl. In some embodiments, the target ALC value may vary, and may be, for example, but not limited to, 0, 250, 500, 750, 1000, 1250, or 1500 cells per microliter.
[0127] In the above embodiment, the first cycle of the one or more immunotherapy treatment cycles and the last cycle of the one or more primary treatment cycles are separated by 0-2 weeks. By way of example and not by way of limitation, each of the two or more immunotherapy treatment cycles are separated by 0-1 weeks or 1-2 weeks, and any value therebetween, such as by way of example and not by way of limitation 0 weeks, 1 week, or 2 weeks.
[0128] In the above embodiment, by way of example and not limitation, the dose of pentostatin is 0.5 mg / m 2 ~4mg / m 2 , 1 mg / m 2 ~4mg / m 2 , 2 mg / m 2 ~4mg / m 2 and, by way of example and not limitation, a dose of 0.5 mg / m 2 , 1 mg / m 2 , 1.5 mg / m 2 , 2 mg / m 2 , 2.5 mg / m 2 , 3 mg / m 2 , 3.5 mg / m 2 , and 4 mg / m 2 The pentostatin can be administered on any day of each of the one or more primary treatment cycles.As an example and not by way of limitation, the pentostatin can be administered to the subject on day 1, or on days 1 and 4 of each of the one or more primary treatment cycles.
[0129] In the above embodiment, cyclophosphamide can be administered to the subject at a dose of 50 mg to 400 mg. By way of example and not limitation, the dose of cyclophosphamide can be any value between any combination of 50, 100, 150, 200, 250, 300, 350, or 400 mg and 400, 350, 300, 250, 200, 150, 100, or 50 mg, and by way of example and not limitation, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, or 400 mg. By way of example and not limitation, cyclophosphamide can be administered on days 1, 2, and 3, or days 1, 2, 3, 4, and 5 of each of the above one or more primary treatment cycles.
[0130] In the above embodiment, the pentostatin and cyclophosphamide can be administered to the subject in a single composition.The single composition can be administered intravenously to the subject.The step of administering the pentostatin and cyclophosphamide to the subject can include administering a first composition comprising pentostatin to the subject and administering a second composition comprising cyclophosphamide to the subject.
[0131] In the above embodiment, the lamivudine can be administered to the subject at a dose of 150 mg to 150 mg twice daily.
[0132] In the above embodiment, the above manufactured T REG The cells may be administered at a dose of, by way of example and not by way of limitation, 1×10 cells / kg of subject body weight during each of one or more of the immunotherapy treatment cycles described above. 6 Cells ~ 5 x 10 per kg of subject body weight 6 Cells, 2 x 10 per kg of subject body weight 6 Cells ~ 5 x 10 per kg of subject body weight 6 Cells, 3 x 10 per kg of subject body weight 6 Cells ~ 5 x 10 per kg of subject body weight 6Cells, 4 x 10 per kg of subject body weight 6 Cells ~ 5 x 10 per kg of subject body weight 6 Cells, 1 x 10 per kg of subject body weight 6 Cells ~ 4 x 10 per kg of subject body weight 6 Cells, 1 x 10 per kg of subject body weight 6 Cells ~ 3 x 10 per kg of subject body weight 6 Cells, 1 x 10 per kg of subject body weight 6 Cells ~ 2 x 10 per kg of subject body weight 6 cells, and any value therebetween, for example and without limitation, 1×10 cells / kg of subject body weight 6 Cells, 2 x 10 per kg of subject body weight 6 Cells, 3 x 10 per kg of subject body weight 6 Cells, 4 x 10 per kg of subject body weight 6 cells or 5 × 10 per kg of subject body weight 6 The subject may be administered a dose of, for example, 100,000 cells per injection. REG Approximately 1 x 10 of cells 6 ~About 200×10 6 As a further example and not by way of limitation, manufactured T REG Approximately 1 x 10 cells per injection 6 ~About 200×10 6 , 10×10 6 ~About 200×10 6 , 50×10 6 ~About 200×10 6 , 100×10 6 ~About 200×10 6 , at least 1 × 10 6 , 10×10 6 , 50×10 6 , 100×10 6 , or 200×10 6 In some embodiments, about 40×10 cells can be administered. 6 Cells / infusion may be administered. In some embodiments, about 120×10 6 The cells / infusion may be administered.REG The cells may comprise a ratio of central memory to effector memory cells selected from 1:1, 3:1, 10:1, 1:3, and 1:10. REG The above composition comprising cells is a normal T REG The above-mentioned produced T REG The cells can be administered to the subject on day 8 of each of the one or more immunotherapy treatment cycles. REG and nT REG may be administered in combination to a subject.
[0133] In some embodiments, the method comprises a first therapeutic cycle, a second therapeutic cycle, optionally one or more additional therapeutic cycles, and one or more immunotherapy treatment cycles, wherein said first therapeutic cycle comprises administering pentostatin to said subject and / or administering cyclophosphamide to said subject, said second therapeutic cycle comprises administering pentostatin to said subject and / or administering cyclophosphamide to said subject, said one or more additional therapeutic cycles comprise administering pentostatin to said subject and / or administering cyclophosphamide to said subject, each of said one or more immunotherapy treatment cycles comprising administering pentostatin to said subject and / or administering cyclophosphamide to said subject and administering a manufactured T REG and administering the cells to said subject.
[0134] In the embodiment, the first treatment cycle can be 14 days long. The step of administering pentostatin to the subject can be performed on day 1 of the first treatment cycle. Pentostatin can be administered at a dose of 1 mg / m during the first treatment cycle. 2Cyclophosphamide can be administered to the subject at a dose of 100 mg during the first treatment cycle. The step of administering cyclophosphamide to the subject can be repeated during the first treatment cycle, and as an example and not by way of limitation, the step of administering cyclophosphamide to the subject can be performed on days 1, 2, and 3 of the first treatment cycle.
[0135] In the embodiment, the second treatment cycle can be 14 days long. The step of administering pentostatin to the subject during the second treatment cycle can be performed on day 1 of the second treatment cycle. Pentostatin can be administered at a dose of 2 mg / m during the second treatment cycle. 2 The subject may be administered cyclophosphamide at a dose of 100 mg during the second treatment cycle. The step of administering cyclophosphamide to the subject during the second treatment cycle may be repeated during the second treatment cycle. As an example and not by way of limitation, the step of administering cyclophosphamide to the subject during the second treatment cycle may be performed on days 1, 2, and / or 3 of the second treatment cycle. Cyclophosphamide may be administered to the subject at a dose of 100 mg during the second treatment cycle.
[0136] In the above embodiment, the subject may be subjected to the one or more additional treatment cycles. Each of the one or more additional treatment cycles may each be 14 days long. The one or more additional treatment cycles may be separated by 0-2 weeks. By way of example and not by way of limitation, each of the two or more additional treatment cycles may be separated by 0-1 week, or 1-2 weeks, for example, by any value between 0 weeks, 1 week, or 2 weeks. The step of administering pentostatin to the subject during each of the one or more additional treatment cycles may be performed on day 1 and / or day 4 of the one or more additional treatment cycles. Pentostatin may be administered at a dose of 2 mg / m2 or more during each of the one or more additional treatment cycles. 2 The step of administering cyclophosphamide to the subject may be repeated during each of the one or more additional treatment cycles. The step of administering cyclophosphamide to the subject during each of the one or more additional treatment cycles may be performed on days 1, 2, 3, 4, and / or 5 of each of the one or more additional treatment cycles. Cyclophosphamide may be administered to the subject at a dose of 100 mg to 200 mg during each of the one or more additional treatment cycles. The additional cycles may further include, prior to administering pentostatin to the subject during each of the one or more additional treatment cycles, measuring a creatinine clearance (CrCl) of the subject and adjusting the dose of pentostatin administered to the subject based on the CrCl, and wherein the CrCl is greater than 60 mL / min / 1.73 m. 2 In this case, pentostatin is 2 mg / m 2 Administered at 60 mL / min / 1.73 m 2 >CrCl>30mL / min / 1.73m 2 In this case, pentostatin is 1 mg / m 2 CrCl < 30 mL / min / 1.73 m 2In such cases, pentostatin is not administered. The above additional cycles can further include measuring the absolute neutrophil count (ANC) before administering cyclophosphamide to the subject during each of the above one or more additional treatment cycles, and adjusting the dose of cyclophosphamide administered to the subject based on the ANC. When ANC > 1000 per microliter, cyclophosphamide is administered at a dose of 100 mg. When ANC is 500 - 999 per microliter, cyclophosphamide is administered at a dose of 50 mg. When ALC < 50 per microliter or ANC < 500 per microliter, cyclophosphamide is not administered. The above one or more additional treatment cycles can include at least two additional treatment cycles. The final cycle of the above at least two additional treatment cycles includes measuring the absolute lymphocyte count (ALC) and the absolute neutrophil count (ANC) before administering cyclophosphamide to the subject during the above final cycle of the above at least two treatment cycles, and adjusting the dose of cyclophosphamide administered to the subject based on the ALC and ANC. Cyclophosphamide can be administered at a dose of 200 mg when ALC > 1250 / microliter. Cyclophosphamide can be administered at a dose of 100 mg when ANC > 1000 / microliter and 750 < ALC < 1250 / microliter. Cyclophosphamide can be administered at a dose of 50 mg when ANC is 500 - 999 / microliter. Cyclophosphamide may not be administered when ANC < 500 / microliter and / or ALC < 750 / microliter.
[0137] In the above embodiments, each of the treatment cycle, the second treatment cycle, and the one or more additional treatment cycles can be separated by 0 to 2 weeks. By way of example and not by way of limitation, each of the treatment cycle, the second treatment cycle, and the one or more additional treatment cycles can be separated by 0 to 1 week, or 1 to 2 weeks, by way of example and not by way of limitation, any value between 0 weeks, 1 week, or 2 weeks.
[0138] In the above embodiment, the method can further include measuring a creatinine clearance (CrCl) of the subject prior to administering pentostatin to the subject in the first treatment cycle, and adjusting a dose of pentostatin administered to the subject based on the CrCl, wherein CrCl>60 mL / min / 1.73 m 2 In this case, pentostatin is 1 mg / m 2 Administered at 60 mL / min / 1.73 m 2 >CrCl>30mL / min / 1.73m 2 If pentostatin is administered at 0.5 mg / m2 and CrCl < 30 mL / min / 1.73 m 2 In this case, pentostatin is not administered.
[0139] In the above embodiment, the method may further include measuring an absolute neutrophil count (ANC) prior to administering cyclophosphamide to the subject in the first treatment cycle, and adjusting the dose of cyclophosphamide administered to the subject based on the ALC and ANC, where if the ANC>1000 per microliter, cyclophosphamide is administered at a dose of 100 mg, if the ANC is 500-999 per microliter, cyclophosphamide is administered at a dose of 50 mg, and if the ANC<500 per microliter, no cyclophosphamide is administered.
[0140] In the above embodiment, the method can further include measuring a creatinine clearance (CrCl) of the subject prior to administering pentostatin to the subject in the second treatment cycle, and adjusting the dose of pentostatin administered to the subject based on the CrCl, 2 In this case, pentostatin is 2 mg / m 2 Administered at 60 mL / min / 1.73 m 2 >CrCl>30mL / min / 1.73m 2 In this case, pentostatin is 1 mg / m 2 CrCl < 30 mL / min / 1.73 m 2 In this case, pentostatin is not administered.
[0141] In the above embodiment, the method may further include measuring an absolute neutrophil count (ANC) prior to administering cyclophosphamide to the subject in the second treatment cycle, and adjusting the dose of cyclophosphamide administered to the subject based on the ANC, where if the ANC>1000 per microliter, cyclophosphamide may be administered at a dose of 100 mg, if the ANC is 500-999 per microliter, cyclophosphamide may be administered at a dose of 50 mg, and if the ANC<500 per microliter, no cyclophosphamide is administered.
[0142] In the above embodiments, the method may further include measuring an absolute lymphocyte count (ALC) in the subject prior to each of the one or more additional treatment cycles, and adjusting the treatment of the subject based on the ALC, wherein if the ALC is <750 per microliter, performing a maintenance treatment cycle on the subject, comprising subjecting the patient to the one or more immunotherapy treatment cycles, and if the ALC is >750 per microliter, subjecting the patient to the one or more additional treatment cycles.
[0143] In the above embodiments, the method may further include measuring an absolute lymphocyte count (ALC) in the subject prior to each of the one or more additional treatment cycles, and adjusting the treatment of the subject based on the ALC, wherein if the ALC is < 750 per microliter, administering to the subject a maintenance treatment cycle comprising administering a nucleoside reverse transcriptase inhibitor, not further administering the one or more additional treatment cycles prior to the maintenance treatment cycle, and continuing the subject patient in the one or more additional treatment cycles if the ALC is > 750 per microliter.
[0144] In the above embodiments, each of the one or more immunotherapy treatment cycles can be, by way of example and not by way of limitation, 18 weeks in length. In some embodiments, the immunotherapy treatment cycles can be spaced 0-4 weeks apart. The immunotherapy treatment cycles can be repeated, including indefinitely. Repetition of the immunotherapy cycles can be according to a regimen or in the event of relapse. By way of example and not by way of limitation, the immunotherapy cycles can occur 1-4 times per year. Pentostatin can be administered at a dose of 2 mg / m on days 1 and 4 of each of the one or more immunotherapy treatment cycles. 2Cyclophosphamide can be administered to the subject at a dose of 100 mg on days 1, 2, 3, 4, and / or 5 of each of the one or more immunotherapy treatment cycles. Each of the one or more immunotherapy treatment cycles can further include administering a nucleoside reverse transcriptase inhibitor to the subject. The nucleoside reverse transcriptase inhibitor can be lamivudine. The lamivudine can be administered to the subject at a dose of 150 mg daily to 150 mg twice daily during each of the one or more immunotherapy treatment cycles. Each of the one or more immunotherapy treatment cycles can further include measuring the creatinine clearance (CrCl) of the subject during each of the one or more immunotherapy treatment cycles and adjusting the dose of lamivudine administered to the subject based on the CrCl, wherein the CrCl is greater than or equal to 50 mL / min / 1.73 m. 2 Lamivudine is administered at 150 mg twice daily with a CrCl > 50 mL / min > 30 mL / min / 1.73 m 2 If lamivudine is administered at 150 mg, CrCl < 30 mL / min / 1.73 m 2 In this case, lamivudine is not administered.
[0145] In the above embodiment, the method comprises administering to the subject a therapeutically effective amount of the produced T REG This can include administering the cells to the subject.
[0146] In the above embodiment, the above manufactured T REG The cells can be administered to the subject on day 8 of each of the one or more immunotherapy treatment cycles. REG The cells can be administered to the subject on any day of the above immunotherapy cycle, for example, days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.
[0147] In the above embodiment, the above manufactured T REGCells were administered at a dose of 1 × 10 per kg of subject body weight. 6 Cells ~ 5 x 10 per kg of subject body weight 6 Cells, for example and without limitation, 1 x 10 cells per kg of subject body weight 6 Cells ~ 5 x 10 per kg of subject body weight 6 Cells, 2 x 10 per kg of subject body weight 6 Cells ~ 5 x 10 per kg of subject body weight 6 Cells, 3 x 10 per kg of subject body weight 6 Cells ~ 5 x 10 per kg of subject body weight 6 Cells, 4 x 10 per kg of subject body weight 6 Cells ~ 5 x 10 per kg of subject body weight 6 Cells, 1 x 10 per kg of subject body weight 6 Cells ~ 4 x 10 per kg of subject body weight 6 Cells, 1 x 10 per kg of subject body weight 6 cells ~3×10 6 Cells, 1 x 10 per kg of subject body weight 6 Cells ~ 2 x 10 per kg of subject body weight 6 cells, and by way of example and not limitation, 1×10 per kg of subject body weight 6 Cells, 2 x 10 per kg of subject body weight 6 Cells, 3 x 10 per kg of subject body weight 6 Cells, 4 x 10 per kg of subject body weight 6 cells or 5 × 10 per kg of subject body weight 6 The amount of the administered cell can be any value between 0.1 and 0.25 μg / mL.
[0148] Each of the one or more treatment cycles can further comprise administering pentostatin to the subject and / or administering cyclophosphamide to the subject. Pentostatin is administered at a dose of 1 mg / m 2 ~2mg / m 2 and examples, but not limited to, 1 mg / m 2 , 1.5 mg / m 2 , or 2 mg / m 2The pentostatin can be administered to the subject at any value between 100 mg and 200 mg, including, but not limited to, 100 mg, 150 mg, or 200 mg. The pentostatin can be administered to the subject on days 1 and 4 of each of the one or more treatment cycles. The cyclophosphamide can be administered to the subject on days 1, 2, 3, 4, and / or 5 of each of the one or more treatment cycles. The subject may have been previously treated with pentostatin and cyclophosphamide. Each of the one or more treatment cycles may further include administering a nucleoside reverse transcriptase inhibitor to the subject. The nucleoside reverse transcriptase inhibitor may be an inhibitor of the NLRP3 inflammasome. The nucleoside reverse transcriptase inhibitor may be lamivudine. Each of the one or more treatment cycles may be 4 weeks apart.
[0149] In the above embodiment, the method further comprises the step of: REG At the same time, normal T cells were REG In the above embodiment, the method may further include administering peripheral lymphocytes to the subject prior to the one or more treatment cycles. In the above embodiment, the method may further include harvesting peripheral lymphocytes from the subject prior to the one or more treatment cycles. In the above embodiment, the method may further include culturing the peripheral lymphocytes after harvesting the peripheral lymphocytes from the subject to produce the produced T cells. REG This can further include obtaining the cells. EXAMPLES
[0150] The following examples illustrate the disclosed methods and the resulting dedifferentiation and iT REG or redifferentiated T cells. These examples are not intended to limit or otherwise modify the scope of the methods, cells, and compositions disclosed in this disclosure.
[0151] Example 1: Combination of Vitamin D and Temsirolimus Decreases T Cell Effector Molecules We directly evaluated the individual effects of vitamin D, mTOR inhibition (using parenteral forms of rapamycin, temsirolimus), and the combination of vitamin D + temsirolimus on human T cell effector molecule expression (see Figure 1).
[0152] 1A-1D show that the combination of vitamin D and temsirolimus reduces the expression of human CD4 + and CD8 + Illustrates reducing effector molecule expression in cells. For columns #2-#5, T cells were subjected to a 3-day dedifferentiation interval that included low levels of anti-CD3 / anti-CD28 costimulation (beads to T cells ratio; 1:3), high doses of temsirolimus (1 μM), vitamin D (0.1 or 1.0 nM), and culture in X-Vivo 20 medium. The first column represents control cultures (no temsirolimus, no vitamin D, use of a 3:1 bead to T cells ratio, and inclusion of the type I polarizing cytokine IFN-α (20,000 IU / mL, unless otherwise specified, this amount is used in Examples 1-11 below for control cultures)). The second column represents cultures that had low bead-to-T cell ratios and temsirolimus but no vitamin D; in contrast, the third column represents cultures that had vitamin D (0.1 nM) but no temsirolimus. The fourth column represents cultures that had high-dose ("HD") vitamin D (1.0 nM) but no temsirolimus. The fifth column represents cultures that had both high-dose vitamin D (1.0 nM) in combination with temsirolimus. At the end of the dedifferentiation period, cells were harvested, RNA was isolated, and RNA expression analysis was performed by the Luminex Quantigene method. All results shown represent relative RNA expression, and results are normalized to a value of 1.0 for the Th1 / Tc1 control culture.
[0153] A 3-day culture interval was used that included low levels of T cell costimulation (a 1:3 ratio of anti-CD3 / anti-CD28 beads to T cells; the typical ratio used in the literature is the reverse, 3:1), temsirolimus (1 μM), vitamin D at doses of either 0.1 or 1.0 nM, or a combination of temsirolimus and high dose vitamin D. After culture, RNA was collected and effector molecule expression levels were compared to control cultures.
[0154] As Figure 1A shows, the various cultures had similar RNA expression of housekeeping control genes, including GAPDH. In contrast, compared to control Th1 / Tc1 cell cultures that did not receive vitamin D or temsirolimus, culture addition of temsirolimus, vitamin D, or a combination of temsirolimus + vitamin D resulted in reduced RNA expression of T cell effector molecules, including the cytotoxic molecule granzyme B (Figure 1B) as well as the cytokine molecules IL-10 (Th2 cytokine, Figure 1C) and IFN-γ (Th1 cytokine, Figure 1D). Thus, granzyme B and IFN-γ as dedifferentiation markers indicate that vitamin D is effective at concentrations between 0.1 and 1.0 nM. Temsirolimus at a dose of 1 μM acts beneficially as a dedifferentiation agent alone (column 2, reduction of granzyme B and IFN-γ) and does not suppress the effect of vitamin D when used in combination (column 5).
[0155] Therefore, using low levels of costimulation (1:3 ratio of anti-CD3 / anti-CD28 beads to T cells) and a short 3 day culture interval, the addition of temsirolimus, vitamin D, or a combination of temsirolimus + vitamin D can be utilized to reduce both Th1 and Th2 cytokine effectors as well as cytotoxic effector mechanisms.
[0156] Example 2: The combination of vitamin D and temsirolimus alters key transcription factors associated with dedifferentiation We also evaluated the effect of vitamin D, temsirolimus, or the combination on the expression of key transcription factors following low-level costimulation.
[0157] Figures 2A-2D show that the combination of vitamin D and temsirolimus reduces the expression of human CD4 + and CD8 + This example illustrates that the combination of vitamin D and temsirolimus increases the expression of stem cell-associated transcription factors and the prototypical T cell molecule IL-7 receptor-α in T cells. + and CD8 + Illustrates reducing effector molecule expression in T cells. For columns #2-#5, T cells were subjected to a 3-day dedifferentiation interval that included low levels of anti-CD3 / anti-CD28 costimulation (beads to T cells ratio; 1:3), high doses of temsirolimus (1 μM), vitamin D (0.1 or 1.0 nM), and culture in X-Vivo 20 medium. The first column represents control cultures (no temsirolimus, no vitamin D, use of a 3:1 bead to T cells ratio, and inclusion of the type I polarizing cytokine IFN-α). The second column represents cultures that had low bead to T cells ratio and temsirolimus but no vitamin D, and in contrast, the third column represents cultures that had vitamin D (0.1 nM) but no temsirolimus. The fourth column represents cultures with high dose ("HD") vitamin D (1.0 nM) but no temsirolimus. The fifth column represents cultures with both high dose vitamin D (1.0 nM) in combination with temsirolimus. At the end of the dedifferentiation period, cells were harvested, RNA was isolated, and RNA expression analysis was performed by Luminex Quantigene method. All results shown represent relative RNA expression, and results are normalized to a value of 1.0 for Th1 / Tc1 control cultures.
[0158] As Figure 2A shows, temsirolimus or the combination of temsirolimus + vitamin D resulted in the upregulation of the Nanog transcription factor, which is recognized as one of the few key factors required for the dedifferentiation of somatic cells towards the iPSC state. Previously, in human fibroblasts, mTOR inhibition using rapamycin was found to increase Nanog expression. In contrast, vitamin D receptor signaling was found to reduce the expression of transcription factors associated with the iPSC state.
[0159] Thus, using low levels of costimulation, temsirolimus increases the iPSC transcription factor Nanog, and this promoting effect of temsirolimus is not abolished by vitamin D at concentrations ranging from 0.1 to 1.0 nM.
[0160] In comparison, neither temsirolimus nor vitamin D alone increased the RNA expression of the KLF4 molecule, which is also one of the classical transcription factors associated with the iPSC state. However, the combination of temsirolimus + vitamin D (1.0 nM) increased KLF4 RNA expression. Therefore, it is preferable to include both temsirolimus and vitamin D in T cell dedifferentiation attempts. As Figure 2B shows, neither temsirolimus nor vitamin D alone acts to upregulate the beneficial dedifferentiation molecule KLF4, but the combination of temsirolimus (1 μM) and vitamin D (1.0 nM) synergistically upregulates KLF4.
[0161] The related transcription factor KLF10 was also upregulated when utilizing a combination of temsirolimus and vitamin D (1.0 nM). As Figure 2C shows, temsirolimus at a dose of 1 μM acts alone to beneficially upregulate the dedifferentiation molecules KLF10, Nanog, and IL-7 receptor alpha. Vitamin D does not act alone to upregulate these molecules, but does not suppress the effects of temsirolimus when used in combination (column 5).
[0162] Finally, we evaluated the cultured cells for RNA expression of IL-7 receptor alpha, which is upregulated in T cells with reduced differentiation status. Importantly, vitamin D alone was unable to upregulate IL-7 receptor alpha, whereas temsirolimus alone was. Nevertheless, the combination of vitamin D (1.0 nM) and temsirolimus resulted in upregulation of IL-7 receptor alpha, as shown in Figure 2D.
[0163] In summary, these data indicate that low levels of costimulation in combination with temsirolimus can be used to force T cell differentiation, with the inclusion of temsirolimus and vitamin D in the culture being preferred for a more complete dedifferentiation pattern.
[0164] Example 3: The combination of vitamin D and temsirolimus reduces key transcription factors associated with Th1 differentiation while maintaining HIF-1-α expression We also evaluated the effect of vitamin D, temsirolimus, or the combination, on the expression of key transcription factors associated with Th1-type differentiation, namely T-BET and STAT1.
[0165] 3A-3C show that the combination of vitamin D and temsirolimus reduces the expression of transcription factors associated with effector Th1 / Tc1 cells without reducing the expression of HIF-1-α, a transcription factor associated with T cell survival. + and CD8 +Illustrates reducing effector molecule expression in T cells. For columns #2-#5, T cells were subjected to a 3-day dedifferentiation interval that included low levels of anti-CD3 / anti-CD28 costimulation (beads to T cells ratio; 1:3), high doses of temsirolimus (1 μM), vitamin D (0.1 or 1.0 nM), and culture in X-Vivo 20 medium. The first column represents control cultures (no temsirolimus, no vitamin D, use of a 3:1 bead to T cells ratio, and inclusion of the type I polarizing cytokine IFN-α). The second column represents cultures that had low bead to T cells ratio and temsirolimus but no vitamin D, and in contrast, the third column represents cultures that had vitamin D (0.1 nM) but no temsirolimus. The fourth column represents cultures with high dose ("HD") vitamin D (1.0 nM) but no temsirolimus. The fifth column represents cultures with both high dose vitamin D (1.0 nM) in combination with temsirolimus. At the end of the dedifferentiation period, cells were harvested, RNA was isolated, and RNA expression analysis was performed by Luminex Quantigene method. All results shown represent relative RNA expression, and results are normalized to a value of 1.0 for Th1 / Tc1 control cultures.
[0166] Importantly, each agent or the combination of agents downregulated both T-BET RNA (Figure 3A) and STAT1 RNA (Figure 3B). As shown in Figures 3A-3C, vitamin D at doses of 0.1-1.0 nM acts alone to beneficially downregulate the differentiation molecules T-BET and STAT1. Temsirolimus at a dose of 1 µM does not detrimentally downregulate the pro-survival transcription factor HIF-1α, even in combination with 1.0 nM vitamin D. However, temsirolimus at a dose of 1 µM acts alone to beneficially downregulate the differentiation molecules T-BET and STAT1, and produces similar results in combination with vitamin D (these two agents are not antagonists).
[0167] In sharp contrast, temsirolimus at a dose of 1 μM, vitamin D at doses of 0.1–1.0 nM, or the combination did not downregulate the key transcription factor HIF-1-α, which is important as a T cell survival factor critical for antitumor efficacy (Figure 3C).
[0168] In summary, these data show that a combination of low-level costimulation, temsirolimus, and vitamin D can be used to reduce transcription factors required for Th1 generation without inhibiting HIF-1-α, the major transcription factor required for overall T cell survival.
[0169] Example 4: Combination of Vitamin D, Temsirolimus, and Anti-IL-2 Receptor Monoclonal Antibody Increases Autophagy Signature We also evaluated the effect of vitamin D, temsirolimus, or their combination on the process of autophagy, which is important for promoting a stem-like dedifferentiated state. The level of autophagy can be determined in part by Western blot analysis, followed by upregulation of the autophagy substrate p62.
[0170] Figure 4 shows that the combination of vitamin D, temsirolimus, and anti-IL-2 receptor blockade induces the expression of the autophagy-related molecule p62. + and CD8 + T cells were subjected to a dedifferentiation protocol that included 3 days of culture using low-level costimulation (1:3 bead to T cell ratio), temsirolimus ("TEM" as shown in Figure 4, at concentrations of 1.0 or 0.3 μM), vitamin D ("D" as shown, at concentrations of 0.01, 0.03, 0.1, 0.3, or 1.0 nM), and anti-IL-2 receptor monoclonal antibody (daclizumab, 50 μg / ml, "DAC" as shown). After the 3-day culture interval, T cells were harvested, proteins were isolated, and Western blot analysis was performed for the autophagy-related gene p62, and the housekeeping gene actin.
[0171] As Figure 4 shows, inclusion of vitamin D in T cell cultures was critical for increased autophagy, as measured by upregulated p62. Vitamin D at doses of 0.01-0.1 nM cooperates with temsirolimus at concentrations of 0.3-1.0 μM to beneficially upregulate the autophagy marker p62 during dedifferentiation. Namely, in Figure 4, culture #6 (fifth column), p62 expression in Western blot analysis was very low, which is consistent with low levels of autophagy. As the figure legend indicates, this culture condition received low levels of co-stimulation, temsirolimus, and the anti-IL-2 receptor monoclonal antibody daclizumab, but no vitamin D.
[0172] In contrast, the other culture conditions each received vitamin D supplementation, and each increased p62 expression (effective dose range of vitamin D, 0.01 nM to 1.0 nM). This Figure 4 also demonstrates that vitamin D without anti-IL-2 receptor monoclonal antibody addition and vitamin D without temsirolimus addition were sufficient to induce T cell autophagy.
[0173] In summary, these data indicate that including vitamin D with low-level costimulation is an efficient method to induce T cell autophagy, either alone or in combination with other T cell inhibitors, i.e., anti-IL-2 receptor reagents or the mTOR inhibitor temsirolimus.
[0174] Example 5: The combination of vitamin D, temsirolimus, and anti-IL-2 receptor monoclonal antibody results in optimal disruption of the mTORC1 complex. We also assessed the effect of various T cell culture conditions on the expression of Raptor, a key component of the mTORC1 signaling complex. Importantly, inhibition of mTORC1 has recently been found to be important for the reprogramming of somatic cells to an iPSC state.
[0175] Figure 5 shows that the combination of vitamin D, temsirolimus, and anti-IL-2 receptor blockade reduces the expression of the mTORC1-associated molecule, RAPTOR. + and CD8 + T cells were subjected to a dedifferentiation protocol that included 3 days of culture using low level costimulation (1:3 bead to T cell ratio), temsirolimus ("TEM" as shown in Figure 5, at concentrations of 1.0 or 0.3 μM), vitamin D ("D" as shown, at concentrations of 0.01, 0.03, 0.1, 0.3, or 1.0 nM), and anti-IL-2 receptor monoclonal antibody (daclizumab, 50 ng / ml, "DAC" as shown). After the 3-day culture interval, T cells were harvested, proteins were isolated, and Western blot analysis was performed for the mTORC1 complex protein Raptor and the housekeeping gene actin.
[0176] As Figure 5 shows, optimal inhibition of the mTORC1 complex, as indicated by a reduction in RAPTOR expression, occurred when T cells were costimulated at a low bead-to-T cell ratio (1:3) in combination with temsirolimus (1.0 μM), vitamin D (0.1 nM), and the anti-IL-2 receptor monoclonal antibody daclizumab (50 μg / nl) (shown in the first column; culture 1).
[0177] As Figure 5 shows, omission of daclizumab resulted in a slight increase in RAPTOR expression, thereby indicating the role of anti-IL-2 receptor reagents for optimal mTORC1 inhibition. Thus, the anti-IL-2 receptor monoclonal antibody daclizumab (dose, 50 μg / mL) plays a beneficial role in suppressing the mTORC1 subunit molecule, Raptor (column 2).
[0178] As Figure 5 shows, optimal inhibition of the mTORC1 subunit molecule RAPTOR by vitamin D is at a vitamin D dose of 0.03 to 0.1 nM, with concentrations lower or higher than this range resulting in suboptimal suppression of RAPTOR. Thus, levels of vitamin D as low as 0.03 nM are sufficient for optimal inhibition of RAPTOR. However, lowering vitamin D levels to 0.01 nM results in suboptimal RAPTOR inhibition. Furthermore, increasing vitamin D levels beyond a concentration of 0.1 nM can be detrimental, as shown by culture 7 (vitamin D at a concentration of 0.3 nM), which had higher levels of RAPTOR expression.
[0179] Furthermore, as Figure 5 shows, optimal downregulation of RAPTOR requires a combination of vitamin D and temsirolimus with the temsirolimus dose optimally at 1.0 μM, as cultures 9 supplemented with temsirolimus at a concentration of 0.3 μM had higher levels of RAPTOR expression.
[0180] Example 6: The combination of vitamin D, temsirolimus, and anti-IL-2 receptor monoclonal antibody disrupts both the mTORC1 and mTORC2 complexes. We also evaluated the mTORC2 complex, which is not directly sensitive to the inhibitory effects of rapamycin but may be affected by conditions that result in prolonged mTORC1 blockade. Importantly, inhibition of mTORC2 can promote a stem cell-like state.
[0181] Figure 6 shows that the combination of vitamin D, temsirolimus, and anti-IL-2 receptor blockade reduces the expression of the mTORC1-associated molecule, RAPTOR, and the mTORC2-associated molecule, Rictor. + and CD8 +T cells were subjected to a dedifferentiation protocol that included 3 days of culture using low level costimulation (1:3 bead to T cell ratio), temsirolimus ("TEM" as shown in Figure 6, at a concentration of 1.0 μM), vitamin D ("D" as shown, at concentrations of 0.03, 0.1, 0.3, or 1.0 nM), and anti-IL-2 receptor monoclonal antibody (daclizumab, 50 ng / ml, "DAC" as shown). After the 3-day culture interval, T cells were harvested, proteins were isolated, and Western blot analysis was performed for the mTORC1 complex protein Raptor; mTORC2 complex protein, Rictor; post-mTORC1 protein, p70S6K; post-mTORC2 protein, SGK1, and the housekeeping gene, GAPDH.
[0182] As Figure 6 shows, compared with control cultures that did not contain any of the three inhibitors, T cell cultures in media containing temsirolimus, vitamin D, and the anti-IL-2 receptor antibody daclizumab showed a decrease in both the mTORC1 molecule RAPTOR and the mTORC2 molecule Rictor. The levels of the post-mTORC1 molecule p70S6K and the post-mTORC2 molecule SGK1 were relatively preserved. Thus, vitamin D (at concentrations of 0.03–1.0 nM) was effective during combination differentiation for downregulation of the mTORC2 subunit Rictor. And temsirolimus at a concentration of 1 μM was effective during combination differentiation for downregulation of the mTORC2 subunit Rictor. Furthermore, the anti-IL-2 receptor monoclonal antibody daclizumab (dose, 50 μg / mL) did not abolish the ability of temsirolimus and vitamin D to downregulate the mTORC2 subunit Rictor.
[0183] Thus, T cell culture using low levels of costimulation and a three-part inhibitory regimen of temsirolimus, vitamin D, and an anti-IL-2 receptor monoclonal antibody represents a novel method to reduce both RAPTOR and Rictor subunits.
[0184] Example 7: The combination of vitamin D, temsirolimus, and anti-IL-2 receptor monoclonal antibody reduces expression of the pro-apoptotic Bcl2 family member gene BIM. Autophagy at the level of mitochondria (mitophagy) can result in altered mitochondrial protein quality, and in particular, in mitophages, there can be a favorable shift from pro-apoptotic family members such as BIM towards anti-apoptotic pro-family member genes, such as bcl2 family member genes. Furthermore, culture methods that reduce apoptotic propensity are associated with increased dedifferentiation capacity.
[0185] Figure 7 shows that the combination of vitamin D, temsirolimus, and anti-IL-2 receptor blockade reduces the expression of the pro-apoptotic molecule, BIM. + and CD8 + T cells were subjected to a dedifferentiation protocol that included 3 days of culture using low level costimulation (1:3 bead to T cell ratio), temsirolimus ("TEM" as shown in Figure 7, at 1.0 or 0.3 μM concentration), vitamin D ("D" as shown, at 0.01, 0.03, 0.1, 0.3, or 1.0 nM concentration), and anti-IL-2 receptor monoclonal antibody (daclizumab, 50 ng / ml, "DAC" as shown). After the 3-day culture interval, T cells were harvested, proteins were isolated, and Western blot analysis was performed for the pro-apoptosis related gene BIM, and the housekeeping gene actin.
[0186] To assess this, we measured BIM levels in T cells cultured with low intensity costimulation (1:3 bead to T cell ratio) and in the presence of various inhibitors. As Figure 7 shows, T cell cultures containing a combination of temsirolimus, vitamin D (0.1 nM), and anti-IL-2 receptor monoclonal antibody daclizumab had the lowest levels of BIM expression. However, Figure 7 also shows that anti-IL-2 receptor monoclonal antibody daclizumab (dose, 50 μg / ml) plays a beneficial role in suppressing BIM, a pro-apoptotic molecule (column 2). Each of the three inhibitors appeared to play a role in BIM inhibition, since the absence of any single inhibitor increased BIM levels.
[0187] Thus, we conclude that the combined inhibitor regimen represents a method for inducing a favorable shift in mitochondrial control of apoptotic propensity.
[0188] Example 8: A triple inhibitor dedifferentiation regimen results in T cells with subsequent proliferation capacity following removal of the inhibitors. To demonstrate that the 3-day regimen consisting of low levels of costimulation, temsirolimus, vitamin D, and anti-IL-2 receptor monoclonal antibody resulted in a dedifferentiated state capable of redifferentiation, we performed experiments in which, after removing the inhibitors from the culture, high levels of costimulation (a 3:1 bead-to-T cell ratio) were used to restimulate the cells on day 3 of culture. After 10 days (13 days of total culture), T cells were harvested, enumerated, and assessed by flow cytometry.
[0189] FIG. 8 illustrates the effect of culture components during the dedifferentiation section on subsequent T cell yield (at day 13 of culture). + and CD8 +T cells were subjected to a 3-day dedifferentiation period that included culture in X-Vivo 20 medium supplemented with low levels of anti-CD3 / anti-CD28 costimulation (bead to T cell ratio, 1:3 or 1:1 as indicated), temsirolimus (1 μM, or low dose ["Lo"], 0.1 μM), vitamin D (0.1 nM, or high dose ["HD"] of 1.0 nM, or low dose of 0.01 nM), anti-IL-2 receptor monoclonal antibody (daclizumab, 50 μg / ml), and 5% human AB serum. The first column represents the control culture (no temsirolimus, vitamin D, or anti-IL-2R antibody). The second column represents cultures without anti-IL-2R antibodies, the fourth column represents cultures without serum supplementation, the fifth column represents low dose vitamin D, the sixth column represents results using high dose vitamin D, the seventh column represents results using low dose temsirolimus, the eighth column represents cultures without temsirolimus, and the ninth column represents results using a higher bead ratio. After the 3 day interval, the medium was replaced with fresh X-Vivo 20 without inhibitors, provided high level co-stimulation (3:1 bead to T cell ratio), and supplemented with T cell growth cytokines IL-2 (100 IU / ml) and IL-7 (10 ng / ml). On day 13 of culture, viable T cells were enumerated and the overall yield is shown relative to the input counts on day 0.
[0190] Figure 8 shows the T cell numbers after the redifferentiation step. As these data show (column #3), T cells maintained over the first 3 day dedifferentiation interval using low levels of costimulation, temsirolimus, vitamin D, and anti-IL-2 receptor monoclonal antibody had a satisfactory T cell yield (>250% of culture input).
[0191] In sharp contrast, very low yields were observed in the culture represented in row #4, which did not receive serum supplementation during the first 3-day culture period. Thus, this data demonstrates that the first 3-day culture period should contain X-Vivo 20 culture medium supplemented with 5% AB serum.
[0192] Also, lowering the vitamin D concentration to 0.01 nM or increasing the vitamin D concentration to 1.0 nM resulted in very low yields (data shown in columns #5 and #6, respectively). Therefore, the preferred concentration of vitamin D is 0.1 nM.
[0193] Furthermore, lowering the temsirolimus concentration to 0.1 μM resulted in a decreased T cell yield (column #7). Therefore, the preferred concentration of temsirolimus is 1.0 μM.
[0194] Finally, when costimulation levels were increased during the dedifferentiation section (bead to T cell ratio changed from 1:3 to 1:1, results shown in last column #9), the resulting T cell numbers were very low. As shown in Figure 8, it is necessary to use low levels of costimulation during dedifferentiation (co-stimulatory bead to T cell ratio of 1:3), because increasing the ratio to 1:1 significantly reduces the ability to produce T cells from the dedifferentiated state (last column). Therefore, the preferred bead to T cell ratio during the dedifferentiation phase of culture is 1:3.
[0195] Example 9: The first 3-component culture section expresses cell surface molecules consistent with reduced differentiation, CD4 + Leads to the generation of T cells. At various times during the redifferentiation phase of the culture, CD4 + T cells were assessed for expression of memory markers by flow cytometry.
[0196] Figures 9A-9C show the memory marker CD4 +The effects of culture components during the dedifferentiation section on T cell expression are illustrated. Human CD4+ and CD8+ T cells were subjected to a 3-day dedifferentiation section that included culture in X-Vivo 20 medium supplemented with low levels of anti-CD3 / anti-CD28 costimulation (1:3 ratio of beads to T cells), temsirolimus (1 μM or 0.1 μM [low dose "Lo"]), vitamin D (0.1 nM or 0.01 nM [low dose "Lo"]), anti-IL-2 receptor monoclonal antibody (daclizumab, 50 μg / ml), and 5% human AB serum (as shown in Figures 9A-9C above). After the 3-day section, the medium was replaced with fresh X-Vivo 20 without inhibitors, providing high level costimulation (3:1 ratio of beads to T cells), and adding the T cell growth cytokines IL-2 (100 IU / ml) and IL-7 (10 ng / ml). T cells were cultured in X-Vivo 20 medium supplemented with 5% human AB serum (as shown in Figures 9A-9C above). After the 3-day section, the medium was replaced with fresh X-Vivo 20 without inhibitors, providing high level costimulation (3:1 ratio of beads to T cells), and adding the T cell growth cytokines IL-2 (100 IU / ml) and IL-7 (10 ng / ml). + and CD45RA + Co-expression of markers (results shown in panel above, assessed on day 13 of culture); CD4 + , CD62L + , and CCR7 + Co-expression of markers (lower left panel; assessed on day 3 of culture); as well as CD4 + , CD62L + , CCR7 + , and CD127 + The co-expression of markers was evaluated by flow cytometry (lower right panel; assessed on day 10 of culture). All results were based on CD4 + Shown relative to values for T cells (last columns in Figures 9A-9C, "Day 0 input values").
[0197] As shown in FIG. 9A, compared to values from input T cells on day 0, T cells initially expanded with a combination of temsirolimus, vitamin D, and anti-IL-2 receptor monoclonal antibody had relatively preserved expression of the CD45RA marker expressed on naive T cells (row #3). In sharp contrast, the absence of these three molecules during the early culture interval resulted in depletion of the naive T cell population (culture #1). Furthermore, the exclusion of temsirolimus during the early culture interval resulted in depletion of the naive T cell population (culture #6).
[0198] As shown in FIG. 9B, each of the T cell cultures initially expanded during the 3-day interval incorporating low levels of costimulation had increased T cell expression of the central memory molecules CD62L and CCR7.
[0199] Finally, as shown in Figure 9C, T cells initially expanded with a combination of temsirolimus, vitamin D, and anti-IL-2 receptor monoclonal antibody showed a significant increase in the expression of T cells that were triple positive for CD62L, CCR7, and IL-7 receptor alpha (CD127) (compared to input cells at day 0). Elimination of the three inhibitors during the initial 3-day culture (column #1) abolished the ability of the initial culture section to promote the expansion of this triple-positive population. In addition, reducing or eliminating temsirolimus alone from the initial culture section also significantly reduced the frequency of triple-positive T cells (columns #5 and 6).
[0200] In summary, these data indicate that an initial three-drug culture interval results in the conversion of CD4+ T cells from a predominantly terminal effector memory population to a less differentiated T cell population, including co-expression of CD62L, CCR7, and CD127, a state of very restricted T cell differentiation.
[0201] Example 10: The first 3-component culture section expresses cell surface molecules consistent with reduced differentiation, CD8 + Leads to the generation of T cells. At various times during the redifferentiation phase of the culture, CD8 + T cells were assessed for expression of memory markers by flow cytometry.
[0202] Figures 10A and 10B show the memory marker CD8 +The effects of culture components during the dedifferentiation section on T cell expression are illustrated. Human CD4+ and CD8+ T cells were subjected to a 3-day dedifferentiation section that included culture in X-Vivo 20 medium supplemented with low levels of anti-CD3 / anti-CD28 costimulation (1:3 ratio of beads to T cells), temsirolimus (1 μM or 0.1 μM [low dose "Lo"]), vitamin D (0.1 nM or 0.01 nM [low dose "Lo"]), anti-IL-2 receptor monoclonal antibody (daclizumab, 50 μg / ml), and 5% human AB serum (as shown in Figures 10A-10B above). After the 3-day section, the medium was replaced with fresh X-Vivo 20 without inhibitors, providing high level costimulation (3:1 ratio of beads to T cells), and adding the T cell growth cytokines IL-2 (100 IU / ml) and IL-7 (10 ng / ml). T cells were cultured in X-Vivo 20 medium supplemented with 5% human AB serum (as shown in Figures 10A-10B above). After the 3-day section, the medium was replaced with fresh X-Vivo 20 without inhibitors, providing high level costimulation (3:1 ratio of beads to T cells), and adding the T cell growth cytokines IL-2 (100 IU / ml) and IL-7 (10 ng / ml). + , CD62L + , and CCR7 + Co-expression of markers (left panel; assessed on day 10 of culture); and CD8 + , CD62L + , CCR7 + , and CD127 + The co-expression of markers was evaluated by flow cytometry (right panel; evaluated on day 10 of culture). All results were consistent with the CD8 + Shown relative to the values for T cells (last columns in Figures 10A-10B, "Day 0 input values").
[0203] As shown in FIG. 10A, each of the T cell cultures initially expanded during the 3-day interval incorporating low levels of costimulation upregulated the CD8 + There was an increase in T cell expression.
[0204] Finally, as shown in Figure 10B, T cells initially expanded with a combination of temsirolimus, vitamin D, and anti-IL-2 receptor monoclonal antibody showed CD8 T cells that were triple positive for CD62L, CCR7, and IL-7 receptor α (CD127). +There was a significant increase in the expression of triple positive T cells (relative to day 0 input cells). Elimination of the three inhibitors during the initial 3 day culture (column #1) abolished the ability of the initial culture section to promote the expansion of this triple positive population. In addition, reducing or eliminating only temsirolimus from the initial culture section also significantly reduced the frequency of triple positive T cells (columns #5 and 6).
[0205] In summary, these data suggest that the initial culture interval of the three drugs induces a highly restricted state of T cell differentiation, conferring CD8+ / CD8+ T cells from a predominantly terminal effector memory population to a less differentiated T cell population, including co-expression of CD62L, CCR7, and CD127. + It has been shown to result in T cell conversion.
[0206] Example 11: Dedifferentiated T cells have an intrinsic bias toward low cytokine potential 11A-11D highlight the components of the dedifferentiation process, including the use of low levels of costimulation (1:3 ratio of anti-CD3 / anti-CD28 beads to T cells, which is reduced compared to the conventional method described in Kalamasz D, Long SA, Taniguchi R, Buckner JH, Berenson RJ, Bonyhadi M. Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies) Journal of immunotherapy (Hagerstown, Md: 1997). 2004; 27(5): 405-418), the mTOR inhibitor temsirolimus; vitamin D, and an anti-IL-2 receptor monoclonal antibody.
[0207] 11A-11D show inflammatory Th1 / Th17 cytokine analysis of dedifferentiated T cells cultured in polarizing neutral medium. + and CD8 +T cells were subjected to a 3-day dedifferentiation procedure that included the following culture components as indicated: temsirolimus (Y indicates a concentration of 1 μM, Y, Lo indicates a concentration of 0.1 μM), vitamin D (Y indicates a concentration of 0.1 nM, Y, Lo indicates a concentration of 0.01 nM), anti-IL-2 receptor monoclonal antibody (daclizumab, 50 μg / ml), costimulation with anti-CD3 / anti-CD28 (3 / 28) coated magnetic beads at a low ratio (beads to T cells ratio, 1:3), and supplementation with 5% human serum. After 3 days, dedifferentiated T cells were costimulated in medium supplemented with the T cell proliferation cytokines rhu IL-2 (100 IU / ml) and rhu IL-7 (10 ng / ml), which are not potent in inducing T cell polarization (typical bead to T cell ratio of 3:1). After 10 days in culture (total, day 13 of culture), T cells were harvested, washed, and restimulated with 3 / 28 beads (3:1 ratio) for 24 hours, and the resulting supernatants were harvested and tested for cytokine content by Luminex multi-analyte method. All results shown are from 1×10 6 Expressed as cytokine levels in pg / ml per cells / ml / 24 hours.
[0208] To assess whether the dedifferentiated T cell state exhibited an inherent bias towards specific cytokine secretion patterns, we cultured dedifferentiated T cells using high levels of costimulation (bead to T cell ratio, 3:1) and maintenance in medium that did not contain any inhibitors but only the T cell growth cytokines IL-2 and IL-7.
[0209] As detailed in Figures 11A-11D, the resulting T cells redifferentiated from each of the dedifferentiated progenitor states secreted very low levels of inflammatory cytokines, including IFN-γ (most values below 1000 pg / ml), TNF-α (most values below 100 pg / ml), and IL-17 (all values below 10 pg / ml). Notably, GM-CSF was secreted at much higher levels under some conditions, in some cases at levels above 10,000 pg / ml. GM-CSF levels were modulated in dedifferentiated states consisting of higher doses of temsirolimus (1.0 μM) and higher doses of vitamin D (0.1 nM). It would therefore be desirable to expand T cells from dedifferentiation methods incorporating these higher concentrations of temsirolimus and vitamin D for modulation of the resulting T cell cytokine secretion of GM-CSF.
[0210] Notably, inclusion of low concentrations of vitamin D (0.01 nM) during the dedifferentiation interval also resulted in somewhat higher levels of IFN-γ and TNF-α compared to the use of higher concentrations of vitamin D (0.1 nM). Thus, it is preferable to use vitamin D at a concentration of about 0.1 nM with respect to regulating the resulting T cell secretion of the inflammatory cytokine IFN-γ.
[0211] Furthermore, as shown in Figures 12A-12D, the resulting T cells redifferentiated from each of the dedifferentiated progenitor state T cells had very low levels of IL-2 secretion, but again, the levels were lower in conditions incorporating higher concentrations of temsirolimus and vitamin D compared to conditions using lower concentrations of these agents.
[0212] 12A-12D show IL-2 and Th2-type cytokine analysis of dedifferentiated T cells cultured in polarizing neutral medium. + and CD8 +T cells were subjected to a 3-day dedifferentiation procedure that included the following culture components as indicated: temsirolimus (Y indicates a concentration of 1 μM, Y, Lo indicates a concentration of 0.1 μM), vitamin D (Y indicates a concentration of 0.1 nM, Y, Lo indicates a concentration of 0.01 nM), anti-IL-2 receptor monoclonal antibody (daclizumab, 50 μg / ml), costimulation with anti-CD3 / anti-CD28 (3 / 28) coated magnetic beads at a low ratio (beads to T cells ratio, 1:3), and supplementation with 5% human serum. After 3 days, dedifferentiated T cells were costimulated in medium supplemented with the T cell proliferation cytokines rhu IL-2 (100 IU / ml) and rhu IL-7 (10 ng / ml), which are not potent in inducing T cell polarization (typical bead to T cell ratio of 3:1). After 10 days in culture (total, day 13 of culture), T cells were harvested, washed, and restimulated with 3 / 28 beads (3:1 ratio) for 24 hours, and the resulting supernatants were harvested and tested for cytokine content by Luminex multi-analyte method. All results shown are from 1×10 6 Expressed as cytokine levels in pg / ml per cells / ml / 24 hours.
[0213] The resulting T cells also had very low levels of secretion of the Th2-type cytokines IL-4 (values below 20 pg / ml) and IL-5 (values below 60 pg / ml). However, levels of IL-13 were elevated in some T cell culture conditions, and lower cytokine secretion was detected in conditions incorporating higher concentrations of temsirolimus and vitamin D compared to conditions using lower concentrations of these agents.
[0214] In summary, these data indicate that redifferentiation of T cells in medium containing T cell growth cytokines (IL-2 and IL-7) without strong polarizing signals (no addition of IFN-α, IL-4, or TGF-β) after the step 1 dedifferentiation process has an inherent bias toward T cells with low cytokine potential; in particular, we demonstrated low levels of the deleterious cytokines IFN-γ, TNF-α, and IL-17. This observation is particularly strong when the dedifferentiation step incorporates low levels of costimulation and proliferation in medium containing temsirolimus at a concentration of 1.0 μM, vitamin D at a concentration of 0.1 nM, and an anti-IL-2 receptor monoclonal antibody.
[0215] Example 12: Hybrid T REG Preferential expansion of dedifferentiated T cells under Th2-polarizing conditions and in the presence of the novel agent pemetrexed The present inventors have demonstrated that T cell redifferentiation is REG The effect of the dedifferentiation components upon incorporation of the Th1 polarizing cytokines IL-2 and TGF-β, or the Th1 polarizing cytokine, IFN-α, was evaluated.
[0216] Indeed, either TBET or GATA3 may mediate the T cell proliferation and proliferation in maintaining immune tolerance. REG It has been shown that T REG Despite this evidence for a role for either TBET or GATA3 in cell function, due to the very strong association of TBET and the resulting Th1-type pathway in autoimmunity, we hypothesized that the produced T REG We therefore chose to prioritize GATA3 expression in T cells. REG Either the step 2 redifferentiation process, which includes both Th2 polarizing signals (IL-2, TGF-β) and the predominant Th2 polarizing signal (IL-4), results in the redifferentiation of human “hybrid” T cells. REG -Th2 cells were generated. REG The deliberate addition of IL-4 to cell ex vivo cultures enhances T REGResults in the literature from experimental mouse models are mixed in this regard, as T cells have been shown to either promote or suppress the phenotype. REG In addition to this conflicting mouse literature regarding the role of exogenous IL-4 in cell production, human T REG Although there is little information on the ex vivo role of IL-4 on human T cells, this study demonstrated that IL-4 REG It was found that the cells retained their functions.
[0217] iT REG Cells are iT REG Human iT cells have been characterized as having a propensity for in vivo differentiation plasticity that allows them to convert into pathogenic Th1 or Th17 subsets, thus harboring a hybrid Th2 component REG On the other hand, differentiation towards a Th2-type phenotype may be favorable for iT cell therapy. REG When encoded in the production, Th2 bias predictably limits plasticity towards a Th1 / Th17 phenotype.
[0218] Furthermore, the inventors have demonstrated that the drug pemetrexed REG We assessed whether preferential iT could be beneficial in promoting cell phenotypes. REG There is precedent for the use of drugs for cell generation, most notably the mTOR inhibitor rapamycin, which has been shown to mediate iT REG However, pemetrexed has been associated with a shift towards iT REG It has not been characterized as having a stimulatory effect. Pemetrexed has a complex mechanism of action as a folate antimetabolite.
[0219] FIG. 13 shows hybrid Th2 / REG13 shows the favorable expansion of dedifferentiated T cells in polarizing conditions compared to Th1 polarizing conditions. Human CD4+ and CD8+ T cells were subjected to a 3-day dedifferentiation procedure ("Step 1"). As shown in FIG. 13, this step 1 dedifferentiation intervention variably included no inhibitor ("None"), temsirolimus alone ("T", 1.0 μM), vitamin D alone ("D", 0.1 nM), anti-IL-R monoclonal antibody basiliximab alone ("B", 10 μg / ml), or various combinations of inhibitors (T, D, or T, D, B). After 3 days, the dedifferentiated T cells were variably transferred to Th1 polarizing conditions (rhu IFN-α, 10,000 IU / ml), T REG Polarized (rhu IL-2, 100IU / ml, rhu TGF-β, 10ng / ml), or hybrid Th2-T REG Co-stimulation was performed (typical bead-to-T cell ratio, 3:1) in medium supplemented with polarizing conditions (IL-2, TGF-β, plus rhu IL-4 [1000 IU / ml]). In addition, T cell cultures were performed without the novel inhibitor molecule pemetrexed ("0") or in the presence of variable concentrations of pemetrexed as indicated (10 nM ["10"], 33 nM ["33"], or 100 nM ["100"]) under variable polarizing conditions. After a total of 10 days of culture, n = 24 cultures were harvested and viable cells were enumerated and graphed above (y-axis represents number of cells × 10 6 The number of input cells was 1.5 × 10 6 (There were 100 of them).
[0220] As FIG. 13 shows, the redifferentiation ability of T cells following step 1 dedifferentiation was dependent on the specific components added during dedifferentiation, the specific cytokines added during redifferentiation, and the presence of pemetrexed during redifferentiation.
[0221] Notably, attempts to redifferentiate sufficient numbers of T cells after step 1 dedifferentiation were unsuccessful under conditions of Th1-type polarization (see Figure 13, cultures #9-#16; all T cell yields were less than the T cell input numbers). A very limited ability to redifferentiate along a Th1-type pathway was observed when dedifferentiation conditions included temsirolimus and vitamin D alone or in combination with an anti-IL-2 receptor reagent, as well as when pemetrexed was not added during step 2 cultures or was not added at concentrations ranging from 10-100 nM.
[0222] In sharp contrast, attempts to redifferentiate sufficient numbers of T cells after dedifferentiation in step 1 have yielded hybrid T REG Under Th2-polarizing conditions, dedifferentiation was successful (see FIG. 13, cultures #2 and #5). Notably, under the most stringent dedifferentiation conditions (containing temsirolimus, vitamin D, and anti-IL-2 receptor monoclonal antibody), T REG -Sufficient T cells in Th2 polarizing conditions were only observed when pemetrexed was added to step 2 cultures at a concentration of 10 nM.
[0223] Using these most stringent dedifferentiation step 1 conditions, pure T cells were obtained during step 2. REG Attempts to redifferentiate sufficient numbers of T cells under polarizing conditions (IL-2+TGF-β, without IL-4) were unsuccessful, even in the presence of pemetrexed (cultures #20 and #21).
[0224] In summary, from a numerical point of view, T REG - Use Th2 hybrid polarizing conditions (IL-2, TGF-β, and IL-4) with pemetrexed at a concentration of 10 nM to optimize successful T cell redifferentiation.
[0225] Example 13: Hybrid T REG Culture of dedifferentiated T cells in Th2 / Th2 conditions results in a limited differentiation state of CD4 + and CD8 + Leads to the generation of T cells We also evaluated the effect of this step 1 dedifferentiation process followed by step 2 redifferentiation in different cytokine polarization / different pemetrexed conditions on T cell memory state. Thus, studies have shown that T cells in a limited differentiation state have improved therapeutic utility for adoptive cell therapy. Thus, limited T cell differentiation would be an advantageous feature of the step 1 / step 2 T cell manufacturing method.
[0226] 14A to 14C show hybrid Th2 / T REG Culture of dedifferentiated T cells under polarizing conditions results in the differentiation of naive and triple-positive T central memory CD4 + This example illustrates the generation of human CD4 T cells. + and CD8 + T cells were subjected to a dedifferentiation procedure and subsequent culture for 3 days in medium containing varying polarizing culture conditions and varying presence of pemetrexed, as described in Figure 13. Of a total of N=24 culture conditions, only cultures with favorable cell yields were further evaluated, showing that all cultures containing pemetrexed ("+") at a concentration of 10 nM. REG All conditions contained IL-2, TGF-β, and IL-4 ("TReg") unless indicated ("TReg, no IL4"). After a total of 10 days of culture, cultures were harvested and assessed by flow cytometry for content of: naive CD4 + T cells (total CD4 + Expressed as a percentage of CD4+ T cells; Figure 14A), central memory CD4 + T cells (total CD4 + % of T cells expressed CD4+ T cells; Figure 14B), as well as triple-positive central memory CD4 + T cells (total CD4 + % of T cells expressed IFN-glucose agonist (Figure 14C).
[0227] As shown in FIG. 14A, the hybrid T REG- Step 2 redifferentiation in the Th2 state (with or without pemetrexed at 10 nM concentration) is favorable in an experimental mouse model of adoptive T cell therapy, CD4 + CD45RA + It resulted in a high frequency of naive T cell subsets.
[0228] In addition, as shown in FIG. REG Step 2 redifferentiation in the Th2 state (with or without pemetrexed at 10 nM concentration) resulted in CD4+ cells with triple positive co-expression of memory markers CD62L, CCR7, and CD127. + These results suggest that the triple-positive memory phenotype is a marker for T cells with a highly primitive differentiation state.
[0229] As shown in Figure 14C, CD4 + The frequency of T cells is pure T REG Compared with the polarization condition, the hybrid T REG - was higher in TH2 polarized conditions.
[0230] Also, as shown in FIG. 14C, the use of more stringent step 1 differentiation conditions, including not only temsirolimus and vitamin D, but also anti-IL-2 receptor monoclonal antibody, significantly increased the number of hybrid T REG -Th2 polarizing conditions were used to yield the highest frequency of CD4 cells that were triple positive for CD62L, CCR7, and CD127.
[0231] 15A to 15B show hybrid Th2 / T REG Culture of dedifferentiated T cells under polarizing conditions induces triple-positive T central memory CD8 + This example illustrates the generation of human CD4 T cells. + and CD8 +T cells were subjected to a dedifferentiation procedure and subsequent culture for 3 days in medium containing varying polarizing culture conditions and varying presence of pemetrexed, as described in Figure 13. Of a total of N=24 culture conditions, only cultures with favorable cell yields were further evaluated, showing that all cultures containing pemetrexed ("+") at a concentration of 10 nM. REG All conditions contained IL-2, TGF-β, and IL-4 ("TReg") unless indicated ("TReg, no IL4"). After a total of 10 days of culture, cultures were harvested and assessed by flow cytometry for content of: central memory CD8 + T cells (total CD8 + % of T cells expressed CD8 T cells (Figure 15A), as well as triple-positive central memory CD8 + T cells (total CD8 co-expressing CD62L, CCR7, and CD127 + % of T cells expressed IFN-glucose agonist (Figure 15B).
[0232] Also, as shown in Figure 15B, the frequency of CD8 cells that were triple positive for CD62L, CCR7, and CD127 was significantly higher than that of pure T REG Compared with the polarization condition, the hybrid T REG Furthermore, as shown in Figures 15A-15B, the use of the more stringent step 1 differentiation conditions, including not only temsirolimus and vitamin D, but also anti-IL-2 receptor monoclonal antibody, enhanced the expression of hybrid T REG -CD8 that were triple positive for CD62L, CCR7, and CD127 using Th2 polarizing conditions + It yielded the highest frequency of T cells.
[0233] In summary, these data suggest that hybrid T REG - T cell redifferentiation using Th2 cytokine polarization (IL-2, TGF-β, and IL-4) and using pemetrexed (10 nM) after dedifferentiation in step 1 favorably differentiates CD4 + and CD8+ It has been shown to result in T cells.
[0234] Example 14: Hybrid T REG Culture of dedifferentiated T cells in Th2-polarizing conditions results in T cells with a primitive Th2 cell cytokine phenotype T cells redifferentiated in the culture conditions of step 2 after dedifferentiation of step 1 were also evaluated for their cytokine secretion patterns. Cytokine secretion is an indicator of T cell effector function and therefore, REG It is generally desirable for the cells to have a reduced cytokine secretion potential, particularly with respect to key inflammatory cytokines such as IL-17, IFN-γ and TNF-α. REG In the case of -Th2 cell populations, such cells are also expected to secrete several classes of Th2 cytokines.
[0235] Figures 16A-C show that culture of dedifferentiated T cells in hybrid Th2 / TReg polarizing conditions results in the production of T cells with a typical Th2 cell cytokine phenotype, as shown by high levels of IL-2 and IL-4 secretion and low levels of IL-5 secretion. + and CD8 + T cells were subjected to a dedifferentiation procedure and subsequent culture for 3 days in medium containing varying polarizing culture conditions and varying presence of pemetrexed, as described in Figure 13. Of a total of N=24 culture conditions, only cultures with favorable cell yields were further evaluated, showing that all cultures containing pemetrexed ("+") at a concentration of 10 nM. REG All conditions contained IL-2, TGF-β, and IL-4 ("TReg") unless indicated ("TReg, no IL4"). After a total of 10 days of culture, T cells were harvested, washed, and restimulated with 3 / 28 beads (3:1 ratio) for 24 hours, and the resulting supernatants were harvested and tested for cytokine content by Luminex multi-analyte method. All results shown are from 1×10 6Expressed as cytokine levels in pg / ml per cells / ml / 24 hours.
[0236] As shown in FIG. 16A, hybrid T REG T cells redifferentiated in -TH2 cytokine polarizing conditions (IL-2, TGF-β, and IL-4) had the highest values for IL-2 secretion, consistent with previous understanding that IL-2 secretion in T cells is a feature of T cells in an early differentiation state, as harbored by T cells redifferentiated in hybrid culture conditions.
[0237] Figures 17A-17C show that hybrid Th2 / T cells secrete low levels of IL-10, IL-13, and IL-17. REG We show that culture of dedifferentiated T cells in polarizing conditions results in the generation of T cells with a predominant Th2 cell cytokine phenotype. + and CD8 + T cells were subjected to a dedifferentiation procedure and subsequent culture for 3 days in medium containing varying polarizing culture conditions and varying presence of pemetrexed, as described in Figure 13. Of a total of N=24 culture conditions, only cultures with favorable cell yields were further evaluated, showing that all cultures containing pemetrexed ("+") at a concentration of 10 nM. REG All conditions contained IL-2, TGF-β, and IL-4 ("TReg") unless indicated ("TReg, no IL4"). After a total of 10 days of culture, T cells were harvested, washed, and restimulated with 3 / 28 beads (3:1 ratio) for 24 hours, and the resulting supernatants were harvested and tested for cytokine content by Luminex multi-analyte method. All results shown are from 1×10 6 Expressed as cytokine levels in pg / ml per cells / ml / 24 hours.
[0238] 18A-18C show that hybrid Th2 / T cells secrete low levels of IFN-γ, TNF-α, and GM-CSF. REGWe show that culture of dedifferentiated T cells in polarizing conditions results in the production of T cells with an obligate Th2 cell cytokine phenotype. Human CD4 + and CD8 + T cells were subjected to a dedifferentiation procedure and subsequent culture for 3 days in medium containing varying polarizing culture conditions and varying presence of pemetrexed, as described in Figure 13. Of a total of N=24 culture conditions, only cultures with favorable cell yields were further evaluated, showing that all cultures containing pemetrexed ("+") at a concentration of 10 nM. REG All conditions contained IL-2, TGF-β, and IL-4 ("TReg") unless indicated ("TReg, no IL4"). After a total of 10 days of culture, T cells were harvested, washed, and restimulated with 3 / 28 beads (3:1 ratio) for 24 hours, and the resulting supernatants were harvested and tested for cytokine content by Luminex multi-analyte method. All results shown are from 1×10 6 Expressed as cytokine levels in pg / ml per cells / ml / 24 hours.
[0239] Furthermore, as shown in FIG. 16B, hybrid T REG -T cells redifferentiated in TH2 conditions (IL-2, TGF-β, and IL-4) had the highest values for IL-4 secretion. Since IL-4 is the main cytokine instructing Th2 polarization, T cells produced in hybrid conditions are indeed Th2 polarized. On the other hand, consistent with their limited differentiation state, cells redifferentiated in hybrid conditions did not secrete high levels of effector Th2 cytokines (IL-5, see FIG. 16C; IL-10, see FIG. 17A; IL-13, see FIG. 17B) or effector Th1 / Th17 cytokines (IFN-γ, see FIG. 18A; TNF-α, see FIG. 18B; GM-CSF, see FIG. 18C; IL-17, see FIG. 17C).
[0240] Importantly, the lack of IL-4 inclusion in the T cell redifferentiation process resulted in higher levels of the proinflammatory cytokines IFN-γ, TNF-α, and GM-CSF (see Figures 18A-18C).
[0241] In summary, these data support the conclusion that T REG Redifferentiation of T cells toward the hybrid T phenotype is important because T cells emerging from this condition have a significantly reduced ability to secrete cytokines associated with inflammatory diseases. REG - indicating that Th2 polarizing conditions should be optimally utilized.
[0242] Example 15: Hybrid T REG Culture of dedifferentiated T cells in Th2 / Th2 conditions enhances hybrid T REG / Results in T cells with a Th2 transcription factor profile The T cell cytokine phenotype is determined by key transcription factors. The association of transcription factors with T cell subsets is as follows: FOXP3 is involved in T REG TBET directs Th1-type cell development, and GATA3 directs Th2-type cell development.
[0243] To evaluate these transcription factors in our method of production, T cells were first subjected to the dedifferentiation procedure in step 1 and then hybrid T REG -TH2 culture conditions (IL-2, TGF-β, and IL-4). In addition, we compared the effects of pemetrexed with a classical mTOR inhibitor. In our experiments, instead of using an oral formulation of the mTOR inhibitor (rapamycin; Sirolimus®), we utilized the water-soluble parent form of the drug, temsirolimus (Toracel®).
[0244] iT REG The phenotype was deemed unstable, and therefore, we attempted to culture hybrid T at delayed time points, including days 20 and 32 of culture. REGThe stability of redifferentiated T cells was assessed using -Th2 culture conditions. In addition, to rigorously test phenotypic stability, T cells received high levels of costimulation (3:1 bead-to-T cell ratio) and were expanded in medium without cytokines or pharmacological agents between days 24 and 32 of culture.
[0245] Figures 19A to 19D show hybrid Th2 / T containing pemetrexed. REG Expanded cultures of dedifferentiated T cells in polarizing conditions produce CD4 T cells that express FOXP3 and GATA3 transcription factors. + This example illustrates the generation of human CD4 T cells. + and CD8 + T cells were subjected to a 3-day dedifferentiation procedure and then co-stimulated (3:1 bead to T cell ratio) with or without the pharmacological inhibitors temsirolimus (1.0 μM) or pemetrexed (10 nM) to form hybrid Th2 / T REG Cultures were grown in medium containing polarizing conditions (IL-2; TGF-β; IL-4). Cultures were restimulated with 3 / 28 beads on both days 14 and 24 of culture. To assess the stability of transcription factor expression on day 24 of culture, the culture medium did not contain exogenous cytokines or pharmacological inhibitors. On days 12, 20, and 32 of culture, T cells were harvested and subjected to surface flow cytometry (CD4 marker) and intracellular staining for the following transcription factors: FOXP3, Tbet, and GATA3. The data above are the percent of CD4 cells out of the total culture population (Figure 19A), T REG The percentage of CD4 cells that expressed the transcription factor FOXP3 (FIG. 19B), the percentage of CD4 cells that expressed the Th1 transcription factor Tbet (FIG. 19C), and the percentage of CD4 cells that expressed the Th2 transcription factor GATA3 (FIG. 19D) are shown.
[0246] As a detail of Figures 19A to 19D, T REGT cells redifferentiated in -Th2 conditions gradually shifted toward a predominance of CD4 cells over time in culture (Figure 19A). As shown in Figure 19B, CD4 cells frequently and stably expressed FOXP3 from days 12 to 32 of culture, regardless of the presence of temsirolimus or pemetrexed in the culture.
[0247] As shown in Figure 19C, even without the presence of pharmacological inhibitors, there was a very low frequency of contamination with the Th1 transcription factor TBET. However, the most consistently reduced TBET values were observed in hybrid polarization conditions that also contained pemetrexed. Finally, as shown in Figure 19D, hybrid T cells supplemented with pemetrexed showed a significantly reduced TBET concentration. REG The highest end-of-culture Th2-associated GATA3 expression was observed in T cells generated under -TH2 conditions.
[0248] Figures 20A to 20D show hybrid Th2 / T REG Expanded culture of dedifferentiated T cells in polarizing conditions produces CD8 T cells that express FOXP3 and GATA3 transcription factors. + This example illustrates the generation of human CD4 T cells. + and CD8 + T cells were subjected to a 3-day dedifferentiation procedure and then co-stimulated (3:1 bead to T cell ratio) with or without the pharmacological inhibitors temsirolimus (1.0 μM) or pemetrexed (10 nM) to form hybrid Th2 / T REG Cultures were grown in medium containing polarizing conditions (IL-2; TGF-β; IL-4). Cultures were restimulated with 3 / 28 beads on both days 14 and 24 of culture. To assess the stability of transcription factor expression on day 24 of culture, the culture medium did not contain exogenous cytokines or pharmacological inhibitors. On days 12, 20, and 32 of culture, T cells were harvested and subjected to surface flow cytometry (CD8 marker) and intracellular staining for the following transcription factors: FOXP3, Tbet, and GATA3. The data above are the percent of CD8 cells out of the total culture population (Figure 20A), T REGThe percentage of CD8 cells that expressed the transcription factor FOXP3 (FIG. 20B), the percentage of CD8 cells that expressed the Th1 transcription factor Tbet (FIG. 20C), and the percentage of CD8 cells that expressed the Th2 transcription factor GATA3 (FIG. 20D) are shown.
[0249] As shown in FIG. 20A, CD8 cell content gradually and modestly decreased over time in culture. REG Cellular functions are largely attributable to the CD4 cell subset, whereas CD8 + T REG The cells are also well described and are CD4 + and CD8 + T, which contains both T cell subsets REG It should be noted that the use of populations may be advantageous for diversifying antigen specificities. Thus, the method we describe uses CD4- and CD8- T cells. REG This may be partially advantageous since it produces both
[0250] As shown in FIG. 20B (upper right panel), CD8 + T cells were indeed enriched for stable FOXP3 expression over time in culture and independent of the presence of pharmacological inhibitors.
[0251] As shown in FIG. 20C (lower left panel), T REG -Redifferentiation under Th2 polarizing conditions generally involves low levels of the Th1 transcription factor TBET and CD8 + T cell expression, although the lowest levels were consistently observed in the presence of pemetrexed.
[0252] Finally, as shown in FIG. 20D (lower right panel), T REG Redifferentiation in -TH2 conditions actually shifted CD8+ cells to Th2-type differentiation, as indicated by increased expression of the GATA3 transcription factor. + T cells were obtained.
[0253] FIG. 40A-40B also shows that CD4 + and CD8+ Flow cytometry of GATA3 and FOXP3 for redifferentiated TREG-Th2 cells in both subsets is shown.
[0254] In summary, these transcription factor analyses demonstrated that hybrid T REG Redifferentiation in Th2 culture conditions + pemetrexed supplementation resulted in CD4+ cells expressing both FOXP3 and GATA3 while limiting expression of TBET. + and CD8 + These results suggest that this may be optimal, as it can preserve both T cell proliferation and T cell death.
[0255] Example 16: Hybrid T REG Culture of dedifferentiated T cells in Th2 conditions results in T cells with an enhanced Th2 cytokine secretion profile In addition to transcription factor measurements, we also assayed hybrid T cells for cytokine secretion capacity. REG -T cells redifferentiated under Th2 polarizing conditions were also evaluated. As shown in Figures 21A-21D, T REG -All redifferentiated cultures grown in Th2-polarizing conditions yielded T cells capable of IL-4 secretion, thereby demonstrating the intrinsic ability of this method to achieve Th2 polarization even in the absence of pharmacological inhibitors.
[0256] 21A to 21D show hybrid Th2 / T REG We illustrate that extended culture of dedifferentiated T cells in polarizing conditions results in the generation of T cells expressing a predominant Th2 cytokine phenotype: IL-4, IL-5, and IL-13 secretion. + and CD8 + T cells were subjected to a 3-day dedifferentiation procedure and then co-stimulated (3:1 bead to T cell ratio) with or without the pharmacological inhibitors temsirolimus (1.0 μM) or pemetrexed (10 nM) to form hybrid Th2 / T REGThe T cells were grown in medium containing polarizing conditions (IL-2; TGF-β; IL-4). Cultures were restimulated with 3 / 28 beads on both days 14 and 24 of culture. On day 24 of culture, the culture medium did not contain exogenous cytokines or pharmacological inhibitors to assess the stability of transcription factor expression. On days 12, 20, and 32 of culture, T cells were harvested, washed, and restimulated with 3 / 28 beads (3:1 ratio) for 24 hours, and the resulting supernatants were harvested and tested for cytokine content by Luminex multi-analyte method. All results shown are from 1 × 10 6 Cytokine levels are expressed in pg / ml per cell / ml / 24 h. The Th2 cytokine IL-10 was also assessed: all values are within 1×10 6 It was less than 20 pg / ml per cell / mL / 24 hours.
[0257] Notably, temsirolimus inhibited T cells secreting the effector Th2 cytokines IL-5 (Figure 21B) and IL-13 (Figure 21C). REG Although the use of pemetrexed blunted the redifferentiation ability of T cells in Th2 conditions, the use of pemetrexed fully preserved the ability of T cells to secrete IL-5 and IL-13. Thus, these data suggest that pemetrexed inhibits T REG -Because it is more compatible with the production of Th2 hybrid subsets, the use of pemetrexed is more effective than traditional T-cell inhibitors such as the mTOR inhibitor temsirolimus. REG This provides further evidence of its preference compared to the use of accelerators.
[0258] Furthermore, T REG -All T cells redifferentiated under Th2 polarizing conditions had relatively low levels of expression of IL-2 (Figure 22A), IFN-γ (Figure 22B), IL-17 (all values below 20 pg / ml), and TNF-α (all values below 20 pg / ml).
[0259] 22A to 22D show hybrid Th2 / T REGWe illustrate that extended culture of dedifferentiated T cells in polarizing conditions results in the generation of T cells expressing a predominant Th2 cytokine phenotype: IL-2, IFN-γ, and GM-CSF secretion. + and CD8 + T cells were subjected to a 3-day dedifferentiation procedure and then co-stimulated (3:1 bead to T cell ratio) with or without the pharmacological inhibitors temsirolimus (1.0 μM) or pemetrexed (10 nM) to form hybrid Th2 / T REG The T cells were grown in medium containing polarizing conditions (IL-2; TGF-β; IL-4). Cultures were restimulated with 3 / 28 beads on both days 14 and 24 of culture. On day 24 of culture, the culture medium did not contain exogenous cytokines or pharmacological inhibitors to assess the stability of transcription factor expression. On days 12, 20, and 32 of culture, T cells were harvested, washed, and restimulated with 3 / 28 beads (3:1 ratio) for 24 hours, and the resulting supernatants were harvested and tested for cytokine content by Luminex multi-analyte method. All results shown are from 1 × 10 6 Cytokine levels are expressed in pg / ml per cells / ml / 24 h. Proinflammatory cytokines IL-17 and TNF-α were also assessed: all values are within 1×10 6 It was less than 20 pg / mL per cell / mL / 24 hours.
[0260] Notably, GM-CSF secretion was significantly increased in T REG This was observed to a higher extent in T cells redifferentiated in T-TH2 hybrid culture conditions (10 nM, FIG. 22C). Inferring from experimental studies in the literature, REG It is unclear whether the potentiation of GM-CSF within the -Th2 hybrid population is necessarily either detrimental or beneficial.
[0261] In summary, these data suggest that T REG- We show that redifferentiation of T cells in a Th2-polarized state is favorable to result in T cells with a reduced ability to secrete Th1- and Th17-type cytokines associated with inflammatory diseases. REG Inclusion of -Th2 polarizing conditions would be advantageous to result in an increased Th2 cytokine production capacity, which would further provide protection against differentiation plasticity towards Th1 and Th17 type subsets.
[0262] Example 17: Use of selective anti-TNF-α reagents prior to lymphocyte collection by apheresis to beneficially alter input T cell TCR repertoire Figures 23A and 23B show the use of RNA-based T cell receptor sequencing to detect widespread up- and down-regulation of T cell TCR specificities following treatment with the TNF-α inhibitor etanercept. In Figure 23, RNA was isolated from peripheral blood mononuclear cells from ALS patients before and after treatment with etanercept therapy. The RNA was subjected to TCR repertoire profiling as previously described by Rosati E, Dowds CM, Liaskou E, Henriksen EKK, Karlsen TH, Franke A. Overview of methodologies for T-cell receptor repertoire analysis. BMC Biotechnol. 2017;17(1):61. In Figure 23A, it is demonstrated that approximately 25% of TCR specificities were upregulated in the post-treatment samples (as shown in red); in sharp contrast, approximately 25% of TCR specificities were downregulated in the post-treatment samples (as shown in blue). As shown in the top right panel (B), etanercept therapy resulted in significant T cell clonal expansion, as several T cell clones increased from a pre-etanercept frequency of 0.01 (near the detection limit of the assay) to post-treatment values ranging from 247 to 486, thereby coinciding with a greater than 4-log T cell expansion. As shown in the bottom right panel (B), etanercept therapy resulted in significant T cell clonal contraction, as several T cell clones decreased from a pre-etanercept frequency of 259 to 598 (near the detection limit of the assay) to post-treatment values of 0.01, thereby coinciding with a greater than 4-log T cell contraction.
[0263] Figures 23A-B show that anti-TNF-α therapy with etanercept, which preferentially inhibits serum cell-free forms of TNF-α that promote TNFR1-expressing Th1-type cells, is associated with widespread changes in up- and down-regulation of T cell receptors. These observations indicate that pre-treatment of subjects with etanercept, or any other anti-TNF-α therapeutic that preferentially inhibits serum cell-free forms of TNF-α (such as monoclonal antibodies, adalimumab), can be used to shift the T cell receptor repertoire away from T cells of Th1-type phenotype based on antigen specificity, thereby enriching for T cells of TREG phenotype based on antigen specificity.
[0264] Example 18: Characterization of TREG-Th2 hybrid populations as cell products enriched for expression of CD25, CD27, 2B4, BTLA, and CTLA4. Figure 24 shows that the iTREG / Th2 hybrid population produced has increased expression of CD25, CD27, 2B4, BTLA, and CTLA4 compared to the control Th1 / Tc1 culture. In Figure 24, the iTREG / Th2 hybrid population was generated by the method detailed previously, using the initial phase of T cell differentiation followed by redifferentiation in medium containing IL-2, TGF-β, and IL-4. On day 11 of ITREG / Th2 production, cells were harvested and subjected to flow cytometry for evaluation of CD4+ and CD8+ T cell expression related molecules, namely CD25, CD27, 2B4, BTLA, and CTLA4, and compared to three separate control conditions evaluating Th1 / Tc1 polarization.
[0265] FIG. 24 shows that hybrid TREG-Th2 cells produced according to the described conditions have increased expression of the following cell surface molecules by flow cytometry compared to control Th1 / Tc1 cells: CD25, CD27, 2B4, BTLA, and CTLA4.
[0266] As illustrated in FIG. 24, the iTREG / Th2 hybrid cell product has CD4+ and CD8+ T cells expressing at least 10%, more preferably 50% higher levels of CD25, CD27, 2B4, BTLA, and CTLA4 compared to control Th1 / Tc1 cells.
[0267] CD25, the IL-2 receptor, is important for the ability of TREG cells to manage autoimmunity, particularly CD8+ T cell-driven responses. Therefore, expression of CD25 on iTREG / Th2 manufactured cell products is a desirable feature.
[0268] CD27, a costimulatory molecule with increased expression on TREG cells, has been shown to contribute to the inhibitory function of TREG. Therefore, expression of CD27 on iTREG / Th2 manufactured cell products is a desirable feature.
[0269] 2B4 (CD244) has recently been shown to inhibit CD8+ T cell responses by attenuating glycolysis and cell division. Therefore, expression of 2B4 on iTREG / Th2 manufactured cell products is a desirable feature.
[0270] BTLA (CD272) is a co-inhibitory receptor, and ligation of BTLA with the herpes virus entry mediator HVEM promotes TREG cell induction and inhibition of effector immune responses. Therefore, expression of BTLA on iTREG / Th2 manufacturing cell products is a desirable feature.
[0271] CTLA4 is an important effector molecule of TREG cells, as recently demonstrated by their ability to limit immunity to malaria infection. Therefore, expression of CTLA4 on iTREG / Th2 manufactured cell products is a desirable feature.
[0272] Example 19: Characterization of TREG-Th2 hybrid populations as enriched cell products for expression of TGIT, TIM3, ICOS, LAIR1, and OX40. FIG. 25 shows that the iTREG / Th2 hybrid population produced has increased expression of TIGIT, TIM3, ICOS, LAIR1, and OX40 compared to the control Th1 / Tc1 culture. In FIG. 25, the iTREG / Th2 hybrid population was generated by the method detailed previously, using the initial phase of T cell differentiation, followed by redifferentiation in medium containing IL-2, TGF-β, and IL-4. On day 11 of ITREG / Th2 production, cells were harvested and subjected to flow cytometry for evaluation of CD4+ and CD8+ T cell expression related molecules, namely TIGIT, TIM3, ICOS, LAIR1, and OX40, and compared to three separate control conditions evaluating Th1 / Tc1 polarization. FIG. 25 shows that hybrid TREG-Th2 cells produced according to the described conditions result in the generation of T cells expressing increased levels of the following cell surface molecules by flow cytometry compared to control Th1 / Tc1 cells: TIGIT, TIM3, ICOS, LAIR1, and OX40 molecules.
[0273] As illustrated in FIG. 25, the iTREG / Th2 hybrid cell product has CD4+ and CD8+ T cells expressing at least 10%, more preferably 50% higher levels of TIGIT, TIM3, ICOS, LAIR1, and OX40 compared to control Th1 / Tc1 cells.
[0274] TIGIT is a cell surface co-inhibitory receptor molecule associated with regulatory T cell function. Therefore, expression of TIGIT on iTREG / Th2-manufactured cell products is a desirable feature.
[0275] TIM3 is a co-inhibitory receptor that mediates the inhibitory effects of TREG cells. Therefore, expression of TIM3 on iTREG / Th2 manufactured cell products is a desirable feature.
[0276] ICOS is a costimulatory molecule that has recently been determined to help maintain immune suppression by regulatory T cells for the control of immune reactivity in the central nervous system. Therefore, expression of ICOS on iTREG / Th2 manufactured cell products is a desirable feature.
[0277] LAIR1 (CD305) is a pleiotropic inhibitory molecule that can block inflammation at multiple steps, including suppression of activated effector memory T cells. Therefore, expression of LAIR1 on iTREG / Th2-manufacturing cell products is a desirable feature.
[0278] OX40 is a costimulatory molecule, therefore expression of OX40 on iTREG / Th2 manufactured cell products is a desirable feature.
[0279] Example 20: Characterization of GATA3 and FOXP3 expression in TREG / Th2 hybrid populations Steady-state apheresis samples were obtained, enriched for lymphocytes by Ficoll gradient, then seeded into G-Rex culture vessels and incubated in complete medium containing vitamin D (0.3 nM), temsirolimus (3.0 μM) and basiliximab (30 μg / mL). After an initial dedifferentiation period, T cells were costimulated with anti-CD3 / anti-CD28 coated magnetic beads at a 3:1 bead-to-T cell ratio and supplemented with cytokines (IL-4 (1000 IU / mL), IL-2 (10,000 IU / mL) and TGF-β (100 ng / mL)). After 6 days of culture, T cells were harvested and stained for surface markers (CD4 and CD8) and intracellular molecule expression (GATA3 and FOXP3) and assessed by flow cytometry. The results in Figures 26A-B show FOXP3 and GATA3 expression for CD4+ and CD8+ T cells at the beginning of culture and after culture (Th2 / TREG) as measured by flow cytometry. The percentages provided indicate the amount of cells considered positive for CD4+ or CD8+ and intracellular markers (indicated by boxes).
[0280] The results shown in Figure 26A-B show results indicating the phenotype of the manufactured Th2 / TREG cell products. T cells of type II cytokine phenotype can be partially characterized by their expression of the transcription factor GATA3, whereas regulatory T cell populations can be partially specified by their expression of the FoxP3 transcription factor. At the initiation of culture, very low frequencies of T cells expressed either GATA3 or FoxP3. In sharp contrast, T cell products manufactured in Th2 / TREG culture conditions expressed high frequencies of T cells that were either single positive for GATA3, single positive for FOXP3, or double positive for both GATA3 and FOXP3 (not shown). Importantly, as shown, this transcription factor profile was expressed in both manufactured CD4+ (upper panel) and CD8+ (lower panel) T cells. Control manufactured cultures without IL-4 significantly reduced the frequency of GATA3 positive T cells, thereby demonstrating the important role of IL-4 in the manufacture of Th2 / TREG hybrid populations (not shown).
[0281] Most of the phenotypic characterization of the T cell product produced according to the TREG / Th2 method detailed in this disclosure can be confirmed at the end of culture. However, it is important to note that the T cell product can be cryopreserved, and therefore the phenotypic characterization of the T cells in the post-thaw state reflects the actual product that is adoptively transferred to the subject. The post-thaw state TREG / Th2 cells can be characterized by: (a) increased expression of CD25, CD27, 2B4, BTLA, CTLA4, TIGIT, TIM3, ICOS, LAIR1, and OX40 by flow cytometry; (b) reduced IFN-g and TNF-a and increased secretion of IL-4 by Luminex cytokine secretion analysis; and (c) changes in the expression of T cell fate transcription factors, i.e., reduced TBET and increased FOXP3 and GATA3.
[0282] Example 21: Characterization of CD73 and CD103 expression in TREG / Th2 hybrid populations Steady-state apheresis samples were obtained, enriched for lymphocytes by Ficoll gradient, then seeded into G-Rex culture vessels and incubated in complete medium containing vitamin D (0.3 nM), temsirolimus (3.0 μM) and basiliximab (30 μg / mL). After an initial dedifferentiation period, T cells were costimulated with anti-CD3 / anti-CD28 coated magnetic beads at a 3:1 bead-to-T cell ratio and supplemented with cytokines (IL-4 (1000 IU / mL), IL-2 (10,000 IU / mL) and TGF-β (100 ng / mL)). After 6 days of culture, T cells were harvested and stained for surface markers (CD4 and CD8), as well as the ectonucleotidase molecule CD73, or the integrin molecule CD103, and evaluated by flow cytometry. The results in Figures 27A-B show CD73 and CD103 expression for CD4+ and CD8+ T cells at the beginning of culture and after culture (Th2 / TREG) as measured by flow cytometry. The percentages provided indicate the amount of cells considered positive for CD4+ or CD8+, and ectonucleotidase or integrin molecules, respectively (indicated by boxes).
[0283] Regulatory T cell populations can suppress pathogenic effector T cell populations by several defined mechanisms, including expression of CD39 and CD73 ectonucleotidase molecules that act to hydrolyze proinflammatory ATP against immunosuppressive adenosine substrates. Indeed, T cells expressing CD39 have increased suppressive function and have been associated with the resolution of inflammatory bowel disease. Furthermore, the suppressive function of human T cells is partially mediated by CD73. As shown below in Figure 27A, T cells produced in Th2 / T culture conditions can have increased expression of the T-associated effector molecule CD73, and CD39 was also highly expressed on T / Th2 produced T cells (not shown). In addition to CD39 / CD73 ectonucleotidase, T cell function also correlates with expression of CD103, an integrin that directs epithelial lymphocyte localization. Indeed, CD103 and IL-2 receptor signaling cooperate to maintain immune tolerance in the intestinal mucosa, and furthermore, CD103-expressing T cells are important for the amelioration of experimental chronic GVHD. As shown below in Figure 27B, T cells produced in Th2 / T culture conditions can have increased expression of the T-related effector molecule CD103.
[0284] Example 22: Characterization of CD150 and CD27 / CD95 expression of TREG / Th2 hybrid populations Steady-state apheresis samples were enriched for lymphocytes by Ficoll gradient, seeded into G-Rex culture vessels and incubated in complete medium containing vitamin D (0.3 nM), temsirolimus (3.0 μM) and basiliximab (30 μg / mL). After this initial dedifferentiation period, T cells were costimulated with anti-CD3 / anti-CD28 coated magnetic beads at a 3:1 bead-to-T cell ratio and supplemented with cytokines (IL-4 (1000 IU / mL), IL-2 (10,000 IU / mL) and TGF-β (100 ng / mL)). After 6 days of culture, T cells were harvested, stained for surface markers and subjected to multicolor flow cytometry analysis for CD4, CD8, CD150, CD27, CD95, CD45RA, CD62L, and CCR7. The results are shown in Figures 28A-B.
[0285] T cells cultured in TREG (RAPA-501) conditions were compared to culture input T cells ("Day 0") and also to control cultured T cells grown without mTOR inhibitors ("Control"). As shown in Figure 28A, both CD4+ and CD8+ T cell subsets contained within the RAPA-501 cell product significantly increased expression of the stem cell marker CD150 compared to culture input T cells and compared to control cultured T cells. As shown in Figure 28B, the RAPA-501 cell product was also enriched for T stem cell memory (TSCM) phenotype compared to culture input cells. The control culture lacked this population as T cells obtained in this condition were effector memory CD45RO+ (not shown). The left panel (culture input T cells) and right panel (RAPA-501 cells) show expression of TSCM markers CD95 and CD27 after gating on TSCM markers CD45RA, CD62L, and CCR7, and similar differences in expression of these TSCM markers were observed for CD8+ T cells (not shown).
[0286] In experimental models, the efficacy of adoptive T cell therapy depends on successful engraftment and in vivo persistence of T cell populations. Importantly, T cell differentiation state helps dictate in vivo persistence, with less differentiated cells increasing persistence. In our initial studies, murine rapamycin-resistant T cells that expressed a T central memory (TCM) phenotype had increased in vivo engraftment potential compared to control T cells. Furthermore, human rapamycin-resistant T cells also increased engraftment in a human-to-human mouse model of xenograft-versus-host disease. Other researchers have determined that T cells with reduced differentiation compared to T effector memory (TEM) populations have increased in vivo persistence and mediated increased in vivo effects, including TCM subsets, naive T cell subsets, and more recently T stem cell memory (TSCM) subsets. This relationship between T cell differentiation state and in vivo T cell function can be operationalized as follows for TREG cells. (1) TCM phenotype TREG cells were more effective in reducing experimental GVHD compared to TEM phenotype TREG cells; and (2) TREG cells that expressed the stem cell marker CD150 were highly effective in preventing stem cell graft rejection. As shown below in Figure 28A, T cells produced in Th2 / TREG culture conditions were enriched for cells with a reduced differentiation state consistent with a T stem cell subset, including expression of the CD150 marker.
[0287] Example 23: Characterization of cytokine secretion of TREG / Th2 hybrid populations Steady-state apheresis samples were enriched for lymphocytes by Ficoll gradient, seeded into G-Rex culture vessels, and incubated in complete medium containing vitamin D (0.3 nM), temsirolimus (3.0 μM), and basiliximab (30 μg / mL). After an initial dedifferentiation period, T cells were costimulated with anti-CD3 / anti-CD28 coated magnetic beads at a 3:1 bead-to-T cell ratio and supplemented with cytokines (IL-4 (1000 IU / mL), IL-2 (10,000 IU / mL), and TGF-β (100 ng / mL)). This culture is referred to as condition "A". Condition "B" was the same culture condition, but without IL-4 addition. Condition "C" reflects standard TREG culture conditions of rapamycin (1 μM), IL-2 (100 IU / mL), and TGF-β (10 ng / mL). Condition "D" reflects a Th1-type control culture made in the presence of IFN-α without an mTOR inhibitor. After culture, T cells were harvested and stimulated with anti-CD3 / anti-CD28 beads, and the resulting supernatants were tested for cytokine content by Luminex assay.
[0288] It may be important to evaluate the cytokine secretion of the manufactured Th2 / TREG cells. First, it is important that the cell product can secrete IL-4, which is the driver cytokine for subsequent Th2 differentiation. Second, it is desirable that the adoptively transferred T cell population is able to secrete IL-2, as this ability indicates a progenitor function that allows T cells to more easily expand in vivo without the need for exogenous IL-2. Finally, it is important that the Th2 / TREG cell population reduces the secretion of Th1-type or Th17-type cytokines IFN-α, TNF-α, IL-17, and GM-CSF. As FIG. 29 shows, the manufactured Th2 / TREG cell product secreted IL-4 and IL-2 while minimizing the secretion of Th1-type or Th17-type cytokines.
[0289] Example 24: Characterization of Th1 / Tc1 suppression by TREG / Th2 hybrid populations Steady-state apheresis samples were enriched for lymphocytes by Ficoll gradient, seeded in G-Rex culture vessels and incubated in complete medium containing vitamin D (0.3 nM), temsirolimus (3.0 μM) and basiliximab (30 μg / mL). After an initial dedifferentiation period, for ex vivo production of Th2 / TREG cells, T cells were co-stimulated with anti-CD3 / anti-CD28 coated magnetic beads at a bead-to-T cell ratio of 3:1 and supplemented with cytokines (IL-4 (1000 IU / mL), IL-2 (10,000 IU / mL) and TGF-β (100 ng / mL)). In parallel, T cells were cultured in the presence of the type I polarizing cytokine IFN-α to generate effector Th1 / Tc1 cells. Th1 / Tc1 cultures were generated from the same donor (autologous, "AUTO") or unrelated donor (allogeneic, "ALLO") as RAPA-501 cell cultures. After ex vivo culture, Th1 / Tc1 effector T cells were seeded into the bottom chamber of a transwell plate and costimulated with anti-CD3 / anti-CD28 coated beads at a bead-to-T cell ratio of 3:1. 24 h after Th1 / Tc1 cell costimulation, RAPA-501 cells were added to the top chamber of the transwell plate at a Th1 / Tc1 to RAPA501 ratio of 1:1. (A) RAPA-501 modulation of cytokine content. At 24 h (before RAPA-501 cells were added to the top chamber) and 48 h of culture (either with or without the addition of RAPA-501 cells), culture supernatants were collected and tested for cytokine content by Luminex assay. Results are expressed in pg / ml / 24 h / 1x106 cells / ml for IL-2, IFN-γ, GM-CSF, and TNF-α content. (B) RAPA-501 cell regulation of Th1 / Tc1 cell expression of PD1 is antigen-independent. At 48 h, autologous or allogeneic Th1 / Tc1 cells were harvested either after or without the addition of RAPA-501 cells at the 24 h time point, and then Th1 / Tc1 cells were subjected to flow cytometry for assessment of PD1 expression.
[0290] During the development of the RAPA-501 cell product, we performed experiments to characterize the molecular mechanisms of the observed T cell suppression. One method to evaluate potential mechanisms is a transwell assay, whereby effector T cells and RAPA-501 cells are separated by a filter that prevents cell-cell contact but allows cell communication by small soluble mediators such as cytokines. Figures 30A-B show that RAPA-501 cells regulate effector T cells in a contact-independent manner (experiments performed in transwell vessels). RAPA-501 cells acted in a T cell receptor-independent manner to suppress the cytokine secretion ability of effector T cells. That is, because no costimulatory beads were added to the transwell chambers containing RAPA-501 cells, RAPA-501 cells did not require costimulation to regulate inflammatory cytokine levels, including IL-2, IFN-γ, GM-CSF, and TNF-α (Figure 30A). The ability of Treg cells to consume IL-2 is a commonly described phenomenon, but previous studies have identified a requirement for cell-cell contact to consume IL-2. Thus, RAPA-501 cells appear to be somewhat uniquely able to regulate the levels of multiple inflammatory cytokines in a contact-independent manner. These results suggest that RAPA-501 cells are suitable candidates for cytokine neutralization. Second, we found that RAPA-501 cells regulated an additional aspect of effector T cell biology in a contact-independent manner (using transwell experiments), namely, the promotion of programmed death-1 (PD-1) checkpoint molecule expression on effector T cells. Importantly, as shown in Figure 30B, RAPA-501 cells upregulated PD1 expression in both autologous and allogeneic Th1 / Tc1 cells, thereby further revealing that one mechanism of RAPA-501 cell suppressive function occurs TCR-independently by a soluble mediator.
[0291] Example 25: Characterization of CNS microglial cell cytokine secretion suppression by TREG / Th2 hybrid populations Human microglial cells (HMC3 cell line) were first activated with IFN-γ (10 ng / ml; 24 hours) and then with LPS (10 ng / ml; 3 hours), and then the treated HMC3 cells were seeded in the lower chamber of a transwell (RAPA-501 to HMC3 ratio, 1:40) without (left panel) or with (right panel) the addition of RAPA-501 cells generated as described above to the upper chamber. RAPA-501 cells were generated using the method described in the patent application to generate T cells of hybrid Th2 / TREG phenotype. After 24 hours, cell-free supernatants were harvested and assessed for IL-6, IFN-γ, and IP-10 content by Luminex assay (cytokine secretion measured in pg / ml / 1×106 cells / ml / 24 hours). The results are shown in FIG. 31.
[0292] Microglial cells are CNS-resident antigen-presenting cells that can develop into pro-inflammatory factors in ALS. The ability of manufactured human Th2 / TREG cells to suppress human microglial cell inflammation was not known to us previously. To address this, we induced the human microglial cell line HMC 3 into a pro-inflammatory state by sequentially culturing it in IFN-γ and subsequently by LPS endotoxin. As Figures 31A-31B show, adding RAPA-501 Th2 / TREG cell products to pro-inflammatory microglial cells reduced the culture supernatant content of the pro-inflammatory cytokines IL-6, IP-10, and IFN-γ. In this experiment, the observed immunosuppressive effects occurred at a highly diluted Treg to inflammatory microglial cell ratio of 1:40 in a transwell vessel, thereby demonstrating that RAPA-501 cells can reduce CNS inflammation in a contact-independent manner (as indicated by the transwell design) and with high potency (as indicated by a Treg to microglial cell ratio of 1:40).
[0293] Example 26: iT of ALS using pentostatin, cyclophosphamide, and lamivudine host modulation platform REG Cell therapy. Figure 32 details the PC regimen and overall treatment approach. The PC regimen is administered in 2-week cycles with escalating doses of pentostatin or cyclophosphamide over cycles 1-4 as indicated (total duration of PC regimen is 8 weeks). Pentostatin is administered on either day 1, or days 1 and 4 of a 14-day cycle, and cyclophosphamide (Cy) is administered on either days 1, 2, and 3, or days 1, 2, 3, 4, and 5 of a 14-day cycle. For cycle 4, if ALC is less than 1250 cells per microliter, the Cy dose is increased to 200 mg per day. After immune depletion and immune suppression are achieved by administration of the PC regimen, the first iT REG Cell infusion will occur during week 8 of treatment. The inflammasome inhibitor lamivudine will be administered continuously at a dose of 150 mg BID from week 8 through week 26 of the protocol.
[0294] Figure 33 shows the iT REG We provide further details on the production of cells and demonstrate the collection of lymphocytes by apheresis regimen before and after the PC regimen. Lymphocytes from ALS patients are collected by routine apheresis (collection of 10-15 liters) performed immediately before or after the PC regimen. Collection before the PC regimen is preferred over iT because T cells are more abundant and are not immunosuppressed. REG In comparison, harvesting after a PC regimen is more advantageous than iT REG This can be advantageous because inflammatory Th1 / Tc1 cells that contaminate the cultures are depleted in vivo prior to production. REG After fabrication, the product is then subjected to iT REG To allow for repeated administration of the cells, they are cryopreserved in therapeutic doses.
[0295] Figure 34 shows multiple iT REG We further detail the cell injection strategy and iT REG The sequence of PC regimens prior to each repeat dose of cells is shown. REGAdministered prior to injection: (1) to deplete and suppress inflammatory Th1 / Tc1 cells that contribute to disease pathogenesis, and (2) to inhibit the adoptively transferred iT REG Increasing in vivo levels of homeostatic cytokines such as IL-7 and IL-15 to allow for in vivo expansion of the population. The PC regimen consisted of 2 mg / m 2 The combination of a fixed dose of pentostatin at 100 mg / day on days 1 to 5 was followed by iT REG Cells are administered (day 8 of the regimen). The inflammasome inhibitor lamivudine is REG It will be administered continuously from week 8 onwards to limit the inflammatory drive during cell therapy.
[0296] Figure 35 shows the iT REG Further details regarding monitoring of patients treated with cells are provided, showing that monitoring of ALS is performed approximately monthly by both patient-reported ALSFRS-R and clinician-reported Appel score, as shown. Immuno-labs to monitor inflammatory status in ALS patients are evaluated approximately monthly, as shown.
[0297] Example 27: Use of selective anti-TNF-α reagents prior to lymphocyte collection by apheresis to beneficially alter input T cell TCR repertoire Figures 36A-36B show that anti-TNF-α therapy with etanercept, which preferentially inhibits serum cell-free forms of TNF-α that promote TNFR1-expressing Th1-type cells, is associated with widespread changes in up- and down-regulation of T cell receptors. Figures 36-36B show the use of RNA-based T cell receptor sequencing to detect widespread up- and down-regulation of T cell TCR specificity following treatment with the TNF-α inhibitor, etanercept. In Figures 36-36B, RNA was isolated from peripheral blood mononuclear cells from ALS patients before and after treatment with etanercept therapy. RNA was subjected to TCR repertoire profiling as previously described by Rosati E, Dowds CM, Liaskou E, Henriksen EKK, Karlsen TH, Franke A. Overview of methodologies for T-cell receptor repertoire analysis. BMC Biotechnol. 2017;17(1):61. As shown in FIG. 36A, it is demonstrated that approximately 25% of the TCR specificities were upregulated in the post-treatment samples (as shown in red); in sharp contrast, approximately 25% of the TCR specificities were downregulated in the post-treatment samples (as shown in blue). As shown in FIG. 36B, etanercept therapy resulted in significant T cell clonal expansion, as several T cell clones increased from a pre-etanercept frequency of 0.01 (near the detection limit of the assay) to post-treatment values ranging from 247 to 486, thereby coinciding with greater than 4-log T cell expansion. As shown in FIG. 36B, etanercept therapy resulted in significant T cell clonal contraction, as several T cell clones decreased from a pre-etanercept frequency of 259 to 598 to a post-treatment value of 0.01, thereby coinciding with greater than 4-log T cell clonal contraction. These observations support the notion that pre-treating subjects with etanercept or any other anti-TNF-α therapeutic that preferentially blocks serum non-cellular forms of TNF-α (such as monoclonal antibodies, adalimumab) can be used to antigen-specifically shift the T cell receptor repertoire away from T cells of Th1-type phenotype, thereby enhancing the potency of T REG型These results demonstrate that the phenotype enriches for T cells.
[0298] Example 28: T cells as a product enriched for expression of CD25, CD27, 2B4, BTLA, and CTLA4 REG - Characterization of the Th2 hybrid population. FIG. 37 shows the hybrid T prepared according to the conditions described. REG -Th2 cells have increased expression of the following cell surface molecules by flow cytometry compared to control Th1 / Tc1 cells: CD25, CD27, 2B4, BTLA, and CTLA4. In FIG. 37, hybrid T cells containing IL-2, TGF-β, and IL-4 are shown to have increased expression of the following cell surface molecules by flow cytometry compared to control Th1 / Tc1 cells: CD25, CD27, 2B4, BTLA, and CTLA4. REG iT / Th2 medium using an initial phase of T cell differentiation followed by redifferentiation by methods previously detailed. REG A CD4 / Th2 hybrid population was generated. Cells were harvested and immunoreacted with the relevant molecules, namely, CD25, CD27, 2B4, BTLA, and CTLA4. + and CD8 + They were subjected to flow cytometry for assessment of T cell expression and compared to three separate control conditions assessing Th1 / Tc1 polarization.
[0299] As shown in FIG. 37, iT REG The / Th2 hybrid cell product has CD4+ and CD8+ T cells expressing at least 10%, more preferably 50% higher levels of CD25, CD27, 2B4, BTLA, and CTLA4 compared to control Th1 / Tc1 cells.
[0300] CD25, the IL-2 receptor, mediates autoimmunity, particularly CD8+ T cell-driven responses. REG It is important for the cell's ability to function. REG / Expression of CD25 on Th2 manufactured cell products is a desirable feature.
[0301] T REG CD27, a costimulatory molecule with increased expression on T REGIt has been shown that iT REG / Expression of CD27 on Th2 manufactured cell products is a desirable feature.
[0302] 2B4 (CD244) has recently been shown to downregulate CD8 by glycolysis and attenuation of cell division. + It has been shown to inhibit T cell responses. REG / Expression of 2B4 on Th2 manufactured cell products is a desirable feature.
[0303] BTLA (CD272) is a co-inhibitory receptor, and ligation of BTLA with the herpesvirus entry mediator HVEM mediates T REG promotes cell induction and inhibition of effector immune responses. REG Expression of BTLA on Th2 manufactured cell products is a desirable feature.
[0304] CTLA4 has been shown to mediate T cell death, as recently demonstrated by its ability to limit immunity to malaria infection. REG iT is an important effector molecule of the cell. REG Expression of CTLA4 on Th2 manufactured cell products is a desirable feature.
[0305] Example 29: T cells as enriched cell products for expression of TIGIT, TIM3, ICOS, LAIR1, and OX40 REG - Characterization of the Th2 hybrid population. FIG. 38 shows the hybrid T prepared according to the conditions described. REG -Th2 cells result in the generation of T cells expressing increased levels of the following cell surface molecules by flow cytometry compared to control Th1 / Tc1 cells: TIGIT, TIM3, ICOS, LAIR1, and OX40. REG iT / Th2 hybrid populations were generated by methods previously detailed using the initial phase of T cell differentiation followed by redifferentiation in medium containing IL-2, TGF-β, and IL-4. REGOn day 11 of Th2 / Th2 production, cells were harvested and CD4 + and CD8 + They were subjected to flow cytometry for the evaluation of T cell expression relevant molecules, namely TIGIT, TIM3, ICOS, LAIR1, and OX40, and compared with three separate control conditions assessing Th1 / Tc1 polarization.
[0306] As shown in FIG. 38, iT REG The / Th2 hybrid cell product has at least 10%, more preferably 50% higher levels of CD4+ and CD8+ T cells expressing TIGIT, TIM3, ICOS, LAIR1, and OX40 compared to control Th1 / Tc1 cells.
[0307] TIGIT is a cell surface co-inhibitory receptor molecule that is associated with regulatory T cell functions, including contributing to the immunosuppressive environment in B-cell non-Hodgkin's lymphoma. REG Expression of TIGIT on Th2 manufacturing cell products is a desirable feature.
[0308] TIM3 has been implicated in the suppression of T cells infiltrating head and neck squamous cell carcinoma. REG iT is a co-inhibitory receptor that mediates the inhibitory effects of iT REG Expression of TIM3 on Th2 manufactured cell products is a desirable feature.
[0309] ICOS is a costimulatory molecule that has recently been determined to help maintain immune suppression by regulatory T cells for the control of immune reactivity in the central nervous system. REG / Expression of ICOS on Th2 manufactured cell products is a desirable feature.
[0310] LAIR1 (CD305) is a pleiotropic inhibitory molecule that can block inflammation at multiple steps, including suppressing activated effector memory T cells. REG Expression of LAIR1 on Th2 manufactured cell products is a desirable feature.
[0311] OX40 is a costimulatory molecule. REG Expression of OX40 on Th2 manufactured cell products is a desirable feature.
[0312] T REG The majority of the phenotypic characterization of the T cell product produced according to the Th2 / Th2 method can be confirmed at the end of the culture. However, it is important to note that the T cell product can be cryopreserved, and therefore the phenotypic characterization of the T cells in the post-thaw state reflects the actual product that will be adoptively transferred to the subject. REG / Th2 cells can be characterized compared to control Th1 / Tc1 cells by: (a) increased expression of CD25, CD27, 2B4, BTLA, CTLA4, TIGIT, TIM3, ICOS, LAIR1, and OX40 by flow cytometry; (b) reduced IFN-g and TNF-a and increased secretion of IL-4 by Luminex cytokine secretion analysis; and (c) altered expression of T cell fate transcription factors, i.e., reduced TBET and increased FOXP3 and GATA3.
[0313] iT REG Apheresis for production. Prior to treatment with the pentostatin / cyclophosphamide regimen, subjects undergo a lymphocyte apheresis procedure. The purpose of this peripheral lymphocyte collection is to collect lymphocytes for iT cell therapy. REG The aim is to manufacture cells.
[0314] Apheresis consisted of collection of 10-15 liters on a CS-3000 or equivalent machine. The apheresis product was sent to the protocol sponsor, Rapa Therapeutics, for iT REG The cells are prepared by ex vivo culture using specific culture conditions.
[0315] Research purpose Primary objective: To evaluate iT in the context of PC regimens and maintenance lamivudine therapy in inflammatory subsets of ALS patients. REG Determine the safety of cell injection.
[0316] Second Objective: IT REG Determine the ability of the therapy to inhibit inflammatory markers in ALS patients. Preliminary methods will assess the effect of iT on patient-reported and clinician-reported ALS scores. REG Determine the effectiveness of therapy.
[0317] Eligibility Criteria Subjects with sporadic or familial ALS diagnosed as suspected, possible, or confirmed by a clinical laboratory according to the World Federation of Neurology El Escorial Criteria. Age 18 to 75 years. Karnofsky performance status ≥70%. Ejection fraction by MUGA or 2D echocardiogram within the normal limits of the institution. Serum creatinine ≤2.0mg / dl. AST and ALT ≤3x upper limit of normal. Bilirubin ≤1.5 (except when due to Gilbert's disease). Pulmonary function tests with corrected DLCO ≥50%.
[0318] To assess secondary study endpoints, subjects must have evidence of inflammatory markers in peripheral blood cell populations after evaluation of at least two separate blood samples during the screening interval. Assays used to assess potential patient inflammatory status include flow cytometry, cytokine secretion analysis, and cell signaling events by Western blot analysis. Other tests may include testing of T cell receptor repertoire or in vitro sensitization to potential self-antigens such as motor neuron proteins or ALS-associated protein aggregates. Cytokine secretion is assessed without stimulation (autonomous cytokine secretion) and following stimulation with anti-CD3 / anti-CD28 costimulation; LPS endotoxin exposure; CD40 ligand exposure; adenosine A2 Aand A3 receptor agonism and antagonism; T cell (PD1, TIM-3) and monocyte (CD47, CD200) checkpoint inhibition; and assessment of T cell receptor clonality by RNA sequencing. The decision as to whether a potential subject is deemed to have sufficient inflammation to be included in the study will be made based on all matrix analyses of these studies, and that decision will be made by the study PI or Lead Associate Investigator in consultation with the Medical Director of the Rapa Therapeutics Lab where the immunoassays will be performed.
[0319] Exclusion criteria include patients actively taking riluzole (Rilutek®) or edaravone (Radicava®) therapy (unless on a stable dose for ≥1 month). The following also represent exclusion criteria: receipt of any investigational intervention within 30 days of the protocol, pulmonary vital capacity measurements less than 60% of predicted, active uncontrolled infection, hypertension not adequately controlled by ≤3 medications, history of cerebrovascular accident within 6 months after enrollment, documented history of pulmonary embolism within 6 months after enrollment, or clinically significant cardiac pathology (class III or IV heart failure according to NYHY as defined by myocardial infarction within 6 months prior to enrollment, uncontrolled angina pectoris, severe uncontrolled ventricular arrhythmia, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities). Patients with a history of coronary artery bypass graft or angioplasty will undergo cardiological evaluation and will be considered on a case-by-case basis. Patients who are seropositive for HIV, hepatitis B, or hepatitis C will be excluded. Patients who are known or suspected to be pregnant will be excluded, as will patients of childbearing age who are unwilling to practice contraception. Patients may be excluded at the discretion of the PI or if allowing them to participate is deemed to pose an unacceptable medical or psychological risk.
[0320] Treatment of ALS patients with PC regimen The purpose of the 8-week PC regimen is to partially deplete and suppress Th1 / Tc1 cells that contribute to ALS disease pathogenesis. In addition, the iT regimen immediately after the PC regimen is REG At the time point of continued cell infusion from week 8 onwards, the PC regimen is also intended to acutely result in the production of increases in T cell homeostatic cytokines, particularly IL-7 and IL-15.
[0321] The PC regimen is administered as 14-day cycles, although additional delays of up to 2 weeks between cycles may be permitted if logistical obstacles arise or additional time is needed to evaluate and / or treat any adverse events. For cycle #1, pentostatin (1 mg / m on day 1) 2 iv) is administered in combination with cyclophosphamide (100 mg daily po on days 1, 2, and 3). Cycle #2 is administered with an increased dose of pentostatin (2 mg / m on day 1), administered unless dose-limiting toxicity occurs. 2 iv) in combination with the same dose of cyclophosphamide (100 mg po daily on days 1, 2, and 3). Cycles #3 and #4, administered as long as no dose-limiting toxicity occurred and absolute lymphocyte counts remained above 750 cells per microliter, consisted of two doses of pentostatin (2 mg / m on days 1 and 4) in combination with 5 days of cyclophosphamide (100 mg po daily on days 1, 2, 3, 4, and 5). 2 iv).
[0322] If the ALC count is below 750 cells per microliter before cycle #3 or cycle #4, no further cycles are administered and the patient proceeds to maintenance therapy with lamivudine. If the absolute lymphocyte count is above 1250 cells per microliter before cycle #4, the dose of cyclophosphamide is doubled (200 mg po daily on days 1, 2, 3, 4, and 5).
[0323] Specifics regarding pentostatin administration:(a) Preparation: Pentostatin is reconstituted by the pharmacy department according to the vial instructions to a concentration of 2 mg / ml. The appropriate patient-specific dose is then added to 0.9% sodium chloride to make up a total volume of 50 mL;(b) Dosage and Administration: Pentostatin doses are adjusted for renal impairment (see below); Each dose of pentostatin is administered intravenously over 30-60 minutes;(c) Premedication and Antiemetic Therapy: Prior to the infusion, inject 1 liter of 0.9% sodium chloride over 30-60 minutes. Pentostatin can be emetogenic. Antiemetic regimen guidelines are as follows (variations allowed at the discretion of the PI): (1) dexamethasone 12 mg by intravenous infusion 60 minutes prior to each dose of pentostatin; (2) additionally, oral dexamethasone may be administered during the first 5 days of each cycle if needed for emesis control; (3) ondansetron may be administered at a dose of 8 mg by intravenous infusion 60 minutes prior to each dose of pentostatin; (4) for the remainder of treatment, ondansetron may be administered at an oral dose of 8 mg (tablet) every 12 hours between days 1 and 14 if needed during the cycle; and (5) aprepitant may be added to the antiemetic regimen as needed in patients with uncontrolled nausea and vomiting.
[0324] Specifications Pertaining to Pentostatin Dose Reduction: Serum creatinine levels are obtained prior to calculating each planned dose of pentostatin and CrCl. CrCl is obtained via 24-hour urine or calculated by the Cockcroft-Gault formula. If a subject experiences an increase in creatinine levels during pentostatin and cyclophosphamide therapy, subsequent doses will be modified as follows: CrCl ≥ 60 (mL / min / 1.73 m 2 ) Administer 100% of the intended pentostatin dose (pentostatin 1 mg / m for cycles #1 and #2) 2 Cycles #3 and #4: Pentostatin 2 mg / m 2); for 30≦CrCl<60: Administer 50% of the intended pentostatin dose (0.5 mg / m for Cycles #1, #2) 2 Cycles #3 and #4: Pentostatin 1 mg / m 2 );For CrCl<30: Hold pentostatin.
[0325] Pentostatin is rarely associated with neurological toxicity (seizures, coma), so particular attention should be paid to evaluating CNS toxicity. If a PC regimen is associated with any new neurological toxicity or worsening of any preexisting neurological toxicity of grade 2 or greater severity, the institution PI should be contacted to discuss whether further pentostatin therapy and further protocol therapy would be permitted.
[0326] Specific Aspects of Cyclophosphamide Administration: Hydration. It is important that patients maintain adequate hydration, as cyclophosphamide can cause cystitis. At a minimum, patients should drink at least 2-4 liters of fluid per day to maintain a clear color in the urine. It is also especially important to empty the bladder before sleep. Oral cyclophosphamide is administered at a fixed dose of 100 mg per day on days 1, 2, and 3 (for cycles #1 and #2) or days 1, 2, 3, 4, and 5 (for cycles #3 and #4). However, for patients who do not have a substantial reduction in ALC (as defined by an ALC of more than 1250 cells per microliter) prior to cycle #4, the cyclophosphamide dose for cycle #4 is increased to 200 mg per day over days 1, 2, 3, 4, and 5. If the patient cannot tolerate oral therapy, IV infusion of cyclophosphamide is permitted. The IV dose is the same as the intended oral dose. For IV infusion, cyclophosphamide will be reconstituted to a concentration of 20 mg / ml by the HUMC Pharmacy Department according to the vial instructions. The appropriate dose (100 mg or 200 mg) will then be diluted in 100 ml of D5W or 0.9% sodium chloride and infused intravenously over 30 minutes.
[0327] PC cycles are not expected to result in a significant decrease in absolute neutrophil counts. However, if the ANC is below a certain value at the time of determination immediately prior to the next cycle, the dose of cyclophosphamide will be adjusted as follows: (1) for ANC values of 1000 cells per microliter or more, 100% of the intended dose will be administered; (2) for ANC values of 500-999 cells per microliter, 50% of the intended dose will be administered; and (3) if the ANC value is 500 cells per microliter, no cyclophosphamide will be administered. In addition, for ANC values below 500 cells per microliter, the decision to initiate G-CSF therapy may be considered by the PI.
[0328] The quantitative goal of the 8-week PC regimen is to reduce ALC levels to approximately 750 cells per microliter. This degree of depletion and suppression of T cells that contribute to disease pathogenesis may be a key step in the development of iT cells to control neuroinflammatory processes. REG We hypothesize that a more severe reduction in host Th1 / Tc1 cells may allow for successful engraftment and biological activity of iT cells. REG It may be necessary to allow the cells to exert their full suppressive function. In such cases, a PC regimen may be required in combination with iT. REG Prior to cell therapy, iT may be enhanced or extended to target lower ALC values, such as 500, 250, or 0 ALC per microliter. REG Cellular therapies may be so effective that even an ALC value of 750 cells per microliter may be considered too stringent. In such cases, PC regimens can be de-intensive or shortened in duration to target higher ALC values, such as 1000, 1250, or 1500 cells per microliter.
[0329] Implementation of lamivudine maintenance therapy Upon completion of the PC regimen, patients will proceed to maintenance therapy with lamivudine, which will continue until the protocol's 6-month study end date. Lamivudine (oral tablets) will be administered at a dose of 150 mg po BID. If the estimated creatinine clearance decreases to less than 50 ml / min, lamivudine will be reduced to a dose of 150 mg po once daily and lamivudine will be discontinued for estimated creatinine clearance values less than 30 ml / min.
[0330] As previously mentioned, the stated purpose of lamivudine is to downregulate the NLRP3 inflammasome, which represents a proximal event in ALS pathogenesis. Therefore, we envision that other inflammasome inhibitors may be suitable or perhaps preferable for use with our protocol platform. For example, inflammasome inhibitors with potentially improved risk:benefit ratios are being developed.
[0331] Lamivudine is a sedative because their mechanisms of action are actually complementary. REG It is important to note that the complementary controls are not expected to be antagonistic to cell therapy. These include rapamycin, which can inhibit a wide variety of T cell responses, and IL-2, which inhibits T cell responses in vivo. REG T cells, which have a narrow therapeutic window in promoting proliferation and can promote inflammatory T cell populations. REG This is in contrast to other interventions proposed for cell therapy.
[0332] supportive care In the case of neutropenia, patients do not need to receive systemic antibiotic prophylaxis. The decision to initiate antibiotics depends on the protocol PI.
[0333] All patients will receive oral antiviral prophylaxis for HSV or VZV with acyclovir (or its prodrug valacyclovir) from the start of protocol therapy until the end of the study.
[0334] All patients will receive oral antifungal prophylaxis (first-line: fluconazole) from the start of protocol therapy until the end of the study. Alternative medications will be allowed as approved by the protocol PI.
[0335] All patients will begin Pneumocystis PJP prophylaxis upon study entry (which will continue until the end-of-study visit). Patients will receive oral cotrimoxazole (trimethoprim 160 mg / sulfamethoxazole 800 mg), one tablet orally on Mondays, Wednesdays, and Fridays. Alternate schedules or medications will be permitted as approved by the protocol PI.
[0336] IT REG Treating ALS patients with cells: Product manufacturing and phenotyping As previously detailed, iT REG The cell product is manufactured from autologous T cells collected by apheresis either at the time of study entry prior to the PC regimen or at the time of completion of the 8-week PC regimen. Each apheresis collection may have unique advantages: earlier collections have higher T cell yields, while post-PC collections consist of T cell populations relatively depleted of Th1 / Tc1 cells.
[0337] iT REG Cells transition from a pro-inflammatory phenotype to an anti-inflammatory T REG It is produced based on the principle of effector T cell conversion to the CD4 phenotype. + , CD25 + , and the relatively rare nT, which is typically characterized by low expression of CD127. REG Expensive and laborious native T cell populations require either monoclonal antibody / column selection methods or flow cytometry to obtain populations. REG No purification step would be necessary. + T REG Cells have been shown to mediate immune suppression, and iT REG iT may be beneficial in providing increased diversity to cell therapies. REG CD8 from cell population + It may not be necessary to deplete T cells.
[0338] A restricted state of differentiation of T that can be defined as a central memory type based on the expression of cell surface markers such as CD62L and CCR7. REG On the other hand, it has been shown that T cells have increased regulatory function in vivo. REG It is also known that cell acquisition allows for the upregulation of molecules that mediate suppressive functions such as IL-10, CTLA-4, the ectonucleotidase molecules CD39 and CD73, and cytolytic molecules such as perforin and fas ligand. These data support the idea that iT cells contain populations of both central and effector memory subsets. REG It has been shown that injecting cell products is beneficial, and therefore the iT reg The cell products are shown to have representation from both subsets.
[0339] In addition, iT REG iT cells must express FoxP3, a transcription factor that directs the regulatory T cell differentiation program. Moreover, it has been shown that FoxP3 expression and the resulting regulatory function can deteriorate over time, making it possible to differentiate iT REG The cell product should have stable FoxP3 expression over long periods in culture.
[0340] Moreover, it has been shown in humans that FoxP3 alone is not sufficient to identify a regulatory T cell phenotype, as FoxP3 can be transiently expressed by bona fide inflammatory T cell subsets. Thus, iT cells that express FoxP3 but also relatively lack co-expression of molecules associated with inflammatory T cell subsets, such as the Th1 / Tc1 transcription factor TBET or the Th1 cytokines IL-2 or IFN-γ, are not specifically identified. REG It is important to produce the cell product.
[0341] Finally, iT REG It is important that the cell products reduce the capacity for differentiation plasticity from a regulatory phenotype to an inflammatory phenotype.REG It is well documented that iT cells can be relatively unstable in their suppressive phenotype, which can lead to their transformation into a proinflammatory T cell subset that may actually contribute to mediating neurodegenerative diseases. REG The cell product should also stably express FoxP3 and show a reduced tendency to convert to the Th1 / Tc1 subset. REG As an additional safeguard against cellular differentiation plasticity, we purposefully excluded IL-4 from the iT REG Incorporate into the cell manufacturing process. Here, the Th2 lineage is T REG Maintenance of cells and T REG The cell suppression function is thought to be important, and T REG This has been described as a default pathway for T cells and can mediate anti-inflammatory effects in the setting of ALS. Despite this evidence for a potentially beneficial role of the Th2-like state of regulatory T cells, REG The cell therapy manufacturing method does not include the intentional addition of exogenous IL-4 during culture (T REG As illustrated in the current examples of manufacture.
[0342] At the end of production, iT REG The cell products were cultured at a therapeutic cell dose (1–5 × 10 6 Cryopreservation is performed in at least four single-use aliquots at 100 x 100 cells / kg.
[0343] IT REG Treating ALS patients using cells:T REG Cell population combinations IT REG The cell population was cultured at 1–5 × 10 per kg of recipient body weight. 6 This dose of T cells is relatively low compared to previous studies. REG Cell therapy is driven by several factors: PC regimens are REG Provide sufficient immunological space for cell engraftment; iT REGCells express a memory profile associated with cell persistence following adoptive transfer; and iT REG The cell product is cryopreserved in at least four clinically relevant therapeutic doses, thereby allowing for multiple treatment cycles.
[0344] As previously detailed, iT REG The cell product contains diverse memory differentiation states (central memory [CM] plus effector memory [EM]), thereby allowing both long-term and immediate control of neuroinflammation. The ratio of such central and effector memory populations can be controlled for optimal outcomes depending on the clinical situation, i.e., iT of CM:EM cells based on clinical parameters. REG The distribution can be 1:1, 3:1, 10:1, 1:3, or 1:10.
[0345] Similarly, depending on the clinical situation, CD4 + iT REG Cells vs. CD8 + iT REG It may be possible to control the ratio of cells to improve the therapeutic effect.
[0346] Finally, iT REG and nT REG Because iT cells express different T cell receptor repertoires and may therefore be complementary in mediating immune suppression, we REG The optimal cell-based therapy is nT REG It is envisioned that this may be achieved by co-administration of cells.
[0347] IT REG Treating ALS patients using cells: Combination with drugs IT REG Cellular therapy, when combined with a platform that includes the immunomodulatory effects of PC regimens and the inflammasome inhibitory effects of lamivudine, may be sufficient to control neuroinflammation.
[0348] However, the inventors have found that the platform change can reduce theREG It is envisioned that cell therapy may be optimized. As an example and not by way of limitation, therapy may be optimized by altering the intensity of the PC regimen, substituting another agent for cyclophosphamide to synergize with pentostatin, or adding a third component to the PC regimen, e.g., adding low dose IL-2 therapy after anti-TNF therapy, which, according to the inventors' reasoning, may be an effective treatment for T cell proliferation in vivo. REG As an example and not by way of limitation, low dose IL-2 therapy is described in Pham MN, von Herrath MG, Vela JL. Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes. Frontiers in Immunology. 2015;6:651.
[0349] Furthermore, we envision that lamivudine may be replaced with more potent or more specific inflammasome inhibitors similar to recently synthesized molecules.
[0350] Finally, the drive for inflammation in ALS is initiated by more proximal events, such as the accumulation of misfolded RNA elements and insufficient autophagy. In this regard, there is a rationale for utilizing agents capable of promoting autophagy, particularly rapamycin, for ALS therapy. However, clinical trials of rapamycin for the treatment of ALS have only just begun (ClinicalTrials.gov Identifier: NCT03359538), and furthermore, this protocol evaluates sequential therapy of rapamycin (which may be associated with substantial toxicity), fixed doses of rapamycin (which may result in a large degree of drug variability between patients), and relatively low doses of rapamycin (which do not guarantee the high drug levels required for potent inhibition of the mTOR pathway and consequent promotion of autophagy). To circumvent these limitations, we have developed an iT REGCombining cell therapy with rapamycin to promote autophagy using the following parameters: limiting drug toxicity and iT REG Use of intermittent rapamycin therapy to limit the potential for rapamycin inhibition of cells (examples include, but are not limited to, 1 week of mTOR inhibitor therapy plus 3 weeks of recovery on mTOR therapy); use of variable dosing of rapamycin, including a loading dose of rapamycin, combined with serum testing of rapamycin levels to ensure homogenous drug levels for more consistent inhibition of the mTOR pathway; and use of high-dose rapamycin therapy to achieve serum rapamycin levels of 30 ng / ml in preference to the typical target of approximately 5-12 ng / ml. See Mossoba ME, Halverson DC, Kurlander R, et al. High-Dose Sirolimus And Immune Selective Pentostatin Plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-Versus-Tumor Responses. Clinical cancer research. 2015;21(19):4312-4320.
[0351] Furthermore, rapamycin therapy may not be optimal for promoting autophagy in neurodegenerative diseases due to poor penetration of the drug into the central nervous system. In this regard, even intravenous therapy with the rapamycin analog temsirolimus did not result in significant levels of the drug in the cerebrospinal fluid. To overcome this limitation, we envision administering temsirolimus through an indwelling Ommaya reservoir in a manner similar to that utilized for the treatment of lysosomal storage diseases to achieve consistent CSF drug levels of mTOR inhibitors to optimally promote autophagy in the context of neurodegenerative diseases.
[0352] IT REG Treating ALS patients with cells: immune monitoring ALS iT REGIn the context of cell therapy, it will be important to quantify the success of cell therapy in terms of its ability to modulate disease-associated neuroinflammatory pathways. That is, monitoring the clinical course of neurodegenerative diseases is inadequate given the large variability in disease progression across patient cohorts. The ability to optimally treat neuroinflammation will depend on iT, including combinations with various pharmacological agents. REG Multiple infusions of cells will be required, therefore it will be important to utilize immune biomarkers to help guide treatment decisions.
[0353] IT REG Therapeutic decisions regarding repeated administration of cell infusions and associated pharmacological agents are based on specialized tests of peripheral blood mononuclear cells developed by the inventors. These tests address several important issues related to inflammatory monitoring, including spontaneous cytokine measurements; T cell and monocyte cooperation in cytokine measurements; the role of recombinant human CD40 ligand, T cell checkpoint inhibitor pathway, and monocyte checkpoint pathway in unmasking cytokine secretion; evaluation of inflammasome activation by various techniques such as protein quantification by Western blot; evaluation of peripheral T cell adenosine receptor biology as an indicator of inflammatory events; use of flow cytometry to evaluate FoxP3 transcription factor co-expression with Th1-associated molecules TBET, IL-2, or IFN-γ; characterization of T cell receptor repertoire by RNA sequencing; and detection of antigen-specific T cell responses to potential neuroautoantigens such as protein aggregates that occur during disease development.
[0354] Protocol Evaluation Clinical evaluation by a physician or mid-level provider will be performed on day 1 of each cycle of the intended 14-day cycle of the PC regimen. Patients will be seen by an on-site provider once during the 14-day PC cycle (ideally around day 8 of the cycle). At these visits, a CBC with differential and complete metabolic panel (a complete metabolic panel typically includes approximately 14 tests, including electrolytes, creatinine, liver transaminases, and bilirubin; the particular panel used is not mandatory for the protocol) will be obtained and lab results will be sent to the protocol investigator.
[0355] Upon completion of the interval containing the PC regimen (approximately month 2), patients will be seen monthly at months 3, 4, 5, and 6, with the month 6 visit representing the end-of-study visit. Tests performed at the time of these clinical evaluations will include: (1) interim history and physical exam; (2) CBC with differential and platelet count; (3) complete metabolic panel; and (4) immune subset enumeration (TBNK panel).
[0356] To monitor the immune parameters of the study, peripheral blood samples will be sent to Rapa Therapeutics to allow for centralized monitoring and deeper analysis. Blood samples consist of 30 ml in green top heparinized tubes (for cell assays) and 5 ml in red top tubes (for serum assays) sent to Rapa Therapeutics.
[0357] Using the same samples sent to Rapa Therapeutics, we will investigate the effect of the PC regimen and lamivudine maintenance therapy on pro- or anti-inflammatory cytokines or cell subsets as measured by RNA expression, supernatant / Luminex assays, flow cytometry, and cell signaling events by phosphorylation analysis by Western blot.
[0358] The serum is evaluated for potential biomarkers of ALS, including but not limited to those described in Beach TG. A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley? Neurology and Therapy. 2017;6(Suppl 1):5-13.
[0359] We characterize the TCR repertoire of patients and assess whether therapeutic interventions affect the repertoire.
[0360] In vitro studies fall under the general category of "immunocharacterization studies." These focus on the separation of different cell subsets by multiparameter FACS analysis or by magnetic beads with subsequent characterization. Specifically, peripheral blood mononuclear cells (PBMCs) are analyzed by flow cytometry for expression of markers indicative of hematopoietic lineage, immune function subsets, cytokine production, and activation state. Cell subsets are analyzed for T cell receptor repertoire diversity. Cells may be activated in vitro with a number of different stimuli, including specific antigens and mitogens known to activate different pathways of T lymphocyte or monocyte function. Assays may include T cell proliferation, cytokine production, and gene expression. Specific assays used in ongoing data analysis may be modified, removed, or replaced as technology and knowledge in the field evolve during the course of the study without constituting a change in the study objectives.
[0361] Response Criteria Patient-reported ALSFS-R scores and clinician-reported Appel scores will be measured at various time points, as described above.
[0362] Toxicity standards Toxicity will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), available at http: / / ctep.info.nih.gov. A copy of the CTCAE version 4.0 can be downloaded from the CTEP homepage. All therapeutic areas and personnel involved in the trial should have access to a copy of the CTCAE version 4.0.
[0363] Any grade 4 or 5 toxicity (CTCAE version 4.0) with attributes probably or definitely related to the study drug (pentostatin, cyclophosphamide, lamivudine) will be considered a dose-limiting toxicity (DLT). The following toxicities are not considered DLTs: biochemical grade 4 toxicity (excluding renal and hepatic values), grade 4 vomiting, grade 4 fever, and grade 4 toxicity related to infection that resolves within 7 days.
[0364] Statistical Considerations This study design incorporates a standard 3+3 methodology for evaluating the safety of the pentostatin and cyclophosphamide regimen and maintenance of lamivudine therapy (platform). If no patient in the first three patients develops a DLT through completion of the pentostatin / cyclophosphamide regimen, the regimen is determined to be safe for expanding the cohort to a total of n=10 patients. On the other hand, if one of the first three patients develops a DLT, the increment is increased to a total of n=6 patients. In such a case, if less than one of the first six patients develops a DLT, the increment can proceed to an increase in the number of n=10 in the cohort.
[0365] Once this platform is successfully developed, the inventors will REG We will evaluate the safety and potential efficacy of cell infusions. First, we will conduct pilot studies to evaluate iT cells that inhibit neuroinflammatory pathways associated with the disease. REG The ability to inject cells multiple times is evaluated.
[0366] Given the documented ability to effectively modulate biomarkers associated with neurodegeneration, we aimed to develop an iT REG Conduct phase II clinical trials (using either historical control data or a randomized cohort design) to evaluate whether cell therapy can improve clinical outcomes in ALS patients.
[0367] Risk / benefit analysis The estimated survival of patients enrolled in this study is expected to be approximately two to four years from study entry.
[0368] The first protocol component consists of four cycles of an immunodepletion and immunosuppression regimen (PC regimen) consisting of pentostatin and cyclophosphamide. We hypothesize that the PC regimen eliminates and suppresses pathogenic immune cells that contribute to ALS progression, and thus patients may benefit from this effect in the form of improved quality of life or ultimately reduced disease progression. However, there may be unexpected toxicities of the PC regimen with respect to the central nervous system. Although dosing modifications have been made to help establish that the PC regimen is relatively safe in this new ALS patient population, it is possible that the PC regimen may have contradictory effects and actually increase the rate of ALS progression or cause some other neurological toxicity. Rarely pentostatin may also cause toxicity to other organs such as the heart or kidney. The most common toxicity expected from the PC regimen is lymphocyte depletion, although this effect is part of the rationale for the treatment. On the other hand, the PC regimen may eliminate myeloid lineage cells, thereby increasing the likelihood of bacterial or fungal infections. PC regimens are expected to be associated with T cell immunosuppression and therefore may result in opportunistic viral infections.
[0369] The second protocol component consists of maintenance therapy with the antiviral drug lamivudine. Patients may benefit from this therapy if the drug acts as hypothesized to reduce inflammation originating from the central nervous system. Lamivudine is generally a very well tolerated drug, with mostly gastrointestinal side effects and pancreatitis.
[0370] The third protocol component is iT REG It consists of multiple injections of cells. Patients can benefit from this therapy because the cell therapy that controls inflammation occurs directly within the microenvironment where inflammation is initiated, because the cell therapy operates through multiple molecular mechanisms of action that cannot be easily replicated through drug therapy, and because the effects of the cell therapy can be long-lasting due to memory cell effects.
[0371] Alternative Protocol Designs Figure 39 provides an alternative protocol design. Lymphocytes are collected by steady-state apheresis and the apheresis product is shipped to Rapa Therapeutics (Rockville, MD). After RAPA-501 cell manufacturing, n=4 doses of RAPA-501 cells are cryopreserved in single-use infusion bags at the clinically indicated cell dose. The treatment interval is 6 months, followed by a 6-month observation interval. Cohort #1 will be 40x10 6 Patients will receive RAPA-501 cells administered over 4 cycles at a dose of 120×10 cells / infusion. Cohort #1 represents the safety cohort and utilizes a standard 3+3 design. Advancement to cohort #2 will occur if 0 / 3 or 1 / 6 or less patients experience dose-limiting toxicity (DLT). Cohort #2 will receive a T cell dose of 120×10 6 In cohort #3, each of the four RAPA-501 cell infusions was preceded by a single agent (40 or 120 × 10 cells per cohort #1 or #2, respectively). 6 To evaluate the highest dose of RAPA-501 cells that can be safely administered as either RAPA-501 cells / infusion or host conditioning with a PC regimen. The PC regimen consists of pentostatin (2 mg / m on days 1 and 4) plus 2 ), cyclophosphamide (100 mg daily, days 1–5), no treatment on days 6 and 7, and RAPA-501 cell infusion on day 8.
[0372] Embodiments of dedifferentiation: 1. A method for dedifferentiating T cells, comprising: seeding a culture input population of cells comprising T cells from the subject at a cell density in a culture medium comprising vitamin D, temsirolimus, and an IL-2 signaling inhibitor; adding anti-CD3 / anti-CD28 coated magnetic beads to the T cells and culture medium at a bead:T cell ratio of 1:1 to 1:12; and incubating the culture input population of cells and culture medium for a period of time to obtain de-differentiated T cells. 2. The method of embodiment 1, further comprising harvesting said dedifferentiated T cells. 3. After collecting the dedifferentiated T cells, packaging at least a portion of the dedifferentiated T cells into a package; 3. The method of embodiment 2, further comprising freezing said package containing said portion of said dedifferentiated T cells. 4. Cultivation of the above cells Prior to inoculating the input population into the above culture medium, 4. The method of any one of embodiments 1 to 3, further comprising harvesting a culture input population of said cells from said subject. 5. The method according to any one of embodiments 1 to 4, wherein said culture medium does not contain IL-2 and no IL-2 is added to said culture medium. 6. The method of any one of embodiments 1 to 5, wherein said cell density is at least 1.5 x 106 T cells per mL. 7. The method of any one of embodiments 1 to 6, wherein said temsirolimus is present in said culture medium at a concentration of about 0.3 μM to about 1 μM. 8. The method of any one of embodiments 1-6, wherein said temsirolimus is present in said culture medium at a concentration of about 1 μM. 9. The method according to any one of embodiments 1 to 8, wherein said IL-2 signaling inhibitor is an anti-IL-2 receptor antibody or a fragment thereof. 10. The method of embodiment 9, wherein said IL-2 signaling inhibitor is basiliximab or daclizumab. 11. The method according to any one of embodiments 1 to 10, wherein said IL-2 signaling inhibitor is present in said culture medium at a concentration of 5 to 50 μg / mL. 12. The method according to any one of the preceding embodiments, wherein said period is about 3 days. 13. The method according to any one of embodiments 1 to 12, wherein the bead:T cell ratio is 1:3. 14. The method according to any one of embodiments 1 to 13, wherein said culture medium further comprises 5% human serum. 15. The method according to any one of embodiments 1 to 14, wherein said culture medium comprises X-Vivo 20 medium. 16. The method according to any one of the preceding embodiments, wherein said vitamin D is present in said culture medium at about 0.03 nM to about 1 nM. 17. The method according to any one of the preceding embodiments, wherein said vitamin D is present in said culture medium at about 0.1 nM. 18. The method further comprises measuring the expression level of RAPTOR or RICTOR in a culture input population of the above cells; The method of any one of embodiments 1-11 and 13-17, wherein the above period lasts until the expression level of RAPTOR or RICTOR in the culture input population of cells is reduced by at least 50%, more preferably 90%, compared to a control population of T cells produced under the same conditions as the culture input population of cells without temsirolimus, an IL-2 signaling inhibitor and vitamin D. 19. The method further comprises measuring the expression levels of RAPTOR or RICTOR and a housekeeping protein in a culture input population of the cells described above; The method of any one of embodiments 1-11 and 13-17, wherein the period lasts until the expression level of RAPTOR or RICTOR, respectively, in the culture input population of cells is reduced by at least 50% compared to a control population of T cells produced under the same conditions as the culture input population of cells without temsirolimus, an IL-2 signaling inhibitor and vitamin D, after normalization for expression levels of housekeeping proteins. 20. The method of embodiment 19, wherein said housekeeping protein is actin or GAPDH. 21. The method according to any one of embodiments 18 to 20, wherein the step of measuring the expression level is carried out by Western blot analysis. 22. The method further comprises measuring the expression level of RAPTOR or RICTOR in a culture input population of the above cells; The method of any one of embodiments 1-11 and 13-17, wherein the above period lasts until the expression level of RAPTOR or RICTOR in the culture input population of cells is reduced by at least 50%, more preferably 90%, compared to a control population of T cells produced under the same conditions as the culture input population of cells without temsirolimus, an IL-2 signaling inhibitor and vitamin D. 23. A dedifferentiated T cell produced by the method according to any one of embodiments 1 to 22. 24. A composition comprising a population of dedifferentiated T cells, At least a portion of said population of said de-differentiated T cells express less than 50% of both RAPTOR or RICTOR compared to a control population of T cells, wherein the control population of T cells is produced under the same conditions as the culture input population of cells without temsirolimus, an IL-2 signaling inhibitor, and vitamin D. 25. A method for dedifferentiating T cells, comprising: seeding a culture input population of cells comprising T cells from the subject at a cell density in a culture medium comprising vitamin D and temsirolimus; adding anti-CD3 / anti-CD28 coated magnetic beads to the T cells and culture medium at a bead:T cell ratio of 1:1 or less to stimulate the T cells; and incubating the culture input population of cells and culture medium for a period of time to obtain de-differentiated T cells. 26. The method of embodiment 25, further comprising harvesting said dedifferentiated T cells. 27. After collecting the dedifferentiated T cells, packaging at least a portion of the dedifferentiated T cells into a package; 27. The method of embodiment 26, further comprising freezing said package containing said portion of said dedifferentiated T cells. 28. Prior to inoculating the input population of cells into the culture medium, 28. The method of any one of embodiments 25 to 27, further comprising harvesting a culture input population of said cells from said subject. 29. The method according to any one of embodiments 25 to 28, wherein said culture medium does not contain IL-2 and no IL-2 is added to said culture medium. 30. The method of any one of embodiments 25 to 29, wherein the cell density is 1.5 × 106 T cells per mL. 31. The method according to any one of embodiments 25 to 30, wherein said temsirolimus is present in said culture medium at a concentration of about 0.3 μM to about 1 μM. 32. The method according to any one of embodiments 25 to 30, wherein said temsirolimus is present in said culture medium at a concentration of about 1 μM. 33. The method of any one of embodiments 25 to 32, wherein the period is about 3 days. 34. The method of any one of embodiments 25 to 33, wherein the bead:T cell ratio is 1:3. 35. The method according to any one of embodiments 25 to 34, wherein the culture medium further comprises 5% human serum. 36. The method according to any one of embodiments 25 to 35, wherein said culture medium comprises X-Vivo 20 medium. 37. The method according to any one of embodiments 25 to 36, wherein said vitamin D is present in said culture medium at about 0.03 nM to about 1 nM. 38. The method according to any one of embodiments 25 to 37, wherein said vitamin D is present in said medium at about 0.1 nM. 39. The method further comprises measuring the expression level of RAPTOR or RICTOR in a culture input population of the above cells; The method of any one of embodiments 25-32 and 34-38, wherein the period lasts until the expression level of RAPTOR or RICTOR in the culture input population of cells is reduced by at least 50% compared to a control population of T cells produced under the same conditions as the culture input population of cells without temsirolimus, an IL-2 signaling inhibitor and vitamin D. 40. The method further comprises measuring the expression levels of RAPTOR, RICTOR and housekeeping proteins in a culture input population of the cells described above; The method of any one of embodiments 25-32 and 34-38, wherein the above period lasts until the expression level of RAPTOR or RICTOR in the culture input population of cells is reduced by 50%, or more preferably by 90%, compared to a control population of T cells produced under the same conditions as the culture input population of cells without temsirolimus, an IL-2 signaling inhibitor and vitamin D, after normalization for expression of housekeeping proteins. 41. The method of embodiment 40, wherein said housekeeping protein is actin or GAPDH. 42. The method according to any one of embodiments 39 to 41, wherein the step of measuring the expression level is carried out by Western blot analysis. 43. The method further comprises measuring the expression level of RAPTOR or RICTOR in a culture input population of the above cells; The method of any one of embodiments 25-32 and 34-38, wherein the above-mentioned period continues until the expression level of RAPTOR or RICTOR in the culture input population of cells is reduced by at least 50%, more preferably 90%, compared to a control population of T cells produced under the same conditions as the culture input population of cells without temsirolimus, an IL-2 signaling inhibitor and vitamin D. 44. A dedifferentiated T cell produced by the method according to any one of embodiments 25 to 43. 45. A dedifferentiated T cell population characterized by at least a 10% reduction, more preferably a 50% reduction, in expression of RNA for the following T cell differentiation molecules: cytolytic molecules, including but not limited to, granzyme B, and cytokine molecules, including but not limited to IFN-γ, compared to a control population of T cells cultured without the culture additive identified by these methods. 46. A dedifferentiated T cell population characterized by at least a 10% increase, more preferably a 50% increase, in expression of RNA for the following T cell differentiation molecules: transcription factors associated with induced pluripotent stem cells, including but not limited to Nanog, KLF4, and KLF10, and molecules associated with naive T cells, including but not limited to IL-7 receptor, CD127, compared to a control population of T cells cultured without the culture additive identified by these methods. 47. A dedifferentiated T cell population characterized by at least a 10% decrease, more preferably a 50% decrease, in RNA expression for the following T cell differentiation molecules: transcription factors associated with Th1 effector T cells, including but not limited to, T-Bet and STAT1, compared to a control population of T cells cultured without the culture additive identified by these methods, but which may concomitantly have comparable expression of transcription factors associated with cell survival, including but not limited to, HIF-1-α. 48. A dedifferentiated T cell population characterized by at least a 10% increase, and more preferably a 50% increase, in expression of molecular markers of autophagy, including, but not limited to, elevated protein levels by Western blot analysis of the autophagy-associated molecule p62, compared to a control population of T cells cultured without the culture additive identified by these methods. 49. The method according to any one of embodiments 1 to 22, wherein the step of adding anti-CD3 / anti-CD28 coated magnetic beads to the T cells and culture medium at a beads:T cell ratio of 1:1 to 1:12 is not performed. 50. The method according to any one of embodiments 25 to 43, wherein the step of adding anti-CD3 / anti-CD28 coated magnetic beads to the T cells and culture medium at a beads:T cell ratio of 1:1 or less to stimulate the T cells is not performed. 51. The following characteristics: at least a 10% decrease, more preferably a 50% decrease, in mRNA expression of one or more of granzyme B, IL-10, and IFN-γ, as compared to a control T cell population incubated under the same conditions without temsirolimus, vitamin D, and an IL-2 signaling inhibitor; at least a 10% increase, more preferably a 50% increase, in mRNA expression of one or more of Nanog, KLF4, KLF10, and CD127, as compared to a control T cell population incubated under the same conditions without temsirolimus, vitamin D, and an IL-2 signaling inhibitor; at least a 10% decrease, more preferably a 50% decrease, in mRNA expression of one or more of T-Bet and STAT1, as compared to a control T cell population incubated under the same conditions without temsirolimus, vitamin D, and an IL-2 signaling inhibitor; HIF-1-α expression within approximately 20% of control T cell populations incubated under the same conditions without temsirolimus, vitamin D, and IL-2 signaling inhibitors, at least a 10% increase, more preferably a 50% increase, in p62 expression compared to a control T cell population incubated under the same conditions without temsirolimus, vitamin D, and an IL-2 signaling inhibitor; the expression level of RAPTOR or RICTOR is reduced by at least 50%, more preferably 90%, as compared to a control population of T cells produced under the same conditions as the culture input population of cells without temsirolimus, an IL-2 signaling inhibitor and vitamin D; the expression levels of RAPTOR or RICTOR, normalized by a housekeeping protein, are reduced by at least 50%, more preferably 90%, as compared to a control population of T cells produced under the same conditions as the culture input population of cells without temsirolimus, an IL-2 signaling inhibitor, and vitamin D; and A population of dedifferentiated T cells characterized by one or more of the following: 52. The following characteristics: at least a 10% reduction, more preferably a 50% reduction, in mRNA expression of one or more of granzyme B, IL-10, and IFN-γ, compared to control T cells incubated under the same conditions without temsirolimus, vitamin D, and an IL-2 signaling inhibitor; at least a 10% increase, more preferably a 50% increase, in mRNA expression of one or more of Nanog, KLF4, KLF10, and CD127, compared to control T cells incubated under the same conditions without temsirolimus, vitamin D, and an IL-2 signaling inhibitor; at least a 10% decrease, more preferably a 50% decrease, in mRNA expression of one or more of T-Bet and STAT1, compared to control T cells incubated under the same conditions without temsirolimus, vitamin D, and an IL-2 signaling inhibitor; HIF-1-α expression within approximately 20% of control T cells incubated under the same conditions without temsirolimus, vitamin D, and IL-2 signaling inhibitors; at least a 10% increase, more preferably a 50% increase, in p62 expression compared to a control T cell population incubated under the same conditions without temsirolimus, vitamin D, and an IL-2 signaling inhibitor; the expression level of RAPTOR or RICTOR is reduced by at least 50%, more preferably 90%, as compared to control T cells produced under the same conditions as the culture input population of cells without temsirolimus, an IL-2 signaling inhibitor and vitamin D; the expression levels of RAPTOR or RICTOR, normalized by a housekeeping protein, are reduced by at least 50%, more preferably 90%, as compared to control T cells produced under the same conditions as the culture input population of cells without temsirolimus, an IL-2 signaling inhibitor and vitamin D; and A dedifferentiated T cell characterized by one or more of the following:
[0373] Regeneration embodiment: 1. A method for differentiating dedifferentiated T cells into TREG / Th2 cells, comprising: Culturing dedifferentiated T cells in a culture medium containing IL-2, IL-4, and TGF-β, and adding anti-CD3 / anti-CD28 coated magnetic beads at a ratio of 3:1 (beads:T cells); and incubating the dedifferentiated T cells for a certain period of time to obtain TREG / Th2 cells. 2. The method of embodiment 1, wherein said culture medium further comprises pemetrexed. 3. The method according to any one of embodiments 1 to 2, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU / mL. 4. The method according to any one of embodiments 1 to 3, wherein said IL-4 is present in said culture medium at a concentration of about 1000 IU / mL. 5. The method according to any one of embodiments 1 to 4, wherein said TGF-β is present in said culture medium at a concentration of about 10 ng / mL. 6. The method of embodiment 2, wherein said pemetrexed is present in said culture medium at a concentration of up to 100 nM. 7. The method of embodiment 2, wherein said pemetrexed is present in said culture medium at a concentration of about 10 nM. 8. The method according to any one of embodiments 6 to 7, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU / mL. 9. The method according to any one of embodiments 6 to 8, wherein said IL-4 is present in said culture medium at a concentration of about 1000 IU / mL. 10. The method according to any one of embodiments 6 to 9, wherein said TGF-β is present in said culture medium at a concentration of about 10 ng / mL. 11. A method for differentiating dedifferentiated T cells into TREG / Th2 cells, comprising: Culturing dedifferentiated T cells, wherein the dedifferentiated T cells express RAPTOR and RICTOR at levels that are reduced by at least 10% compared to control T cells, in a culture medium comprising IL-2, IL-4, and TGF-β; Addition of anti-CD3 / anti-CD28 coated magnetic beads at a ratio of 3:1 (beads:T cells); and incubating the dedifferentiated T cells for a certain period of time to obtain TREG / Th2 cells. 12. The method of embodiment 11, wherein said culture medium further comprises pemetrexed. 13. The method according to any one of embodiments 11 to 12, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU / mL. 14. The method according to any one of embodiments 11 to 13, wherein said IL-4 is present in said culture medium at a concentration of about 1000 IU / mL. 15. The method according to any one of embodiments 11 to 14, wherein said TGF-β is present in said culture medium at a concentration of about 10 ng / mL. 16. The method of embodiment 12, wherein said pemetrexed is present in said culture medium at a concentration of up to 100 nM. 17. The method of embodiment 12, wherein said pemetrexed is present in said culture medium at a concentration of about 10 nM. 18. The method according to any one of embodiments 16 to 17, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU / mL. 19. The method according to any one of embodiments 16 to 18, wherein said IL-4 is present in said culture medium at a concentration of about 1000 IU / mL. 20. The method according to any one of embodiments 16 to 19, wherein said TGF-β is present in said culture medium at a concentration of about 10 ng / mL. 21. The method according to any one of embodiments 1 to 20, wherein said culture medium is X-Vivo 20 supplemented with 5% human AB serum. 22. The method according to any one of the preceding embodiments, wherein the period is between 3 and 40 days. 23. A TREG / Th2 cell produced by the method according to any one of embodiments 1 to 22. 24. A method for differentiating dedifferentiated T cells into TREG cells, comprising: Culturing dedifferentiated T cells having reduced expression of RAPTOR and RICTOR compared to a control population of T cells in a culture medium containing IL-2 and TGF-β; Addition of anti-CD3 / anti-CD28 coated magnetic beads at a ratio of 3:1 (beads:T cells); and incubating the dedifferentiated T cells for a certain period of time to obtain TREG cells. 25. The method of embodiment 24, wherein said culture medium further comprises pemetrexed. 26. The method according to any one of embodiments 24 to 25, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU / mL. 27. The method according to any one of embodiments 24 to 26, wherein said TGF-β is present in said culture medium at a concentration of about 10 ng / mL. 28. The method of embodiment 25, wherein said pemetrexed is present in said culture medium at a concentration of up to 100 nM. 29. The method of embodiment 25, wherein said pemetrexed is present in said culture medium at a concentration of about 10 nM. 30. The method according to any one of embodiments 28 to 29, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU / mL. 31. The method according to any one of embodiments 28 to 30, wherein said TGF-β is present in said culture medium at a concentration of about 10 ng / mL. 32. A method for differentiating dedifferentiated T cells into TREG cells, comprising: Culturing dedifferentiated T cells, wherein the dedifferentiated T cells express RAPTOR and RICTOR at levels that are reduced by at least 10% compared to control T cells, in a culture medium comprising IL-2 and TGF-β; Addition of anti-CD3 / anti-CD28 coated magnetic beads at a ratio of 3:1 (beads:T cells); and incubating the dedifferentiated T cells for a certain period of time to obtain TREG cells. 33. The method of embodiment 32, wherein said culture medium further comprises pemetrexed. 34. The method according to any one of embodiments 32-33, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU / mL. 35. The method according to any one of embodiments 32 to 34, wherein said TGF-β is present in said culture medium at a concentration of about 10 ng / mL. 36. The method of embodiment 33, wherein said pemetrexed is present in said culture medium at a concentration of up to 100 nM. 37. The method of embodiment 33, wherein said pemetrexed is present in said culture medium at a concentration of about 10 nM. 38. The method according to any one of embodiments 36 to 37, wherein said IL-2 is present in said culture medium at a concentration of about 100 IU / mL. 39. The method according to any one of embodiments 36 to 38, wherein said TGF-β is present in said culture medium at a concentration of about 10 ng / mL. 40. The method according to any one of embodiments 24 to 39, wherein said culture medium is X-Vivo 20 medium supplemented with 5% AB serum. 41. The method according to any one of embodiments 24 to 40, wherein the period is from 3 days to 40 days. 42. The method of any one of embodiments 1-41, wherein said dedifferentiated T cells have reduced expression of RAPTOR and RICTOR compared to a control population of T cells. 43. A TREG cell produced by a method according to any one of embodiments 1 to 22 and 24 to 42. 44. TREG cells or hybrid TREG / Th2 cells produced by the method of any one of embodiments 1-22 and 24-42, wherein the lymphocytes collected by apheresis for subsequent T cell culture are obtained at steady state or after treatment of the subject with an anti-TNF-α therapeutic agent that is relatively selective in neutralizing serum, a cell-free form of TNF-α, most notably the recombinant receptor molecule etanercept, or the monoclonal antibody adalimumab. 45. TREG cells or hybrid TREG / Th2 cells produced by the method of any one of embodiments 1-22 and 24-42, wherein the TREG cells or hybrid TREG / Th2 cells or populations thereof have increased expression by flow cytometry of at least one of the following molecules: CD25, CD27, 2B4, BTLA, CTLA4, TIGIT, TIM3, ICOS, LAIR1, OX40, and combinations thereof, compared to control Th1 / Tc1 cells. 46. TREG cells or hybrid TREG / Th2 cells produced by the method of any one of embodiments 1-22 and 24-42, wherein the TREG cells or hybrid TREG / Th2 cells or populations thereof have reduced secretion of inflammatory cytokines, including IFN-γ and TNF-α, compared to control Th1 / Tc1 cells. 47. TREG cells or hybrid TREG / Th2 cells produced by the method of any one of embodiments 1-22 and 24-42, wherein said TREG cells or hybrid TREG / Th2 cells or populations thereof have altered expression of T cell fate transcription factors, most notably reduced TBET and increased FOXP3, compared to control Th1 / Tc1 cells. 48. TREG cells or hybrid TREG / Th2 cells produced by the method of any one of embodiments 1-22 and 24-42, wherein the TREG cells or hybrid TREG / Th2 cells or populations thereof have additional phenotypic traits, including increased secretion of the Th2 cytokine IL-4 and increased expression of the Th2 transcription factor GATA3, compared to control Th1 / Tc1 cells. 49. A population of TREG or TREG / Th2 cells having at least 5% of CD4+ or CD8+ T cells expressing GATA3. 50. A population of TREG or TREG / Th2 cells with at least 5% of CD4+ or CD8+ T cells expressing FoxP3. 51. A population of TREG or TREG / Th2 cells having at least 10% of CD4+ or CD8+ T cells expressing CD73. 52. A population of TREG or TREG / Th2 cells having at least 10% of CD4+ or CD8+ T cells expressing CD103. 53. A population of TREG or TREG / Th2 cells having at least 20% of CD4+ or CD8+ T cells expressing CD150. A population of TREG or TREG / Th2 cells expressing at least 5 pg / mL / 1 x 106 cells / day of IL-4 after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 54.3:1. A population of TREG or TREG / Th2 cells expressing at least 100 pg / mL / 1 x 106 cells / day of IL-2 after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 55.3:1. A population of TREG or TREG / Th2 cells expressing at least 100 pg / mL / 1 x 106 cells / day of IFN-γ or GM-CSF after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 56.3:1. A population of TREG or TREG / Th2 cells expressing <100pg / mL / 1x106 cells / day of TNF-α or IL-17F following costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 57.3:1. 58. The following characteristics: at least a 10% increase in expression of one or more of CD25, CD27, 2B4, BTLA, CTLA4, TIGIT, TIM3, ICOS, LAIR1, OXO40, and combinations thereof, as measured by flow cytometry, compared to control Th1 / Tc1 cells; at least 10% reduced secretion of IFN-γ compared to control Th1 / Tc1 cells; at least 10% reduced secretion of TNF-α compared to control Th1 / Tc1 cells; at least 10% decreased expression of TBET compared to control Th1 / Tc1 cells; at least 10% increased expression of FOXP3 compared to control Th1 / Tc1 cells; CD4 expressing GATA3 as measured by flow cytometry + or CD8 + At least 5% T cells; CD4 expressing FOXP3 as measured by flow cytometry + or CD8 + At least 5% T cells; CD4 expressing CD73 as measured by flow cytometry + or CD8 + At least 5% T cells; CD4 expressing CD103 as measured by flow cytometry + or CD8 + At least 5% T cells; CD4 expressing both FOXP3 and GATA3 as measured by flow cytometry + or CD8 + At least 5% of the cells CD4 expressing CD150 as measured by flow cytometry + or CD8 + At least 20% T cells; T REG or T REG / The expression of one or more of GATA3, FoxP3, CD73, CD103, and CD150 is increased by at least 50% compared to the T cell-specific T cell population from which the Th2 cell population was generated; At least 5 pg / mL / 1 x 10 of IL-4 after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1 6 Secretion of cells / day, At least 100 pg / mL / 1 x 10 of IL-2 after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1 6 Secretion of cells / day, 100 pg / mL / 1 × 10 of IFN-γ after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1 6 Secretion of less than cells / day 100 pg / mL / 1 × 10 of GM-CSF after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1 6 Secretion of less than cells / day 10 pg / mL / 1 × 10 of TNF-α after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1 6 Secretion of less than cells / day 10 pg / mL / 1 × 10 of IL-17 after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1 6 secretion of less than cells / day, and A population of TREG or TREG / Th2 cells having one or more of the following combinations: 59. The following characteristics: at least a 10% increase in expression of one or more of CD25, CD27, 2B4, BTLA, CTLA4, TIGIT, TIM3, ICOS, LAIR1, OXO40, and combinations thereof, as measured by flow cytometry, compared to control Th1 / Tc1 cells; at least 10% reduced secretion of IFN-γ compared to control Th1 / Tc1 cells; at least 10% reduced secretion of TNF-α compared to control Th1 / Tc1 cells; at least 10% decreased expression of TBET compared to control Th1 / Tc1 cells; at least 10% increased expression of FOXP3 compared to control Th1 / Tc1 cells; At least 5 pg / mL / 1 x 10 of IL-4 after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1 6 Secretion of cells / day, At least 100 pg / mL / 1 x 10 of IL-2 after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1 6 Secretion of cells / day, 100 pg / mL / 1 × 10 of IFN-γ after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1 6 Secretion of less than cells / day 100 pg / mL / 1 × 10 of GM-CSF after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1 6 Secretion of less than cells / day 10 pg / mL / 1 × 10 of TNF-α after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1 6 Secretion of less than cells / day 10 pg / mL / 1 × 10 of IL-17 after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1 6 Secretion of less than cells / day Expression of GATA3, FOXP3, CD73, and CD103, and TREG or TREG / Th2 cells having one or more of the following combinations: 60. Dedifferentiated T cells have the following characteristics: at least a 10% decrease, more preferably a 50% decrease, in mRNA expression of one or more of granzyme B, IL-10, and IFN-γ, as compared to a control T cell population incubated under the same conditions without temsirolimus, vitamin D, and an IL-2 signaling inhibitor; at least a 10% increase, more preferably a 50% increase, in mRNA expression of one or more of Nanog, KLF4, KLF10, and CD127, as compared to a control T cell population incubated under the same conditions without temsirolimus, vitamin D, and an IL-2 signaling inhibitor; at least a 10% decrease, more preferably a 50% decrease, in mRNA expression of one or more of T-Bet and STAT1, as compared to a control T cell population incubated under the same conditions without temsirolimus, vitamin D, and an IL-2 signaling inhibitor; HIF-1-α expression within approximately 20% of control T cell populations incubated under the same conditions without temsirolimus, vitamin D, and IL-2 signaling inhibitors, at least a 10% increase, more preferably a 50% increase, in p62 expression compared to a control T cell population incubated under the same conditions without temsirolimus, vitamin D, and an IL-2 signaling inhibitor; the expression level of RAPTOR or RICTOR is reduced by at least 50%, more preferably 90%, as compared to a control population of T cells produced under the same conditions as the culture input population of cells without temsirolimus, an IL-2 signaling inhibitor and vitamin D; the expression levels of RAPTOR or RICTOR, normalized by a housekeeping protein, are reduced by at least 50%, more preferably 90%, as compared to a control population of T cells produced under the same conditions as the culture input population of cells without temsirolimus, an IL-2 signaling inhibitor, and vitamin D; and 42. The method according to claim 1, comprising one or more of the following combinations: 61. Dedifferentiated T cells have the following characteristics: at least a 10% reduction, more preferably a 50% reduction, in mRNA expression of one or more of granzyme B, IL-10, and IFN-γ, compared to control T cells incubated under the same conditions without temsirolimus, vitamin D, and an IL-2 signaling inhibitor; at least a 10% increase, more preferably a 50% increase, in mRNA expression of one or more of Nanog, KLF4, KLF10, and CD127, compared to control T cells incubated under the same conditions without temsirolimus, vitamin D, and an IL-2 signaling inhibitor; at least a 10% decrease, more preferably a 50% decrease, in mRNA expression of one or more of T-Bet and STAT1, compared to control T cells incubated under the same conditions without temsirolimus, vitamin D, and an IL-2 signaling inhibitor; HIF-1-α expression within approximately 20% of control T cells incubated under the same conditions without temsirolimus, vitamin D, and IL-2 signaling inhibitors; at least a 10% increase, more preferably a 50% increase, in p62 expression compared to a control T cell population incubated under the same conditions without temsirolimus, vitamin D, and an IL-2 signaling inhibitor; the expression level of RAPTOR or RICTOR is reduced by at least 50%, more preferably 90%, as compared to control T cells produced under the same conditions as the culture input population of cells without temsirolimus, an IL-2 signaling inhibitor and vitamin D; the expression levels of RAPTOR or RICTOR, normalized by a housekeeping protein, are reduced by at least 50%, more preferably 90%, as compared to control T cells produced under the same conditions as the culture input population of cells without temsirolimus, an IL-2 signaling inhibitor and vitamin D; and 42. The method according to claim 1, comprising one or more of the following combinations:
Claims
1. 1. A method of treating amyotrophic lateral sclerosis in a subject in need thereof, comprising: subjecting the subject to one or more primary treatment cycles, each of the one or more primary treatment cycles comprising: administering pentostatin to the subject; and / or subjecting the subject to a first treatment cycle comprising administering cyclophosphamide; The subject, A therapeutically effective amount of the manufactured T REG and subjecting the patient to one or more immunotherapy treatment cycles comprising administering a composition comprising the cells.
2. 10. The method of claim 1, wherein each of the one or more immunotherapy treatment cycles further comprises administering to the subject a nucleoside reverse transcriptase inhibitor.
3. The method of claim 2, wherein the nucleoside reverse transcriptase inhibitor is an inhibitor of the NLRP3 inflammasome.
4. 3. The method of claim 2, wherein the nucleoside reverse transcriptase inhibitor is lamivudine.
5. 10. The method of claim 1, wherein each of the one or more primary treatment cycles is from 2 weeks to 5 weeks in length.
6. Each of the one or more immunotherapy treatment cycles comprises: administering pentostatin to the subject; and / or The method of any one of claims 1 to 5, further comprising administering to the subject cyclophosphamide.
7. 3. The method of claim 2, wherein each of the one or more immunotherapy treatment cycles is 18 weeks in length.
8. Pentostatin, 0.5 mg / m 2 ~4 mg / m 2The method of claim 1, wherein the subject is administered a dose of
9. 2. The method of claim 1, wherein the pentostatin is administered on day 1, or days 1 and 4, of each of the one or more first treatment cycles.
10. 2. The method of claim 1, wherein the dose of cyclophosphamide is from 50 mg to 400 mg.
11. 2. The method of claim 1, wherein the cyclophosphamide is administered on days 1, 2, and 3, or days 1, 2, 3, 4, and 5 of each of the one or more first line treatment cycles.
12. 10. The method of claim 1, wherein the method comprises two or more primary treatment cycles, each of the two or more primary treatment cycles being 0 to 2 weeks apart.
13. 3. The method of claim 2, wherein a first cycle of said one or more immunotherapy treatment cycles and a last cycle of said one or more primary treatment cycles are separated by 0 to 2 weeks.
14. 5. The method of claim 4, wherein the lamivudine is administered to the subject at a dose of 150 mg daily to 150 mg twice daily.
15. 10. The method of claim 1, wherein the pentostatin and cyclophosphamide are administered to the subject in a single composition.
16. said step of administering to said subject pentostatin and cyclophosphamide administering to the subject a first composition comprising pentostatin; and administering to the subject a second composition comprising cyclophosphamide.
17. 15. The method of claim 14, wherein the single composition is administered intravenously to the subject.
18. 7. The method of claim 6, wherein the step of administering pentostatin to the subject during each of the one or more immunotherapy treatment cycles is performed on days 1 and 4 of each of the one or more immunotherapy treatment cycles.
19. 20. The method of claim 6 or claim 18, wherein the step of administering pentostatin to the subject during each of the one or more immunotherapy treatment cycles is performed on days 1, 2, 3, 4, and 5 of each of the one or more immunotherapy treatment cycles.
20. Pentostatin is administered at a dose of 1 mg / ml during each of said one or more immunotherapy treatment cycles. 2 ~2mg / m 2 The method of any one of claims 6 and 18-19, wherein the subject is administered a dose of
21. Pentostatin is administered at a dose of 2 mg / ml during each of the one or more immunotherapy treatment cycles. 2 The method of claim 20, wherein the subject is administered a dose of
22. 22. The method of any one of claims 6 and 18-21, wherein cyclophosphamide is administered to the subject at a dose of 100 mg to 200 mg during each of the one or more immunotherapy treatment cycles.
23. 23. The method of claim 22, wherein cyclophosphamide is administered to the subject at a dose of 100 mg.
24. The manufactured T REG 24. The method of any one of claims 1-23, wherein cells are administered to the subject on day 8 of each of the one or more immunotherapy treatment cycles.
25. 25. The method of any one of claims 1 to 24, wherein the method comprises two or more immunotherapy treatment cycles, each of the two or more immunotherapy treatment cycles being 0 to 4 weeks apart.
26. 25. The method of any one of claims 1 to 24, wherein the method comprises two or more immunotherapy treatment cycles, each of the two or more immunotherapy treatment cycles being at least 4 weeks apart.
27. The manufactured T REG or (b) administering to said subject at least one of said immunotherapy treatment cycles at a dose of 1×10 cells / kg of said subject's body weight during each of said one or more immunotherapy treatment cycles. 6 Cells ~ 5 x 10 per kg of subject's body weight 6 The method of any one of claims 1 to 26, wherein a dose of cells is administered to the subject.
28. The manufactured T REG 28. The method of any one of claims 1 to 27, wherein the cells comprise a ratio of central memory cells to effector memory cells selected from 1:1, 3:1, 10:1, 1:3, and 1:
10.
29. Manufactured T REG The composition comprising cells is a native thymus-derived T REG The method of any one of claims 1 to 28, further comprising cells.
30. Prior to said one or more first treatment cycles, The method of any one of claims 1 to 29, further comprising harvesting peripheral lymphocytes from the subject.
31. After collecting peripheral lymphocytes from the subject, The peripheral lymphocytes are cultured to produce the T REG 31. The method of claim 30, further comprising obtaining the cells.
32. After said one or more first treatment cycles, The method of any one of claims 1 to 31, further comprising harvesting peripheral lymphocytes from the subject.
33. after harvesting peripheral lymphocytes from the subject after the one or more first line treatment cycles, The peripheral lymphocytes are cultured to produce the T REG 33. The method of claim 32, further comprising obtaining the cells.
34. After each of said one or more first treatment cycles, 34. The method of any one of claims 1-33, further comprising measuring an absolute lymphocyte count (ALC) in said subject and proceeding with said one or more immunotherapy treatment cycles if the ALC is less than 750 per μL.
35. 1. A method of treating amyotrophic lateral sclerosis in a subject in need thereof, comprising: comprising a first therapeutic cycle, a second therapeutic cycle, optionally one or more additional therapeutic cycles, and one or more immunotherapy therapeutic cycles; The first treatment cycle comprises: administering pentostatin to the subject; and / or administering cyclophosphamide to the subject; The second treatment cycle comprises: administering pentostatin to the subject; and / or administering cyclophosphamide to the subject; Each of the one or more additional treatment cycles comprises: administering pentostatin to the subject; and / or administering cyclophosphamide to the subject; Each of the one or more immunotherapy treatment cycles comprises: administering pentostatin to the subject; and / or administering cyclophosphamide to the subject; Manufactured T REG and administering the cells to the subject.
36. 36. The method of claim 35, wherein the step of administering pentostatin to the subject is performed on day 1 of the first treatment cycle.
37. Pentostatin is administered at a dose of 1 mg / ml during the first treatment cycle. 2 The method of claim 36, wherein the subject is administered a dose of
38. 38. The method of any one of claims 35-37, wherein the step of administering cyclophosphamide to the subject is repeated during the first treatment cycle.
39. 39. The method of claim 38, wherein said step of administering cyclophosphamide to said subject is performed on days 1, 2, and 3 of said first treatment cycle.
40. 40. The method of any one of claims 35-39, wherein cyclophosphamide is administered to the subject at a dose of 100 mg during the first treatment cycle.
41. 36. The method of claim 35, wherein the first treatment cycle is 14 days in length.
42. 36. The method of claim 35, wherein the second treatment cycle is 14 days in length.
43. 36. The method of claim 35, wherein each of the one or more additional treatment cycles is each 14 days in length.
44. 36. The method of claim 35, wherein each of the first therapeutic cycle, the second therapeutic cycle, and the one or more additional therapeutic cycles are separated by 0 to 2 weeks.
45. prior to administering pentostatin to the subject in the first treatment cycle, measuring creatinine clearance (CrCl) of the subject and adjusting a dose of pentostatin administered to the subject based on the CrCl; 2 In this case, pentostatin is 1 mg / m 2 Administered at 60 mL / min / 1.73 m 2 >CrCl≧30mL / min / 1.73m 2In this case, pentostatin is 0.5 mg / m 2 CrCl < 30 mL / min / 1.73 m 2 36. The method of claim 35, wherein pentostatin is not administered.
46. prior to administering cyclophosphamide to the subject in the first treatment cycle, 36. The method of claim 35, further comprising measuring an absolute neutrophil count (ANC) and adjusting the dose of cyclophosphamide administered to the subject based on the ANC and ANC, where if ANC>1000, cyclophosphamide is administered at a dose of 100 mg, if ANC is 500-999, cyclophosphamide is administered at a dose of 50 mg, and if ANC<500, no cyclophosphamide is administered.
47. 47. The method of any one of claims 35-46, wherein said step of administering pentostatin to said subject during said second treatment cycle is performed on day 1 of said second treatment cycle.
48. Pentostatin is administered at 2 mg / ml during the second treatment cycle. 2 The method of claim 35, wherein the subject is administered a dose of
49. 49. The method of any one of claims 35-48, wherein the step of administering cyclophosphamide to the subject during the second treatment cycle is repeated during the second treatment cycle.
50. 50. The method of claim 49, wherein said step of administering cyclophosphamide to said subject during said second therapeutic cycle is performed on days 1, 2, and / or 3 of said second therapeutic cycle.
51. 41. The method of any one of claims 35-40, wherein cyclophosphamide is administered to the subject at a dose of 100 mg during the second treatment cycle.
52. prior to administering pentostatin to the subject during the second treatment cycle, measuring creatinine clearance (CrCl) of the subject and adjusting a dose of pentostatin administered to the subject based on the CrCl; 2 In this case, pentostatin is 2 mg / m 2 Administered at 60 mL / min / 1.73 m 2 >CrCl≧30mL / min / 1.73m 2 In this case, pentostatin is 1 mg / m 2 CrCl < 30 mL / min / 1.73 m 2 36. The method of claim 35, wherein pentostatin is not administered.
53. prior to administering cyclophosphamide to the subject during the second treatment cycle, 36. The method of claim 35, further comprising measuring an absolute neutrophil count (ANC) and adjusting the dose of cyclophosphamide administered to the subject based on the ANC, where if ANC>1000, cyclophosphamide is administered at a dose of 100 mg, if ANC is 500-999, cyclophosphamide is administered at a dose of 50 mg, and if ANC<500, no cyclophosphamide is administered.
54. Prior to each of said one or more additional treatment cycles, 36. The method of claim 35, further comprising measuring an absolute lymphocyte count (ALC) in the subject and adjusting the treatment of the subject based on the ALC, wherein if ALC<750, subjecting the subject to a maintenance treatment cycle comprising subjecting the patient to the one or more immunotherapy treatment cycles, and if ALC>750, subjecting the patient to the one or more additional treatment cycles.
55. 55. The method of claim 54, wherein each of the one or more immunotherapy treatment cycles is 18 weeks in length.
56. ALC<750, REGThe cells are administered at a dose of 1 x 10 per kg of the subject's body weight during each of the one or more immunotherapy cycles. 6 Cells ~ 5 x 10 per kg of subject's body weight 6 55. The method of claim 54, wherein the subject is administered a dose of cells.
57. The manufactured T REG 57. The method of claim 56, wherein cells are administered to the subject on day 8 of each of the one or more immunotherapy treatment cycles.
58. Pentostatin is administered at 2 mg / m on days 1 and 4 during each of the one or more immunotherapy treatment cycles. 2 The method of claim 35, wherein the subject is administered a dose of
59. 36. The method of claim 35, wherein cyclophosphamide is administered to the subject at a dose of 100 mg on days 1, 2, 3, 4, and / or 5 of each of the one or more immunotherapy treatment cycles.
60. Each of the one or more immunotherapy treatment cycles comprises:
54. The method of any one of claims 35 to 53, further comprising administering to the subject a nucleoside reverse transcriptase inhibitor.
61. 61. The method of claim 60, wherein the nucleoside reverse transcriptase inhibitor is lamivudine.
62. 62. The method of claim 61, wherein the lamivudine is administered to the subject at a dosage of 150 mg daily to 150 mg twice daily during each of the one or more immunotherapy treatment cycles.
63. 63. The method of any one of claims 35-62, wherein the subject is subjected to the one or more additional cycles of treatment.
64. 64. The method of claim 63, wherein the step of administering pentostatin to the subject during each of the one or more additional treatment cycles is performed on day 1 and / or day 4 of the one or more additional treatment cycles.
65. Pentostatin is administered at a dose of 2 mg / ml during each of said one or more additional treatment cycles. 2 65. The method of claim 64, wherein the subject is administered a dose of
66. 66. The method of any one of claims 63-65, wherein the step of administering cyclophosphamide to the subject is repeated during each of the one or more additional treatment cycles.
67. 67. The method of claim 66, wherein said step of administering cyclophosphamide to said subject during each of said one or more additional therapeutic cycles is performed on days 1, 2, 3, 4, and / or 5 of each of said one or more additional therapeutic cycles.
68. 68. The method of any one of claims 63-67, wherein cyclophosphamide is administered to the subject at a dose of 100 mg to 200 mg during each of the one or more additional treatment cycles.
69. prior to administering pentostatin to the subject during each of the one or more additional treatment cycles, measuring creatinine clearance (CrCl) of the subject and adjusting a dose of pentostatin administered to the subject based on the CrCl; 2 In this case, pentostatin is 2 mg / m 2 Administered at 60 mL / min / 1.73 m 2 >CrCl≧30mL / min / 1.73m 2 In this case, pentostatin is 1 mg / m 2 CrCl < 30 mL / min / 1.73 m 2 64. The method of claim 63, wherein pentostatin is not administered.
70. prior to administering cyclophosphamide to the subject during each of the one or more additional treatment cycles, 64. The method of claim 63, further comprising measuring an absolute neutrophil count (ANC) and adjusting the dose of cyclophosphamide administered to the subject based on the ANC, wherein if ANC>1000, cyclophosphamide is administered at a dose of 100 mg, if ANC is 500-999, cyclophosphamide is administered at a dose of 50 mg, and if ANC<50 or ANC<500, no cyclophosphamide is administered.
71. the one or more additional therapeutic cycles comprising at least two additional therapeutic cycles, a final cycle of the at least two additional therapeutic cycles comprising administering to the subject cyclophosphamide during the final cycle of the at least two additional therapeutic cycles, 64. The method of claim 63, comprising measuring an absolute lymphocyte count (ALC) and an absolute neutrophil count (ANC) and adjusting a dose of cyclophosphamide administered to the subject based on the ALC and ANC, wherein if ALC > 1250, cyclophosphamide is administered at a dose of 200 mg, if ANC > 1000 and 750 < ALC < 1250, cyclophosphamide is administered at a dose of 100 mg, if ANC is 500-999, cyclophosphamide is administered at a dose of 50 mg, and if ANC < 500 and / or ALC < 750, no cyclophosphamide is administered.
72. 64. The method of claim 63, wherein each of the one or more additional treatment cycles is separated by 0 to 2 weeks.
73. Prior to each of said one or more additional treatment cycles, 64. The method of claim 63, further comprising measuring an absolute lymphocyte count (ALC) in the subject and adjusting the treatment of the subject based on the ALC, wherein if ALC<750, administering to the subject a maintenance treatment cycle comprising administering a nucleoside reverse transcriptase inhibitor, not further administering the one or more additional treatment cycles prior to the maintenance treatment cycle, and if ALC>750, continuing the subject patient in the one or more additional treatment cycles.
74. 74. The method of claim 73, wherein each of the one or more immunotherapy treatment cycles is four weeks in length.
75. During each of said one or more immunotherapy treatment cycles, measuring creatinine clearance (CrCl) of the subject and adjusting a dose of lamivudine administered to the subject based on the CrCl; 2 If lamivudine is administered at 150 mg twice daily, 50 mL / min > CrCl ≥ 30 mL / min / 1.73 m 2 If lamivudine is administered at 150 mg daily, CrCl < 30 mL / min / 1.73 m 2 62. The method of any one of claims 60 to 61, wherein lamivudine is not administered.
76. 1. A method of treating amyotrophic lateral sclerosis in a subject in need thereof, comprising: A therapeutically effective amount of the manufactured T REG The method comprises one or more treatment cycles comprising administering the cells.
77. The manufactured T REG The cells are administered at a concentration of 1×10 per kg of the subject's body weight. 6 cells, and 5×10 per kg of the subject's body weight 6 77. The method of claim 76, wherein the antibody is administered in doses of cells.
78. The manufactured T REG77. The method of claim 76, wherein the cells comprise a ratio of central memory to effector memory cells selected from 1:1, 3:1, 10:1, 1:3, and 1:
10.
79. Each of the one or more treatment cycles comprises: administering pentostatin to the subject; and / or 77. The method of claim 76, further comprising administering to the subject cyclophosphamide.
80. Pentostatin at 1 mg / m 2 ~2mg / m 2 80. The method of claim 79, wherein the subject is administered a dose of
81. 80. The method of claim 79, wherein the dose of cyclophosphamide is between 100 mg and 200 mg.
82. 80. The method of claim 79, wherein the pentostatin is administered to the subject on days 1 and 4 of each of the one or more treatment cycles.
83. 80. The method of claim 79, wherein the cyclophosphamide is administered to the subject on days 1, 2, 3, 4, and / or 5 of each of the one or more treatment cycles.
84. 80. The method of claim 79, wherein the subject was previously treated with pentostatin and cyclophosphamide.
85. 85. The method of any one of claims 76-84, wherein each of the one or more treatment cycles further comprises administering to the subject a nucleoside reverse transcriptase inhibitor.
86. 86. The method of claim 85, wherein the nucleoside reverse transcriptase inhibitor is an inhibitor of the NLRP3 inflammasome.
87. 87. The method of claim 86, wherein the nucleoside reverse transcriptase inhibitor is lamivudine.
88. 88. The method of claim 87, wherein the lamivudine is administered to the subject at a dose of 150 mg daily to 150 mg twice daily.
89. Normal T REG The cells were then cultured in the same manner as in Example 1. REG 89. The method of any one of claims 76 to 88, further comprising administering to the subject simultaneously with the cells.
90. 90. The method of any one of claims 76-89, wherein each of the one or more treatment cycles is at four week intervals.
91. Prior to said one or more treatment cycles, 91. The method of any one of claims 76 to 90, further comprising harvesting peripheral lymphocytes from the subject.
92. After collecting peripheral lymphocytes from the subject, The peripheral lymphocytes are cultured to produce the T REG 92. The method of claim 91, further comprising obtaining the cells.
93. 1. A method of treating amyotrophic lateral sclerosis in a subject in need thereof, comprising: A therapeutically effective amount of the manufactured T REG Administering a cell.
94. The manufactured T REG The cells are administered at a concentration of 1×10 per kg of the subject's body weight. 6 cells, and 5×10 per kg of the subject's body weight 6 94. The method of claim 93, wherein the antibody is administered in doses of cells.
95. The manufactured T REG 94. The method of claim 93, wherein the cells comprise a ratio of central memory to effector memory cells selected from 1:1, 3:1, 10:1, 1:3, and 1:
10.
96. The manufactured T REGPrior to administering the cells to the subject, administering pentostatin to the subject; and / or 94. The method of claim 93, further comprising administering to the subject cyclophosphamide.
97. Pentostatin, 0.5 mg / m 2 ~4 mg / m 2 97. The method of claim 96, wherein the subject is administered a dose of
98. 97. The method of claim 96, wherein the dose of cyclophosphamide is between 50 mg and 400 mg.
99. 94. The method of claim 93, wherein the subject was previously treated with pentostatin and cyclophosphamide.
100. 100. The method of any one of claims 93-99, further comprising administering to the subject a nucleoside reverse transcriptase inhibitor.
101. The method of claim 100, wherein the nucleoside reverse transcriptase inhibitor is an inhibitor of the NLRP3 inflammasome.
102. 102. The method of claim 101, wherein the nucleoside reverse transcriptase inhibitor is lamivudine.
103. 103. The method of claim 102, wherein the lamivudine is administered to the subject at a dose of 150 mg daily to 150 mg twice daily.
104. Normal T REG The cells were then cultured in the same manner as in Example 1. REG 104. The method of any one of claims 93 to 103, further comprising administering to the subject simultaneously with the cells.
105. The manufactured T REG Prior to administering the cells to the subject, harvesting peripheral lymphocytes from the subject; The peripheral lymphocytes are cultured to produce the T REG 96. The method of any one of claims 93 to 95, further comprising obtaining the cells.
106. The method of any one of claims 1 to 105, further comprising administering to the subject an anti-TNF-α therapy.
107. Dedifferentiated T cells REG A method for differentiating into Th2 cells, comprising: Culturing the dedifferentiated T cells in a culture medium containing IL-2, IL-4, and TGF-β; Addition of anti-CD3 / anti-CD28 coated magnetic beads at a ratio of 3:1 (beads:T cells); The dedifferentiated T cells are incubated for a period of time to give T REG / Obtaining Th2 cells.
108. 108. The method of claim 107, wherein the culture medium further comprises pemetrexed.
109. The method of any one of claims 107-108, wherein the IL-2 is present in the culture medium at a concentration of about 100 IU / mL.
110. The method of any one of claims 107 to 109, wherein the IL-4 is present in the culture medium at a concentration of about 1000 IU / mL.
111. 111. The method of any one of claims 107 to 110, wherein the TGF-β is present in the culture medium at a concentration of about 10 ng / mL.
112. 109. The method of claim 108, wherein the pemetrexed is present in the culture medium at a concentration of up to 100 nM.
113. 109. The method of claim 108, wherein the pemetrexed is present in the culture medium at a concentration of about 10 nM.
114. The method of any one of claims 112-113, wherein the IL-2 is present in the culture medium at a concentration of about 100 IU / mL.
115. The method of any one of claims 112 to 114, wherein the IL-4 is present in the culture medium at a concentration of about 1000 IU / mL.
116. 116. The method of any one of claims 112 to 115, wherein the TGF-β is present in the culture medium at a concentration of about 10 ng / mL.
117. Dedifferentiated T cells REG A method for differentiating into Th2 cells, comprising: culturing de-differentiated T cells, wherein the de-differentiated T cells express RAPTOR and RICTOR at levels that are reduced by at least 10% compared to control T cells, in a culture medium comprising IL-2, IL-4, and TGF-β; Addition of anti-CD3 / anti-CD28 coated magnetic beads at a ratio of 3:1 (beads:T cells); The dedifferentiated T cells are incubated for a period of time to give T REG / Obtaining Th2 cells.
118. 118. The method of claim 117, wherein the culture medium further comprises pemetrexed.
119. The method of any one of claims 117-118, wherein the IL-2 is present in the culture medium at a concentration of about 100 IU / mL.
120. 120. The method of any one of claims 117-119, wherein the IL-4 is present in the culture medium at a concentration of about 1000 IU / mL.
121. 121. The method of any one of claims 117 to 120, wherein the TGF-β is present in the culture medium at a concentration of about 10 ng / mL.
122. 119. The method of claim 118, wherein the pemetrexed is present in the culture medium at a concentration of up to 100 nM.
123. 119. The method of claim 118, wherein the pemetrexed is present in the culture medium at a concentration of about 10 nM.
124. The method of any one of claims 122-123, wherein the IL-2 is present in the culture medium at a concentration of about 100 IU / mL.
125. 125. The method of any one of claims 122-124, wherein the IL-4 is present in the culture medium at a concentration of about 1000 IU / mL.
126. 126. The method of any one of claims 122-125, wherein the TGF-β is present in the culture medium at a concentration of about 10 ng / mL.
127. The method of any one of claims 107 to 126, wherein the culture medium is X-Vivo 20 supplemented with 5% human AB serum.
128. 128. The method of any one of claims 107 to 127, wherein the period is from 3 days to 40 days.
129. T produced by the method of any one of claims 107 to 128 REG / Th2 cells.
130. Dedifferentiated T cells REG 1. A method for differentiating a cell, comprising: Culturing dedifferentiated T cells having reduced expression of RAPTOR and RICTOR relative to a control population of T cells in a culture medium comprising IL-2 and TGF-β; Addition of anti-CD3 / anti-CD28 coated magnetic beads at a ratio of 3:1 (beads:T cells); The dedifferentiated T cells are incubated for a period of time to give T REG and obtaining the cells.
131. 131. The method of claim 130, wherein the culture medium further comprises pemetrexed.
132. The method of any one of claims 130-131, wherein the IL-2 is present in the culture medium at a concentration of about 100 IU / mL.
133. 133. The method of any one of claims 130 to 132, wherein the TGF-β is present in the culture medium at a concentration of about 10 ng / mL.
134. 132. The method of claim 131, wherein the pemetrexed is present in the culture medium at a concentration of up to 100 nM.
135. 132. The method of claim 131, wherein the pemetrexed is present in the culture medium at a concentration of about 10 nM.
136. The method of any one of claims 134-135, wherein the IL-2 is present in the culture medium at a concentration of about 100 IU / mL.
137. 137. The method of any one of claims 134 to 136, wherein the TGF-β is present in the culture medium at a concentration of about 10 ng / mL.
138. Dedifferentiated T cells REG 1. A method for differentiating a cell, comprising: Culturing de-differentiated T cells, wherein the de-differentiated T cells express RAPTOR and RICTOR at levels that are reduced by at least 10% compared to control T cells, in a culture medium comprising IL-2 and TGF-β; Addition of anti-CD3 / anti-CD28 coated magnetic beads at a ratio of 3:1 (beads:T cells); The dedifferentiated T cells are incubated for a period of time to give T REG and obtaining the cells.
139. 139. The method of claim 138, wherein the culture medium further comprises pemetrexed.
140. 140. The method of any one of claims 138-139, wherein the IL-2 is present in the culture medium at a concentration of about 100 IU / mL.
141. 141. The method of any one of claims 138-140, wherein the TGF-β is present in the culture medium at a concentration of about 10 ng / mL.
142. 140. The method of claim 139, wherein the pemetrexed is present in the culture medium at a concentration of up to 100 nM.
143. 140. The method of claim 139, wherein the pemetrexed is present in the culture medium at a concentration of about 10 nM.
144. The method of any one of claims 142-143, wherein the IL-2 is present in the culture medium at a concentration of about 100 IU / mL.
145. 145. The method of any one of claims 142-144, wherein the TGF-β is present in the culture medium at a concentration of about 10 ng / mL.
146. The method of any one of claims 130 to 145, wherein the culture medium is X-Vivo 20 medium supplemented with 5% AB serum.
147. 147. The method of any one of claims 130 to 146, wherein the period is from 3 days to 40 days.
148. The method of any one of claims 107-147, wherein the de-differentiated T cells have reduced expression of RAPTOR and RICTOR compared to a control population of T cells.
149. T produced by the method according to any one of claims 107 to 128 and 130 to 148. REG cell.
150. The T lymphocytes produced by the method of any one of claims 107 to 128 and 130 to 148, in which the lymphocytes collected by apheresis for subsequent T cell culture are obtained at steady state or after treatment of the subject with anti-TNF-α therapeutics that are relatively selective in neutralizing serum, cell-free forms of TNF-α, most notably the recombinant receptor molecule etanercept, or the monoclonal antibody adalimumab, REG Cells or Hybrid T REG / Th2 cells.
151. T REG Cells or Hybrid T REG 151. The method of claim 107-128 and 130-148, wherein the Th2 cells or populations thereof have increased expression by flow cytometry of at least one of the following molecules: CD25, CD27, 2B4, BTLA, CTLA4, TIGIT, TIM3, ICOS, LAIR1, OX40, and combinations thereof, compared to control Th1 / Tc1 cells. REG Cells or Hybrid T REG / Th2 cells.
152. T REG Cells or Hybrid T REG The T / Th2 cells or populations thereof have reduced secretion of inflammatory cytokines, including IFN-γ and TNF-α, compared to control Th1 / Tc1 cells, produced by the method of any one of claims 107 to 128 and 130 to 148. REG Cells or Hybrid T REG / Th2 cells.
153. T REG Cells or Hybrid T REG The T / Th2 cells or populations thereof have altered expression of T cell fate transcription factors, most notably a decrease in TBET and an increase in FOXP3, compared to control Th1 / Tc1 cells. REGCells or Hybrid T REG / Th2 cells.
154. T REG Cells or Hybrid T REG 151. The method of claim 107, wherein the Th2 cells or populations thereof have additional phenotypic traits, including increased secretion of the Th2 cytokine IL-4 and increased expression of the Th2 transcription factor GATA3, compared to control Th1 / Tc1 cells. REG Cells or Hybrid T REG / Th2 cells.
155. GATA3 expressing CD4 + or CD8 + T with at least 5% of T cells REG Or T REG / Th2 cell population.
156. FoxP3 expressing CD4 + or CD8 + TREG or T REG / Th2 cell population.
157. CD4 expressing CD73 + or CD8 + T cells with at least 10% REG Or T REG / Th2 cell population.
158. T with at least 10% of CD4+ or CD8+ T cells expressing CD103 REG Or T REG / Th2 cell population.
159. T cells with at least 20% of CD4+ or CD8+ T cells expressing CD150. REG Or T REG / Th2 cell population.
160. T cells expressing at least 5 pg / mL IL-4 after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:
1. REG Or T REG / Th2 cell population.
161. T cells expressing at least 100 pg / mL IL-2 after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:
1. REG Or T REG / Th2 cell population.
162. T cells expressing at least less than 100 pg / mL IFN-γ or GM-CSF after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:
1. REG Or T REG / Th2 cell population.
163. T cells expressing at least less than 100 pg / mL TNF-α or IL-17F after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:
1. REG Or T REG / Th2 cell population.
164. The manufactured T REG The cells have the following characteristics: at least 10% increased expression of one or more of CD25, CD27, 2B4, BTLA, CTLA4, TIGIT, TIM3, ICOS, LAIR1, OXO40, and combinations thereof as measured by flow cytometry relative to control Th1 / Tc1 cells; at least 10% reduced secretion of IFN-γ compared to control Th1 / Tc1 cells; at least 10% reduced secretion of TNF-α compared to control Th1 / Tc1 cells; expression of TBET reduced by at least 10% compared to control Th1 / Tc1 cells; at least 10% increased expression of FOXP3 compared to control Th1 / Tc1 cells; CD4 expressing GATA3 as measured by flow cytometry + or CD8 ー At least 5% of T cells CD4 expressing FOXP3 as measured by flow cytometry + or CD8 ー At least 5% of T cells CD4 expressing CD73 as measured by flow cytometry + or CD8 ー At least 5% of T cells CD4 expressing CD103 as measured by flow cytometry + or CD8 ー At least 5% of T cells CD4 expressing both FOXP3 and GATA3 as measured by flow cytometry + or CD8 ー At least 5% of the cells CD4 expressing CD150 as measured by flow cytometry + or CD8 + At least 20% of T cells At least 5 pg / mL / 1x10 of IL-4 after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1 6 Expression in cells / day, At least 100 pg / mL / 1x10 of IL-2 after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1 6 Expression in cells / day, IFN-γ at 100 pg / mL / 1×10 after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1 6 Expression at less than cells / day GM-CSF at 100 pg / mL / 1 x 10 after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1 6 Expression at less than cells / day TNF-α at 10 pg / mL / 1×10 after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1 6 Expression at less than cells / day IL-17 at 10 pg / mL / 1×10 after costimulation with anti-CD3 / anti-CD28 beads at a bead:T cell ratio of 3:1 6 Expression at less than cells / day, and The method of any one of claims 1 to 106, comprising one or more of:
